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The Impact of Falls 
in the Elderly
Nicole D.A. Boyé, Esther M.M. van Lieshout, Ed F. van Beeck, 







The number of falls in the elderly is a major public health problem in our society. In the past 
decade life expectancy increased from 75 years in 1990 to 79 years in 2009 in the United 
States (US). It has been estimated that the number of persons aged 65 years and older in the 
US will double by 2050.  
In 2000 falls accounted for 45% of all injury-related inpatient stays, with almost 
750,000 hospitalizations. Fractures were the most common primary injury diagnosis, 
including 314,006 hip fractures. Injury following a fall is associated with a decreased quality 
of life and poor functional outcome, in severe injuries these effects continue for a prolonged 
period of time. 
In 2006 fall-related medical costs in the population aged ≥65 in the US amounted to 
US$19 billion for non-fatal and US$0.2 billion for fatal injuries. 
In this paper we provide a literature overview on the impact of falls in the elderly, the 




The number of falls in the elderly is a major public health problem in our society. In past 
decades life expectancy has risen from 77 years in 1990 to 81 years in 2009 in the 
Netherlands. Similar trends were noted in other countries; from 75 to 79 years in the US, and 
from 76 to 80 years in the UK. This gives an estimate of the increasing life expectancy in 
western countries worldwide 2. In 2010 Vincent et al. estimated that the number of persons 
aged 65 years and older in the US will double by 2050 3. In 2010 14 percent of the population 
in the US was 85 years or older, by 2050 that proportion is expected to increase to more than 
21 percent. Currently 15.6 percent of the population in the Netherlands is aged 65 years or 
older; this is estimated to increase to 25 percent by 2050 4. 
 How should we prepare our society for the growing number of elderly and the array of 
health problems associated with increased age? Approximately one out of three persons aged 
≥ 65 years experiences a fall every year 5. The most important risk factors for falls are old age 
(>80 years), a history of falls, gait deficit, balance deficit, use of assistive device, visual 
deficit, arthritis, impaired activities of daily living (ADL), depression, and cognitive 
impairment. Other risk factors include the environment (e.g., insufficient lighting, rugs, and 
loose wiring), and comorbidities like orthostatic hypotension, vertigo, and Parkinson’s disease 
6-9. Approximately 33 percent of persons over 65 years use so-called fall-risk-increasing drugs 
(FRIDs) such as cardiovascular and psychotropic drugs 10-12. 
Low-level falls are deemed as fairly innocent in the young, yet falls in the older 
population are associated with substantial higher morbidity and mortality rates. This will put a 
substantial burden on healthcare workers and institutions, and will result in rising healthcare 
costs as long as the population of elderly continues to grow. In order to solve this public 
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(FRIDs) such as cardiovascular and psychotropic drugs 10-12. 
Low-level falls are deemed as fairly innocent in the young, yet falls in the older 
population are associated with substantial higher morbidity and mortality rates. This will put a 
substantial burden on healthcare workers and institutions, and will result in rising healthcare 
costs as long as the population of elderly continues to grow. In order to solve this public 
health problem we need insight into the outcome of falls in the older population, such as the 
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type of injury, mortality, disability, fear of falling, and social isolation. Also, the burden of 
falls on healthcare systems including emergency departments (ED), hospitals, long-term care 
and rehabilitation facilities, and the costs of falls for our society and economy need to be 
investigated. Falls-prevention programs provided by healthcare givers are now being 
developed and implemented worldwide, assessing and managing risk factors for falls. In this 
paper we provide a literature overview on the impact of falls in the elderly, including 
predominant injuries following a fall, the quality of life after a fall, the costs of treatment, and 
the effectiveness of fall prevention. 
 
Burden on Healthcare 
 
In 2009 the number of persons aged 65 and older treated at an ED for a non-fatal fall in the 
US was 1,594,335 13. Greenspan et al. showed that of all injury-related hospitalizations in 
2000, discharge rates from hospitals were highest for those aged 65 years and older; adults 85 
years and older had the highest hospitalization rates of any age group (5,499 per 100,000). 
Falls were the leading cause of hospitalization. With almost 750,000 hospitalizations, falls 
accounted for 45% of all inpatient stays. Fractures were the most common primary injury 
diagnosis, including 314,006 hip fractures 14. 
Falls are also the leading cause of traumatic brain injury, between 2002 and 2006, an 
average of 144,338 persons aged ≥65 sustained traumatic brain injury in the US annually, of 
which 107,221 visited the ED, 29,860 were hospitalized and 7,257 resulted in death 15.  
In 2008 there were 34,091 fall related hospitalizations including 14,258 with hip 
fractures 16 and 3,010 with significant traumatic head injury 17 in persons aged 65 years and 
older in the Netherlands. In 1999, there were over 647,721 fall-related ED visits in the UK for 
persons aged 60 or older, leading to 204,424 hospital admissions 18.  
Close et al. documented healthcare use of older fallers (≥ 70 years old) in Australia. 
From 2008 through 2010, older fallers constituted 17% of all ED visits, which led to hospital 
admission in 42.7% of the cases, after hospitalization 9.5% became first-time resident of long-




In 2006 there were 10,300 fatal and 2.6 million non-fatal fall-related injuries in the population 
aged ≥65 in the US 20. Accidental injury, often resulting from a fall, ranks as the ninth leading 
cause of death among people over 65 years of age in the US 21. 
Older adults are more prone to injury than younger persons, and similar injury 
mechanisms will result in more severe consequences for the elderly. For instance, the 
increased fracture incidence at older age is partly attributable to osteoporosis. The most 
common injuries due to falls in persons aged 65 years or older in the Netherlands are 
superficial injuries, hip fractures, upper extremity fractures, and traumatic brain injury 16. 
About 30% of people with a hip fracture will die in the following year, and many more will 
experience significant functional loss 22. Data from recent studies in Europe and North 
America indicate that the incidence of hip fractures is declining 22-25. This decline has been 
observed since 1985 25 and by some as early as 1950 26. Having an explanation for this trend 
could be helpful in developing programs for further reduction of the hip fracture incidence 
rate. However, there seems yet to be no clear answer to this incidence decline. One of the 
most striking observations is the disparity in decline of the male and female incidence rates, 
Chevalley et al. reported no decrease in hip fracture rates between 1991 and 2000 in males in 
Switzerland 23, and Hartholt et al. reported a continuing increase in hip fracture rates in the 
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observed since 1985 25 and by some as early as 1950 26. Having an explanation for this trend 
could be helpful in developing programs for further reduction of the hip fracture incidence 
rate. However, there seems yet to be no clear answer to this incidence decline. One of the 
most striking observations is the disparity in decline of the male and female incidence rates, 
Chevalley et al. reported no decrease in hip fracture rates between 1991 and 2000 in males in 
Switzerland 23, and Hartholt et al. reported a continuing increase in hip fracture rates in the 
oldest men aged 80 years and older in the Netherlands between 1980 and 2008 27. One 
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explanation for this observation could be the lack of awareness and preventive measures 
against osteoporosis in men. However, the overall decline in hip fracture incidence rates 
observed in both males and females in the US and Canada cannot be explained by this 22,25. 
Several other explanations have been suggested such as improved nutrition status, increasing 
body weight, declining smoking rates, and hormone replacement therapy yet there is no 
definitive answer. A combination of all these factors is probably the reason for the lower 
incidence rate of hip fractures in western countries.  
Traumatic brain injury is associated with serious consequences. Recent studies in the 
US 15, the Netherlands 17, and Finland 28 showed an increase in fall-related traumatic brain 
injury. Falls cause 60.7% of traumatic brain injuries among persons aged 65 years and older 
in the US 15. Rates for ED visits, hospitalization and death due to traumatic brain injury in the 
US all increased from 2002 to 2006, with hospitalization rates increasing from 67.6 to 90.7 
per 100,000 in persons aged 65 or older 15. A similar increase in hospitalization rates after 
traumatic brain injury was also seen in the Netherlands 17. A definite cause is yet unknown, 
the observed increase could in part be due to the increased mobility of the elderly, the 
implementation of new treatment guidelines, the increased use of radiographic imaging, or the 
rising life expectancy in western countries.  
 
Health-Related Quality of Life 
 
In addition to the effects on morbidity and mortality as described above, falls result in a 
significant reduction in health-related quality of life and substantial functional impairment 
one year after sustaining a hip fracture 29,30. Compared with the general older population, 
fallers with hip factures, upper extremity fractures or skull/brain injury all displayed a higher 
prevalence of functional problems. In a Dutch population-based study, patients aged 65 years 
or older who had sustained a hip fracture reported problems in all domains of the EuroQol-5D 
(EQ-5D), including mobility (90% of patients), self-care (54%), usual activities (73%), 
pain/discomfort (69%), anxiety/depression (28%) and cognition (38%) up to nine months 
after the fall 31. Marottoli et al. studied physical function following a hip fracture in persons 
aged 65 and older; at baseline, 86% of patients could dress independently versus 49% at six 
months. Similarly, 90% could transfer independently versus 32% at six months; 75% could 
walk across a room independently versus 15% at six months; 63% could climb a flight of 
stairs versus 8% at six months; and 41% could walk one-half mile versus 6% at six months 32. 
Injury following a fall is associated with a decreased quality of life and poor functional 




In 2006 fall-related medical costs in the population aged ≥65 years in the US amounted to 
US$19 billion (equivalent to €13.8 billion) for non-fatal and US$0.2 billion (€0.15 billion) for 
fatal injuries 20. The estimated population aged ≥65 in 2006 in the US was 37 million 33,34, 
which amounts to a per capita cost of US$517 (€382). Between 2003 and 2007 the average 
annual cost for fall-related injuries in the Netherlands was US$ 0.64 billion (€0.47 billion), in 
2005 the population aged ≥65 in the Netherlands was 2.3 million 35, which amounts to a per 
capita cost of US$280 (€207). In 1999, the total cost to the UK government from 
unintentional falls in persons aged 60 or older was US$1.6 billion (€1.15 billion) 18, the UK 
population aged ≥60 in 1999 was 12.2 million 36 thus the per capita cost was approximately 
US$130 (€96). In 2005 Roudsari et al., estimated the mean cost per fall-related hospitalization 
in the US to be US$17,483 (€12,674), the mean cost per ED visit US$236 (€171) and the 
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US$130 (€96). In 2005 Roudsari et al., estimated the mean cost per fall-related hospitalization 
in the US to be US$17,483 (€12,674), the mean cost per ED visit US$236 (€171) and the 
mean cost per outpatient visit US$412 (€299) 37. Between 2003 and 2007 the average cost per 
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hip fracture in the Netherlands was US$24,639 (€18,223), the cost per patient admitted to a 
hospital with traumatic brain injury after a fall was US$19,309 (€14,281) and overall cost per 
fall US$9,530 (€7,048) 31.  
 
Falls Prevention Initiatives 
 
Much effort has been put into prevention programs, assessing risk factors, such as previous 
falls, impaired balance and gait, and fall-risk-increasing drugs. There have been successful 
single intervention studies, implementing exercise programs which mainly consisted of 
muscle strengthening and balance exercises 38,39, and a study featuring withdrawal of fall-risk-
increasing drugs (FRIDs) 40. The withdrawal of FRIDs should place minimal burden on the 
healthcare system, fallers taking FRIDs are easily identified, and withdrawal is shown to be 
safely possible and effective for both cardiovascular and psychotropic drugs 41. Campbell et 
al. demonstrated how withdrawal of psychotropic medication significantly reduced falls; 
however, permanent withdrawal was difficult to achieve 40. There are also falls prevention 
programs with multiple interventions; these are called multifactorial intervention programs. 
The most common interventions featured in successful multifactorial intervention studies are 
exercise, medication review, an assessment of vision, hearing, cardiovascular function and 
psychological state with proper referrals, and an assessment of the home environment and 
assistive devices 5,9,42-46. Efficacy of such interventions varies, and in some multifactorial 
intervention studies no reduction in falls could be shown 47,48. Thus there is room for 
improvement and further research concerning this complex problem. Identifying the 
population that will benefit most from falls-prevention programs and determining which 
components of multifactorial interventions are most effective could improve current results. 
With such a broad range of risk factors, falls-prevention is not a simple task. 
DISCUSSION 
 
In this paper, different aspects of falls and the impact of falls on the elderly, healthcare 
systems, and society have been reviewed based on current literature. In the past decades there 
has been a growing awareness in western societies, concerning the increasing burden of falls. 
Although the mortality rate following a fall and the incidence rates of hip fractures have 
decreased, hospitalization rates for traumatic brain injury are increasing. The absolute number 
of falls and injury following a fall continues to rise, as do the costs. Factors which have 
reduced injury severity following a fall are preventative measures and treatment for 
osteoporosis, an improved nutrition status, increasing body weight, declining smoking rates, 
hormone replacement therapy, and more recently falls-prevention programs. Yet the decline 
in hip fracture rates is not explained by these factors alone, a definitive answer concerning the 
reduction in hip fracture rates could help us further in preventing fractures following falls. 
Falls affect a large proportion of the elderly population and have a substantial impact, with 
consequences such as higher morbidity and mortality rates, disability, fear of falling, social 
isolation, loss of independence, and institutionalization. Fall-related injuries and loss of 
function, quality of life and independence place a substantial burden on healthcare systems 
due to the large amount of visits to emergency departments, hospital admissions, admissions 
to long-term care and rehabilitation facilities, and other healthcare services needed. The 
elderly population in our society will continue to increase during the coming decades. This 
may be a reflection of the change in life style and the advances in public health and medical 
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In this thesis 
 
Part I starts with a literature overview on the impact of falls in the elderly, the burden on 
healthcare, and the costs for society.  
Part II is descriptive, providing insight into various factors related to falls. An 
important aspect regarding falls in older adults are the circumstances leading to injurious falls. 
Falls are the most significant cause of traumatic brain injuries (TBI) and hip fractures in older 
adults, and these circumstances highlight subgroups that may benefit from targeted falls 
prevention strategies 1-3. The location and activity surrounding falls requiring an emergency 
department (ED) visit, falls resulting in TBI, and falls resulting in hip fractures, are discussed 
in Chapter 2.1. In Chapter 2.2 the association between serum 25-hydroxy-vitamin D and 
physical performance in older men and women is presented. A decrease in physical 
performance, such as impaired mobility, reduced muscle strength or poor balance, predisposes 
to falls and related injuries 4-6. Muscle tissue is an important target tissue of vitamin D 7. 
Furthermore, vitamin D deficiency has been shown to be a key contributor to a decline in 
physical performance and an increase in fall incidence 8-15. Additionally, guidelines 
concerning falls prevention make a clear distinction between single and recurrent fallers 16. Iin 
Chapter 2.3 the differences in functional status, physical performance and health related 
quality of life between single and recurrent fallers are discussed.  
And finally, Part III presents the background of and data from the Improving 
Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) Study. Including the 
study protocol in Chapter 3.1, the main outcomes in Chapter 3.2, and the cost-utility 
analysis in Chapter 3.3. The use of certain drugs, i.e. the so-called fall-risk increasing drugs 
(FRIDs) 17-20, mainly psychotropic and cardiovascular drugs, has been associated with 
increased risk of falls and related injuries 17, 18, 20, 21, and withdrawal of FRIDs appears to be 
feasible and effective 19, 22-24. Although FRIDs withdrawal is frequently incorporated in 
multifactorial intervention trials, evidence regarding overall FRID withdrawal as a single 
intervention is scarce 25.  
The aim of the IMPROveFALL study and this thesis is to gain insight into the [cost]-
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injurious falls in older 







Background: Fall-induced injuries in persons aged 65 years and older are a major public 
health problem. Data regarding circumstances leading to specific injuries, such as traumatic 
brain injury (TBI) and hip fractures in older adults are scarce.  
Objective: To investigate the activity distributions leading to indoor and outdoor falls 
requiring an Emergency Department (ED) visit, and those resulting in TBIs and hip fractures.  
Participants: 5880 older adults who visited the ED due to a fall. 
Methods: Data is descriptive and stratified by age and gender. 
Results: Two-thirds of all falls occurred indoors. However, there were higher proportions of 
outdoor falls at ages 65-79 years (48%). Walking up or down stairs (51%) and housekeeping 
(17%) were the most common indoor activities leading to a TBIs. Walking (42%) and sitting 
or standing (16%) were the most common indoor activities leading to a hip fracture. The most 
common outdoor activities were walking (61% for TBIs and 57% for hip fractures) and 
cycling (10% for TBIs and 24% for hip fractures).  
Conclusion: In the present study we found that the indoor activities distribution leading to 
TBIs and hip fractures differed. Notably, about half of the traumatic brain injuries and hip 
fractures in men and women aged 65-79 years occurred outdoors. This study provides new 
insights into patterns leading to injurious falls by age, gender and injury type, and may guide 
the targeting of falls prevention at specific activities and risk groups, including highly 







Falls affect approximately a third of the population aged 65 years and older, and are 
associated with major adverse consequences such as disability, loss of quality of life, 
institutionalization, and high morbidity and mortality rates 1-8. Furthermore, falls place a 
substantial burden on healthcare systems due to the large amount of visits to emergency 
departments, hospital admissions, admissions to long-term care and rehabilitation facilities, 
and related healthcare costs 3,4,7,9-11 making falls prevention a public health priority 12,13.  
The most common injuries due to falls in the population aged 65 years and older in the 
Netherlands are superficial injuries, hip fractures, upper extremity fractures, and traumatic 
brain injury (TBI)10. Approximately 30% of people with a hip fracture will die within a year, 
and many more will experience significant functional loss 2. Similarly, TBI is associated with 
serious consequences. Falls cause 61% of TBIs among persons aged 65 years and older in the 
United States 14. Furthermore, recent studies in the United States 14, the Netherlands 15, and 
Finland 16 showed an increase in fall-related TBIs.  
An important yet overlooked aspect regarding falls in the elderly is the paucity of 
evidence regarding patterns in the circumstances leading to injurious falls. Falls are the most 
important cause of TBIs and hip fractures in older adults, thus these patterns are valuable 
because they could highlight subgroups that may benefit from targeted falls prevention 
strategies 2,15,17. However, data on circumstances leading to major consequences of falls in 
older adults, such as hip fractures and TBIs are scarce; and the number of events in the 
available studies is relatively low 18-21.  
In this study, we investigated the indoor and outdoor activities leading to injurious 
falls in a large number of older men and women who visited the Emergency Department (ED) 
after experiencing a fall.  
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For the present study, screening data were extracted from the IMPROveFALL study 22. The 
IMPROveFALL study is a randomized multicenter trial investigating the effect of withdrawal 
of fall-risk increasing drugs versus ‘care as usual’ on reducing falls in community-dwelling 
older men and women. Patients meeting the following criteria were screened for potential 
enrolment in the IMPROveFALL study: aged 65 years or older, visited the ED due to a fall. A 
fall was defined as coming to rest unintentionally on the ground or a lower level with or 
without losing consciousness, but not induced by acute medical conditions, e.g. stroke, or 
exogenous factors such as a traffic accident 23. All patients meeting the screening criteria were 
included in the current study. Screening was performed at two academic and five regional 
hospitals in the Netherlands, all located in highly urbanized areas. Screening started in 
October 2008 and was completed in October 2011. The local Medical Research Ethics 
Committees at all participating sites approved the study. 
 
Data collection 
Data regarding age, gender, dwelling, date of ED visit, location of fall, activity during fall, 
and injuries sustained were collected from ED records. Records were made by ED personnel, 
were free-form, and paper or electronic depending on the hospital. Records were collected and 
managed by the research nurse and research physician. ED personnel were not aware of 
specific data being collected from records, therefore, there was a fair amount of missing data. 
Regarding the location of the fall, 27% of the data were missing; and regarding activity prior 
to the fall, 34% of the data was missing. Data regarding hospital stay and hospital mortality 
were not collected.  
Age was categorised as 65 to 79 years old or 80 years and older. Dwelling was 
categorised as community-dwelling or living in a care facility (assisted living facility or 
nursing home). Location at time of fall was categorised as indoors or outdoors. Activity at 
time of fall was categorised as walking, sitting or standing, walking up or down stairs, 
lavatory visit, sports and recreation, out of bed, housekeeping, cycling, or other. Season 
during which fall occurred was categorised as winter (December, January and February), 
spring (March. April and May), summer (June, July and August) , and autumn (September, 
October and November). Injuries were defined by the International Classification of Diseases 
10th revision (ICD-10) 24 and categorised as superficial injury, open wound, head injuries (i.e., 
superficial injury, open wound, skull/facial fracture, and TBI), and fractures (i.e., spine, rib, 
shoulder and upper arm, elbow and forearm, wrist and hand, pelvis, hip, knee and lower leg, 
or ankle and foot). Activity distributions leading to indoor and outdoor falls were described 




In total data of 5880 fall-related ED visits of persons aged 65 years and older were included in 
this study. The mean age was 80 years with a standard deviation of 8, and the study 
population consisted of 1824 (31%) men and 4056 (69%) women.  
The overall gender and age specific circumstances surrounding a fall are shown in 
table 1. Data concerning dwelling was obtained from 5489 patients. Most patients were 
community-dwelling (n=4734, 86%), with  95% of both men and women aged 65-79 years, 
and 83% of the men and 75% of women aged ≥ 80 years being community-dwelling, the 
remaining were residing in a care facility. Data concerning location of the fall were obtained 
from 4279 patients. Most falls occurred indoors (n=2773, 65%).  
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Table 1. Circumstances surrounding injurious falls stratified by gender and age 
 Total  Men    Women  
  
n = 5880 
65-79y 
n = 1095 
≥ 80y 
n = 729 
Total 
n = 1824 
 65-79y 
n = 1851 
≥ 80y 
n = 2205 
Total 
n = 4056 
Dwelling n = 5489 n = 1065 n = 673 n = 1738  n = 1753 n = 1998 n = 3751 
Community 4734 (86) 1013 (95) 561 (83) 1574 (91)  1663 (95) 1497 (75) 3160 (84) 
Care facility 755 (14) 52 (5) 112 (17) 164 (9)  90 (5) 501 (25) 591 (16) 
Location n = 4279 n = 815 n = 562 n = 1377  n = 1306 n = 1596 n =2902 
Indoor 2773 (65) 428 (53) 390 (69) 818 (59)  673 (52) 1282 (80) 1955 (67) 
Outdoor 1506 (35) 387 (48) 172 (31) 559 (41)  633 (48) 314 (20) 947 (33) 
Activity n = 3871 n = 818 n = 472 n = 1290  n = 1302 n = 1279 n = 2581 
Walking 1898 (49) 314 (38) 232 (49) 546 (42)  690 (53) 662 (52) 1352 (52) 
Sitting & Standing 371 (10) 63 (8) 56 (12) 119 (9)  90 (7) 162 (13) 252 (10) 
Walking up or down stairs 409 (11) 142 (17) 45 (10) 187 (15)  142 (11) 80 (6) 222 (9) 
Lavatory visit 161 (4) 22 (3) 21 (4) 43 (3)  42 (3) 76 (6) 118 (5) 
Sports & Recreation 51 (1) 21 (3) 3 (1) 24 (2)  20 (2) 7 (1) 27 (1) 
Out of bed 107 (3) 15 (2) 18 (4) 33 (3)  19 (2) 55 (4) 74 (3) 
Housekeeping 331 (9) 85 (10) 38 (8) 123 (10)  88 (7) 120 (9) 208 (8) 
Cycling 200 (5) 74 (9) 13 (3) 87 (7)  88 (7) 25 (2) 113 (4) 
Other 343 (9) 82 (10) 46 (10) 128 (10)  123 (9) 92 (7) 215 (8) 
Season n = 5880 n = 1095 n = 729 n = 1824  n = 1851 n = 2205 n = 4056 
Winter 1258 (21) 265 (24) 160 (22) 425 (23)  437 (24) 396 (18) 833 (21) 
Spring 1472 (25) 292 (27) 194 (27) 486 (27)  448 (24) 538 (24) 986 (24) 
Summer 1802 (31) 306 (28) 201 (28) 507 (28)  549 (30) 746 (34) 1295 (32) 
Autumn 1348 (23) 232 (21) 174 (24) 406 (22)  417 (23) 525 (24) 942 (23) 
Data are given as number (percentages).  
 
However, this differed between the age and gender categories; there were higher proportions 
of outdoor falls at ages 65-79 years (48%), and overall 41% of the men fell outdoors. Data 
concerning activity were obtained from 3871 participants. Overall, the most common activity 
at time of the fall was walking (n=1898, 49%). Other common activities were walking up or 
down stairs (n=409, 11%) and sitting / standing (n=371, 10%). Data concerning the season 
during which the fall occurred was obtained from all 5880 patients. Overall most falls 
occurred during summer (n=1802, 31%), 28% of men and 32% of women fell during summer. 
The least amount of falls occurred during autumn (22%) for men, and winter (21%) for 
women. 
Of the ED records with missing data regarding either the location or activity at time of 
the fall, the mean age was 81 years with a standard deviation of 8, and the population 
consisted of 687 (27%) men, and 1822 (73%) women. Furthermore, 1819 (81%) were 
community-dwelling, and 421 (19%) resided in a care-facility. 
The age and gender specific injuries following a fall are shown in table 2. Data 
concerning injury were collected from all 5880 patients. Falls caused superficial injury in 
1951 patients (33%), open wounds in 461 (8%), TBIs in 254 (4%) and fractures in 2700 
(46%) of the population. The most common fracture was a hip fracture (n=883, 15%).  
  
All injurious falls 
The location and activity surrounding a fall requiring an ED visit was obtained from 3371 
records and are shown in figure 1. The overall most common indoor activities were walking 
(n=658, 34%) and walking up or down stairs (n=322, 17%) [Figure 1 A, B]. The overall most 
common outdoor activities were walking (n=946, 66%) and cycling (n=200, 14%) [Figure 1 
C, D]. 
 
Traumatic brain injury  
Overall, 254 falls resulted in a TBI. The location and activity surrounding a fall leading to a 
TBI was obtained from 176 records and are shown in figure 2. Falls resulting in TBIs had a 
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Overall, 254 falls resulted in a TBI. The location and activity surrounding a fall leading to a 
TBI was obtained from 176 records and are shown in figure 2. Falls resulting in TBIs had a 
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similar indoor (n=92, 52%) and outdoor (n=84, 48%) prevalence. The most common indoor 
activities were walking up or down stairs (n=47, 51%) and housekeeping (n=16, 17%) [Figure 
2 A, B]. The most common outdoor activities were walking (n=51, 61%) and cycling (n=8, 
10%) [Figure 2 C, D].  
 
Table 2. Injuries following a fall stratified by gender and age 
 Total  Men    Women  
  
n = 5880 
65-79y 
n = 1095 
≥ 80y 
n = 729 
Total 
n = 1824 
 65-79y 
n = 1851 
≥ 80y 
n = 2205 
Total 
n = 4056 
Superficial injury 1951 (33) 385 (35) 244 (34) 629 (35)  603 (33) 719 (33) 1322 (33) 
Open wound 461 (8) 103 (9) 96 (13) 199 (11)  109 (6) 153 (7) 262 (7) 
Injuries to the head         
SI head 629 (11) 150 (14) 97 (13) 247 (14)  160 (9) 222 (10) 382 (9) 
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Indoor (A, B) and outdoor (C, D) activities leading to a fall requiring an Emergency 
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Activities leading to a fall stratified by the seasons, winter (A), spring (B), summer (C), 
autumn (D), and location (indoor and outdoor). Data are shown in percentages. 
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In this study two-thirds of all falls occurred indoors. However, this differed between the age 
and gender categories, with higher proportions of outdoor falls at ages 65-79 years and among 
men. The overall most common indoor activities leading to injurious falls were walking and 
walking up or down stairs. The overall most common outdoor activities were walking and 
cycling. We found that the indoor activities leading to major injuries, i.e. TBIs and hip 
fractures differed. Walking up or down stairs and housekeeping were the most common 
activities leading to a TBIs whereas walking and sitting / standing were the most common 
activities leading to a hip fracture. Notably, about half of the traumatic brain injuries and hip 
fractures in men and women aged 65-79 years occurred outdoors. The most common outdoor 
activities leading to both injuries were walking and cycling. To our knowledge this is the 
largest study investigating patterns leading to fall-related TBIs and hip fractures in 
community dwelling older adults. 
Falls are the leading cause of TBIs and hip fractures in the elderly population 4,15,17. 
Falls cause 61% of traumatic brain injuries in persons aged 65 years and older in the US 17, 
and recent studies in the US, the Netherlands, and Finland showed an increase in fall-related 
TBIs 15-17. About 30% of people with a hip fracture will die in the following year, and many 
more will experience significant functional loss 2. Furthermore, TBIs and hip fractures 
contribute considerably to healthcare costs 4. Therefore, interventions targeted toward this 
group have the potential to be very (cost-) effective. The two most common indoor activities 
leading to a TBI were walking up or down stairs and housekeeping. Furthermore, about half 
of the hip fractures in men and women aged 65-79 years occurred outdoors, and 
approximately a third of those while cycling. These all suggest high activity levels. Up to 
now, little to no special attention has been paid to outdoor activities such as cycling and 
‘higher level’ activities such as housekeeping. Few have incorporated strategies for falls 
prevention derived from these specific circumstances. Partly, this can be accomplished by 
education of the risk groups. Healthy and highly functional older adults may be unaware that 
their higher activity levels may increase their risk for falling and subsequent injuries 25. 
Another possibility is the elimination of outdoor environmental hazards involving sidewalks, 
curbs, and streets, such as by promptly repairing uneven surfaces, removing debris, and 
painting curbs 26,27. Furthermore, promotion of measures which can reduce the severity of 
injuries following a fall, such as bicycle helmets, should also be considered 28.  
It should be noted that in the Netherlands about 27% of all travel is done by bicycle. 
As a consequence, the data presented is more relevant in countries where cycling is common. 
Other western countries where cycling is a common mode of transportation are, Denmark 
(18% of all travel), Finland (11%), Germany (10%), and Sweden (10%) 29. Whereas in the 
United States and the United Kingdom only 1% of all trips are by bicycle 29.  
In this study, most falls occurred during summer (31%), and the least during winter 
(21%), this differed from other studies 30-32, where most falls occurred during winter, and a 
recent study which showed seasons had no effect on fall rates 33. Possibly more falls occurred 
during summer due to people being more active during the warm summer months compared 
to winter. Furthermore, snow and ice might not have been a major factor as in previous 
studies, due to the relatively mild winters in urban areas of the Netherlands. The most 
common indoor and outdoor activities leading to a fall during the four seasons were similar, 
noteworthy were the rates for walking outdoors during winter (77%), and cycling outdoors 
during summer (22%).  
Various studies have investigated circumstances surrounding falls in older adults 25-
27,34-45. However, these studies investigated falls in general and not falls resulting in major 
injuries. Furthermore, the study population of two of the latest studies consisted of older 










In this study two-thirds of all falls occurred indoors. However, this differed between the age 
and gender categories, with higher proportions of outdoor falls at ages 65-79 years and among 
men. The overall most common indoor activities leading to injurious falls were walking and 
walking up or down stairs. The overall most common outdoor activities were walking and 
cycling. We found that the indoor activities leading to major injuries, i.e. TBIs and hip 
fractures differed. Walking up or down stairs and housekeeping were the most common 
activities leading to a TBIs whereas walking and sitting / standing were the most common 
activities leading to a hip fracture. Notably, about half of the traumatic brain injuries and hip 
fractures in men and women aged 65-79 years occurred outdoors. The most common outdoor 
activities leading to both injuries were walking and cycling. To our knowledge this is the 
largest study investigating patterns leading to fall-related TBIs and hip fractures in 
community dwelling older adults. 
Falls are the leading cause of TBIs and hip fractures in the elderly population 4,15,17. 
Falls cause 61% of traumatic brain injuries in persons aged 65 years and older in the US 17, 
and recent studies in the US, the Netherlands, and Finland showed an increase in fall-related 
TBIs 15-17. About 30% of people with a hip fracture will die in the following year, and many 
more will experience significant functional loss 2. Furthermore, TBIs and hip fractures 
contribute considerably to healthcare costs 4. Therefore, interventions targeted toward this 
group have the potential to be very (cost-) effective. The two most common indoor activities 
leading to a TBI were walking up or down stairs and housekeeping. Furthermore, about half 
of the hip fractures in men and women aged 65-79 years occurred outdoors, and 
approximately a third of those while cycling. These all suggest high activity levels. Up to 
now, little to no special attention has been paid to outdoor activities such as cycling and 
‘higher level’ activities such as housekeeping. Few have incorporated strategies for falls 
prevention derived from these specific circumstances. Partly, this can be accomplished by 
education of the risk groups. Healthy and highly functional older adults may be unaware that 
their higher activity levels may increase their risk for falling and subsequent injuries 25. 
Another possibility is the elimination of outdoor environmental hazards involving sidewalks, 
curbs, and streets, such as by promptly repairing uneven surfaces, removing debris, and 
painting curbs 26,27. Furthermore, promotion of measures which can reduce the severity of 
injuries following a fall, such as bicycle helmets, should also be considered 28.  
It should be noted that in the Netherlands about 27% of all travel is done by bicycle. 
As a consequence, the data presented is more relevant in countries where cycling is common. 
Other western countries where cycling is a common mode of transportation are, Denmark 
(18% of all travel), Finland (11%), Germany (10%), and Sweden (10%) 29. Whereas in the 
United States and the United Kingdom only 1% of all trips are by bicycle 29.  
In this study, most falls occurred during summer (31%), and the least during winter 
(21%), this differed from other studies 30-32, where most falls occurred during winter, and a 
recent study which showed seasons had no effect on fall rates 33. Possibly more falls occurred 
during summer due to people being more active during the warm summer months compared 
to winter. Furthermore, snow and ice might not have been a major factor as in previous 
studies, due to the relatively mild winters in urban areas of the Netherlands. The most 
common indoor and outdoor activities leading to a fall during the four seasons were similar, 
noteworthy were the rates for walking outdoors during winter (77%), and cycling outdoors 
during summer (22%).  
Various studies have investigated circumstances surrounding falls in older adults 25-
27,34-45. However, these studies investigated falls in general and not falls resulting in major 
injuries. Furthermore, the study population of two of the latest studies consisted of older 
Chapter 2.1
46
adults dwelling in care-facilities, an older and frailer population, in which the majority of falls 
occurred indoors 33,44. Two recent studies suggest that different types of fall-risk assessment 
are needed for indoor and outdoor fallers. And propose that, prevention recommendations 
would be more effective if targeted differently for frail, inactive older people at risk for indoor 
falls and relatively active healthy older people at risk for outdoor falls 41,42.  
The following limitations should be acknowledged when interpreting the results of this 
study. First, all data were gathered from ED records, we did not include persons who visited a 
general practitioner or persons who did not seek medical attention after a fall. Therefore, this 
is not a report on circumstances surrounding all falls in older adults. Nevertheless, our 
objective was to investigate falls resulting in injuries, not falls in general. Second, the 
Netherlands has more bicyclists and pedestrians that most Western countries, reducing the 
generalizability. Third, part of the data regarding either the location or the activity at time of 
fall was missing from ED records, which may have introduced bias into the results. Overall, 
the patient characteristics of the missing records differed slightly regarding age, gender and 
dwelling. However, the most significant difference was the hospital where data was gathered, 
possibly due to differences in recordkeeping methods. Furthermore, these results are 
otherwise scarce and remain valuable, especially for the subgroup of older men and women 
with ‘higher level’ activities. Strengths of this study include the study population size, and 
that data was collected from ED records and thus included detailed information concerning 
injuries sustained. 
In conclusion, in the present study we found distinct fall and injury patterns, i.e. where 
and how, leading to TBIs and hip fractures in older men and women. Notably, about half of 
the traumatic brain injuries and hip fractures in men and women aged 65-79 years occurred 
outdoors. This study provides new insights into patterns leading to injurious falls by age, 
gender and injury type, and may guide the targeting of falls prevention at specific activities 
and risk groups, including highly functional older men and women. 
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Vitamin D and physical 
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Background: Vitamin D deficiency is considered a key contributor to impaired physical 
performance. However, many studies demonstrating this relationship were conducted in 
female-only populations, and recent studies investigating men specifically found no 
association. Nevertheless, evidence regarding an underlying gender-specific mechanism is 
lacking.  
Objectives: To investigate whether serum 25-hydroxy vitamin D [25(OH)D] is associated 
with physical performance in both men and women. 
Design: Cross-sectional. 
Setting: Community. 
Participants: 616 older adults who visited the Emergency Department due to a fall. 
Measurements: Physical performance was assessed with the Timed “Up & Go” test, the 
“Five Time Sit to Stand” test, handgrip strength, and the tandem stand test. Multivariate linear 
regression was used to assess the association between physical performance, and (log 
transformed) serum 25 (OH)D concentration, and adjust for potential confounders.  
Results: In men, the serum 25(OH)D concentration was significantly associated with better 
handgrip strength, with a regression coefficient (B) and [95% CI] of 3.86 [2.04; 5.69], faster 
TUG times -2.82 [-4.91; -0.73], and faster FTSS times  -3.39 [-5.67; -1.11]. In women, a 
higher serum 25(OH)D concentration was significantly associated with faster TUG times -
2.68 [-4.87; -0.49].  
Conclusion: In the present study, we found a positive association between vitamin D and 
physical performance in both men and women. Intervention studies are needed which include 
vitamin D deficient, older, community-dwelling men and women, to further investigate the 
effect of vitamin D supplementation in this particular group.  
INTRODUCTION 
 
A decrease in physical performance, such as impaired mobility, reduced muscle strength or 
poor balance, predisposes to falls and related injuries 1-3. Furthermore, it results in loss of 
quality of life 4, threatens functional independence 5-7, and increases the risk of morbidity and 
mortality 8,9. Therefore, identification of modifiable causes of physical impairment can aid in 
the prevention of decline of functional-independence, future falls, associated morbidity, and 
loss of quality of life 10. 
Muscle tissue is an important target tissue of vitamin D 11. Furthermore, vitamin D 
deficiency has been shown to be a key contributor to a decline in physical performance and 
increase in fall incidence 12-19. However, most studies demonstrating the relationship between 
vitamin D levels and physical performance were conducted in female-only populations 12,15-18. 
In addition, recent studies investigating the relationship between serum 25(OH)D levels and 
physical performance in men found no significant associations 20,21. However, these studies 
were conducted in a population of highly functional, younger men with a low prevalence of 
vitamin D deficiency. Furthermore, evidence regarding an underlying gender-specific 
mechanism is lacking.  
Therefore, we assessed whether serum 25(OH)D was associated with physical 
performance in community-dwelling older men and women who visited the emergency 
department (ED) after experiencing a fall. We hypothesized that this association is as strong 
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For this study, baseline data of the IMPROveFALL study were used, a detailed description of 
the methods can be found elsewhere 22. In short, patients meeting the following inclusion 
criteria were eligible for enrolment: aged 65 years or older, visited the ED due to a fall, use of 
one or more fall-risk increasing drugs 22-26; Mini-Mental State Examination (MMSE) score of 
at least 21 out of 30 points 27, ability to walk independently, community dwelling, and 
provision of written informed consent by patient. Enrolment started in October 2008 and was 




A fall was defined as coming to rest unintentionally on the ground or a lower level with or 
without losing consciousness, but not induced by acute medical conditions, e.g. stroke, or 
exogenous factors such as a traffic accident 28. At the baseline assessment, a geriatric 
assessment was performed. Medical history, prescription medication, supplements and 
lifestyle factors (e.g., education, smoking, and alcohol intake) were documented. The number 
of comorbidities was derived from the following chronic comorbidities: any malignancy, 
diabetes mellitus, cardiac disease (i.e. hypertension, myocardial infarction, cardiomyopathy, 
congestive heart failure, arrhythmia, and valve disease), chronic obstructive pulmonary 
disease, stroke, neurological disorders (i.e. Parkinson’s disease, epilepsy, neuropathy, 
myopathy, spinal disc herniation, and multiple sclerosis), peripheral vascular disease, renal 
insufficiency, and arthritis. Collected data were verified with records from the patient’s 
general physician and local pharmacist. Height and weight were measured using standardized 
equipment and procedure. Body mass index (BMI) was calculated as body weight (in 
kilograms) divided by height² (in meters). 
 
Biochemistry 
Non-fasting blood samples were collected at the baseline assessment. Serum 25(OH)D3 levels 
(in nmol/l) were measured using a radio-immuno-assay (DiaSorin, Saluggia (Vercelli) - Italy). 
Intra-assay and inter-assay coefficients of variation were <10%. Serum 25(OH)D groups were 
chosen based on levels of vitamin D deficiency as described in the literature 11,29; i.e. severe 
vitamin D deficiency < 25 nmol/l, moderate vitamin D deficiency 25 – 49.9 nmol/L, and 
sufficient vitamin D levels, of 50-74.9 nmol/L, and ≥ 75 nmol/L. 
 
Physical performance 
Physical performance was assessed with handgrip strength measurements, the Timed “Up & 
Go” (TUG) test, the Five Time Sit to Stand (FTSS) test, and the tandem stand test. Handgrip 
strength 30, was measured in kilograms using a digital strain-gauged dynamometer (Takei 
TKK 5401, Takei Scientific Instruments Co, Ltd., Tokyo, Japan). The participant was asked 
to stand upright with arms hanging beside his or her body. Subsequently, grip strength was 
measured with the left and right hand. In the TUG test 31,32, time was measured while the 
participant stood up from a sitting position, walked three meters along a line, performed a 180 
degree turn, walked back to the chair and sat down, as fast as safely possible. In the FTSS test 
3,31, time was measured while the participant stood up and sat down five consecutive times, as 
fast as safely possible. The participant was not permitted to use their hands or the chair’s arm 
supports during standing up or sitting down. In the tandem stand test, the participant had to 
stand fully independent for 10 seconds with one foot in front of the other. The test was scored 
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All analyses were performed using the Statistical Package of the Social Sciences (SPSS 
version 17.0, Chicago, Ill.). Baseline characteristics were compared using Student t-test 
analyses for continuous variables and chi-square analyses for dichotomous variables. Linear 
regression and binary logistic regression models were constructed to adjust for potential 
confounders. The crude model was solely age-adjusted. Potential confounders that were 
considered for inclusion in the multivariate model besides age, were number of comorbidities, 
degree of urbanization, marital status, level of education, current or past smoker, alcohol units 
p/day, MMSE, and BMI. Confounders that led to a change in the regression coefficient (B) of 
10% or more were retained in the multivariate-adjusted regression model. Participants with 
incomplete or missing performance test measures were excluded from related analyses, 
handgrip strength (n=7), TUG test (n=55), FTSS test (n=95), and the tandem stand test (n=4).  
Missing measures were mostly due to injuries following fall (e.g. upper or lower extremity 
fractures), or pre-existing conditions. Due to a right-skewed distribution, serum 25-(OH)D 
levels were log transformed (natural log) for the regression models. Furthermore, a general 
linear model (GLM) was used to multivariately compare all continuous outcomes, and chi-
square analyses to compare the tandem stand outcomes. All analyses were stratified by 




In total, 616 participants were enrolled in the IMPROveFALL study. Serum 25(OH)D 
concentration was obtained from 600 participants, 230 (38%) men and 370 (62%) women 
respectively. The gender-specific baseline characteristics are shown in Table 1; the mean age 
was 76 years with a standard deviation (SD) of 7. The mean ± SD serum 25(OH)D 
concentration was 59 ± 29 nmol/L.  







Age (years) 76.4 ± 6.7 76.5 ± 7.0 0.820 
Serum 25(OH)D  58.9 ± 30.9 58.7 ± 27.8 0.939 
Mini Mental State Examination score 27.0 ± 2.3 26.9 ± 2.4 0.716 
Body mass index (kg/m2) 27.1 ± 3.9 27.9 ± 4.9 0.027 
Level of education (secondary) 185 (80) 250 (68) <0.001 
Degree of urbanization (urban) 190 (83) 323 (87) 0.142 
Smoking    
                                       Current 28 (12) 40 (11) 0.609 
                                       Past 152 (66) 122 (33) <0.001 
                                       Never  76 (33) 245 (66) <0.001 
Alcohol units p/day   <0.001 
                                       0   92 (40) 212 (57)  
                                       <1 24 (10) 63 (17)  
                                       1-3 66 (29) 78 (21)  
                                       >3 48 (21) 17   (5)  
Vitamin D supplements 14   (6) 61 (17) <0.001 
Number of comorbidities 2.1 ± 1.2 2.1 ± 1.2 0.654 
Number of medications 5.9 ± 2.9 6.5 ± 3.5 0.027 
Number of FRIDs 2.5 ± 1.5 2.7 ± 1.6 0.378 
Data are given as mean values ± standard deviation, or as number (percentages). FRID: fall-
risk increasing drugs. 
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Stratification according to vitamin D status is shown in Table 2. Of the participants, 55 (9%) 
had severe vitamin D deficiency (25(OH)D < 25 nmol/L), 209 participants (35%) had 
moderate vitamin D deficiency (25(OH)D 25-49.9 nmol/L), 172 participants (29%) were 
vitamin D-sufficient and had 25(OH)D levels of 50-74.9 nmol/L, and 164 participants (27%) 
had 25(OH)D levels ≥ 75 nmol/L.  
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Regression models of the physical performance according to log-transformed serum 25(OH)D 
concentration were constructed (Table 3). The results for the men were as follows, in the fully 
adjusted model a higher serum 25(OH)D concentration was significantly associated with 
better handgrip strength, with a regression coefficient (B) and [95% CI] of 3.86 [2.04; 5.69], 
faster TUG times -2.82 [-4.91; -0.73], and faster FTSS times  -3.39 [-5.67; -1.11]. In women, 
a higher serum 25(OH)D concentration was significantly associated with faster TUG times -






25(OH)D      < 25    nmol/L 19  (8)  36 (10) 
25(OH)D 25 – 49.9 nmol/L 83 (36)  126 (34) 
25(OH)D 50 – 74.9 nmol/L 72 (31)  100 (27) 
25(OH)D      ≥ 75    nmol/L 56 (24)  108 (29) 
Table 3. Results of regression analysis of strength and physical performance according to log 
transformed serum 25 (OH)D concentration and gender 
 Model 1  Model 2  
Men (n = 230)     
Handgrip strength (n=228) 4.02  [2.30; 5.75]*** 3.86  [2.04; 5.69]*** 
Timed “Up & Go” (n=211) -3.02  [-5.03; -1.02]** -2.82  [-4.91; -0.73]** 
Five Time Sit to Stand (n=197) -3.11  [-5.27; -0.94]** -3.39  [-5.67; -1.11]** 
Tandem stand (n=230) 0.59 [1.05; 3.11]* 0.55 [0.93; 3.19] 
Women (n = 370)     
Handgrip strength (n=365) 0.80 [-0.13; 1.72] 0.67  [-0.26; 1.61] 
Timed “Up & Go” (n=334) -3.19  [-5.34; -1.04]** -2.68  [-4.87; -0.49]* 
Five Time Sit to Stand (n=308) -2.69  [-4.90; -0.49]* -2.13  [-4.30; 0.04] 
Tandem stand (n=366) 0.15 [0.77; 1.76] 0.04 [0.68; 1.59] 
Data are shown as B with the 95% confidence interval between square brackets. 
Model 1: adjusted for age. Model 2: adjusted for age, number of comorbidities, smoking, 
degree of urbanization, body mass index, and Mini Mental State Examination score. *p < 
0.05; **p < 0.01; ***p < 0.001. 
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A general linear model was used in order to compare the means of the handgrip strength, 
TUG, and FTSS (Figure 1 A, B and C) according to gender and vitamin D group. The 
percentage of completed tandem stands according to vitamin D group in men was 68%, 59%, 
64% and 86% respectively, p = 0.009. The percentage of completed tandem stands according 
to vitamin D group in women was 44%, 61%, 66% and 63% respectively, p = 0.153.  
 
Figure 1. Strength and physical performance according to serum 25 (OH) D group and 
gender 
 
General linear model analysis of the handgrip strength (A), Timed “Up & Go” test (B), and 
Five Time Sit to Stand test (C) with mean ± standard error. Adjusted for age, number of 




As was hypothesized, serum 25(OH)D levels were significantly associated with physical 
performance, not only in community-dwelling older women, but also in men.  
As mentioned in the introduction, there are several studies which have demonstrated 
the relationship between vitamin D and physical performance 15-21,33,34. Although most of 
these were conducted with female-only populations 15-18, some studies including both men 
and women had similar results 12,19,33.This includes a 3-year follow-up study which reported 
poorer physical performance and a greater decline in physical performance in older vitamin D 
deficient men and women 19. However, recent studies investigating men specifically did not 
find an association between vitamin D levels and physical performance 20,21,34. Lack of an 
association in the previously mentioned populations may be due to the target population; 
young, healthy men, and the low prevalence of vitamin D deficiency 20,21,34. Our population 
consisted of older men with a mean age of 76 years, of which a large proportion was vitamin 
D deficient, 44% had 25(OH)D levels <50 nmol/L. Making it a particularly adequate 
population to investigate the relationship between vitamin D and physical performance. 
Furthermore, community-dwelling elderly who have recently experienced a fall are certainly 
part of the target group, which have the greatest need for fall prevention strategies. A recent 
meta-analysis assessing the effects of interventions designed to reduce the incidence of falls 
in older people living in the community observed that only trials recruiting participants with 
lower vitamin D levels at enrolment had a reduction in rate of falls and risk of falling 35.  
The following limitations should be taken into account when interpreting our results. 
First, the cross-sectional design of the study limits the ability to infer a causal relationship 
between serum 25(OH)D levels and physical performance, and does not dismiss the 
possibility of reverse causality. Nevertheless, the comparable population characteristics argue 
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against this, all participants had experienced a recent fall and were community-dwelling 
(similar frailty). Furthermore, similar to previous studies, the analyses were multivariately 
adjusted for a wide range of confounders including comorbidities and BMI (with the 
exception of nutrition and physical activity). Second, serum parathyroid hormone (PTH) 
levels were not determined. Vitamin D deficiency leads to an increase of serum PTH which 
increases bone turnover and bone loss, and is related to a decrease in muscle strength 36. 
Third, the use of the MMSE as an exclusion criterion could have resulted in the exclusion of 
the frailest persons. A major strength of this study is the substantial proportion of the 
participants deficient in vitamin D included in the study, which enabled analysis of the 
physical performance in both vitamin D deficient and sufficient men and women. 
In addition, it was striking to note how few of the older fallers in our study were 
prescribed vitamin D supplements, especially in the male population; though 44% of the men 
and women were deficient in vitamin D, only 6% of the men and 17% of the women used 
vitamin D supplements. The under-prescribing of vitamin D in this age group has previously 
been reported 37. Yet, despite evidence that vitamin D supplementation has been shown to 
increase muscle strength and reduce the risk of falls 38, vitamin D deficiency is still common 
in community-dwelling elderly, with a prevalence of 40-100% in U.S. and European older 
men and women 11. Furthermore, while we set the levels ≥50 nmol/L as vitamin D sufficient, 
another opinion is that optimal vitamin D levels should be ≥75 nmol/L (39). This is 
interesting to note when considering figure 1, where it seems levels closer to 75 nmol/L result 
in continued physical performance benefits, especially in men. 
In conclusion, in the present study higher serum 25(OH)D concentrations were 
associated with better strength and physical performance in community-dwelling older men 
and women. Intervention studies are needed to further investigate the effect of vitamin D 
supplementation in this particular group.  
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Background: Although guidelines concerning falls prevention make a clear distinction 
between single and recurrent fallers, differences in functional status, physical performance 
and quality of life in single and recurrent fallers have not been thoroughly investigated. 
Therefore we investigated the differences in functional status, physical performance and 
health related quality of life (HRQoL) between single and recurrent fallers. 
Methods: From October 2008 to October 2011 616 community-dwelling older adults, who 
visited the Emergency Department due to a fall were enrolled. Physical performance was 
assessed with the Timed “Up & Go” (TUG) test, the “Five Time Sit to Stand” (FTSS) test, 
handgrip strength, and the tandem stand test. Functional status was measured using the 
Activities of Daily Living and Instrumental Activities of Daily Living scales. HRQoL was 
measured using the EQ-5D, and the SF-12 version 2. A general linear model was used to 
compare means of the scores. 
Results: Recurrent falls in community dwelling elderly were associated with poorer physical 
performance as measured with the TUG test (p < 0.001), FTSS test (p = 0.011), handgrip 
strength (p < 0.001), and tandem stand (p < 0.001), and lower HRQoL scores as measured 
with the EQ-5D (p = 0.006) and SF-12 (p = 0.006 and p = 0.012).  
Conclusion: Our findings provide further evidence that recurrent fallers have poorer physical 
performance and quality of life than single fallers. Recurrent falls might be a symptom of 




Falls affect a large proportion of the population aged 65 years and older and are associated 
with consequences such as disability, loss of quality of life, institutionalization 1-3, and high 
morbidity and mortality rates 4,5. In order to reduce the incidence of falls, guidelines on falls 
prevention recommend detailed assessments and a multifactorial intervention for persons with 
a history of recurrent falls 6. Fallers are classified in different ways. A single faller is 
generally defined as someone who has fallen at least once during a defined time period, 
usually 6 or 12 months. A recurrent faller is someone who has fallen twice or more during a 
defined time period 7.  
 Several studies have reported specific differences between single and recurrent fallers, 
using varying outcome measures like sensory and motor function outcomes 8, certain physical 
performance tests 9-11, the Mini-Mental State Examination (MMSE) 12, posturography 13,14, 
and dual-tasking tests 15,16. Most studies compared the prevalence of specific risk factors in 
single and recurrent fallers 17-20. In addition to investigating physical performance and 
functional status, we assessed the health related quality of life (HRQoL). To the best of our 
knowledge, no previous study has investigated quality of life measures in single and recurrent 
fallers. 
Therefore the aim of this descriptive study was to determine physical functioning and 
HRQoL in community-dwelling older men and women who visited the Emergency 
Department (ED) after experiencing a fall 21, and to evaluate if these differed in single and 
recurrent fallers. Validated and commonly used tools of measuring physical performance, 
functional status, and HRQoL were used.  
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For this study, baseline data of the Improving Medication Prescribing to reduce Risk Of 
FALLs (IMPROveFALL) study were used, a detailed description of the methods can be found 
elsewhere 21. In short, patients meeting the following inclusion criteria were eligible for 
enrolment: aged 65 years or older, visited the ED due to a fall, use of one or more fall-risk 
increasing drugs 22, Mini-Mental State Examination (MMSE) score of at least 21 out of 30 
points 23, ability to walk independently, community dwelling, and provision of written 
informed consent by patient. Enrolment was performed in two academic and four regional 
hospitals, started in October 2008 and was completed in October 2011. The local Medical 
Research Ethics Committees at all participating sites approved the study. 
 
Fall history 
A fall was defined as coming to rest unintentionally on the ground or a lower level with or 
without losing consciousness, but not induced by an acute medical condition, e.g., stroke, or 
exogenous factors such as a traffic accident 24. The history of falls was ascertained during an 
interview with the clinical investigator. The number of falls in the 12 months prior to the 
outpatient research clinic visit was used to divide participants into two groups, single and 
recurrent fallers. A single faller was defined as someone who had fallen once in the 12 
months preceding inclusion, a recurrent faller was defined as someone who had fallen twice 
or more in the 12 months preceding inclusion. 
 
Data collection 
At the baseline assessment, a geriatric assessment was performed. Medical history, 
prescription medication, and sociodemographic factors were documented. The number of 
comorbidities was derived from the following chronic comorbidities; any malignancy, 
diabetes mellitus, cardiac disease (i.e. hypertension, myocardial infarction, cardiomyopathy, 
congestive heart failure, arrhythmia, and valve disease), chronic obstructive pulmonary 
disease, stroke, neurological disorders (i.e. Parkinson’s disease, epilepsy, neuropathy, 
myopathy, spinal disc herniation, and multiple sclerosis), peripheral vascular disease, renal 
insufficiency, and arthritis. Collected data were verified with records from the patient’s 
general physician and local pharmacist. Height and weight were measured using standardized 
equipment and procedure. Body mass index (BMI) was calculated as body weight (in 
kilograms) divided by height² (in meters).  
 
Physical performance 
Physical performance was assessed with the Timed “Up & Go” (TUG) test, the Five Time Sit 
to Stand (FTSS) test, handgrip strength, and the tandem stand test. In the TUG test, time was 
measured while the participant stood up from a sitting position, walked three meters along a 
line, performed a 180 degree turn, walked back to the chair, and sat down, as fast as safely 
possible 25,26. In the FTSS test, time was measured while the participant stood up and sat 
down five consecutive times, as fast as safely possible. The participant was not permitted to 
use their hands or the chair’s arm supports during standing up or sitting down 25,27. Handgrip 
strength was measured in kilograms using a digital strain-gauged dynamometer (Takei TKK 
5401, Takei Scientific Instruments Co, Ltd., Tokyo, Japan). The participant was asked to 
stand upright with arms hanging beside his or her body. Subsequently, grip strength was 
measured with the left and right hand 28. In the tandem stand test, the participant had to stand 
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fully independent for 10 seconds with one foot in front of the other. The test was scored as 
completed or failed 25. All tests were performed twice and the best score was recorded. 
 
Functional status 
Functional status was measured using the activities of daily living (ADL) score 29 which 
evaluates independence while bathing, dressing, going to the toilet, continence, getting around 
the house, and feeding. And the instrumental activities of daily living (IADL) score 30 which 
evaluates independence while using the telephone, handling finances, taking medications, 
preparing light meals, housekeeping, shopping, and using transportation outside of home. 
ADL is scored 0-12 points, a higher score indicates greater disability; and IADL is scored 0-
14 points, a higher score also indicates greater disability. 
 
Health related quality of life 
Based on the recommendations of Prevention of Falls Network Europe (ProFaNe), HRQoL 
was measured using the Dutch versions of the EQ-5D utility score, and the Short Form-12 
(SF-12) version 2 31. The EQ-5D questionnaire covers five health domains (i.e., mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression). The EQ-5D is a validated and 
extensively used general health questionnaire to measure quality of life 32. The SF-12 contains 
12 questions and is designed and validated to assess the quality of life in large population 
studies; it consists of eight items measuring physical and mental health outcomes. These items 
are physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional and mental health. Information from these items is used to 
construct the physical and mental component summary measures (PCS and MCS) 33. 
 
Statistical analysis 
Analyses were performed using the Statistical Package of the Social Sciences (SPSS version 
17.0, Chicago, Ill.).Baseline characteristics between single fallers and recurrent fallers were 
compared using Student t-test analyses for continuous variables and Chi-squared analyses for 
dichotomous variables. A general linear model was used to compare means of the TUG, 
FTSS, handgrip strength, ADL, IADL, EQ-5D utility score, SF-12 PCS and SF-12 MCS 
scores. Data were adjusted for age, gender, BMI, MMSE and number of comorbidities. The 
individual domains of the EQ-5D and the tandem stand test were assessed with Chi-squared 
analyses. Participants with incomplete or missing functional status, performance tests or 
HRQoL scores were excluded from related analyses, TUG test (n=57), FTSS test (n=99), 
handgrip strength (n=7), tandem stand test (n=4), and SF-12 (n=4). The missing measures of 
the physical performance tests were mostly due to injuries following fall (e.g. upper or lower 




From October 2008 to October 2011, 616 community-dwelling men and women who visited 
the ED due to a fall were enrolled in the IMPROveFALL study, of which 338 (55%) reported 
no prior falls, and 278 (45%) reported one or more prior falls in the 12 months preceding 
inclusion. The baseline characteristics are shown in table 1. Age, gender, MMSE scores and 
BMI, smoking, alcohol intake and number of comorbidities did not differ between single and 
recurrent fallers.  
The physical performance, functional status and HRQoL outcomes are shown in table 
2. Recurrent fallers scored significantly poorer than the single fallers in all the physical 
performance tests. The mean ADL an IADL scores did not differ significantly between single 
and recurrent fallers. Finally, recurrent fallers scored significantly lower than single fallers in 
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all of the HRQoL measures. Furthermore, the recurrent fallers reported significantly more 
problems than the single fallers, in all five domains of the EQ-5D (table 3). 
 
Table 1. Baseline characteristics according to history of falls 






Age (years) 76.0 ± 6.7 77.0 ± 7.1 0.069 
Gender (female) 199 (59) 182 (66) 0.094 
Mini Mental State Examination score 27.1 ± 2.3 26.8 ± 2.3 0.054 
Body mass index (kg/m2) 27.3 ± 4.5 28.0 ± 4.7 0.072 
Smoking 42 (12) 29 (10) 0.440 
Alcohol (units per day)   0.834 
                                       0   165 (49) 145 (52)  
                                       <1 51 (15) 38 (14)  
                                       1-3 83 (25) 67 (24)  
                                       >3 39 (12) 28 (10)  
Number of comorbidities 2.1 ± 1.1 2.1 ± 1.3 0.410 
Continuous data are shown as mean values ± standard deviation and were analyzed using a 
Student’s t-test. Categorical data are given as number with percentages, and were analyzed 




Table 2. Physical performance, functional status, and health-related quality of life according 
to history of falls 






Physical Performance    
Timed “Up & Go” (seconds) 10.9 ± 0.5 14.2 ± 0.6 < 0.001 
Five Time Sit to Stand (seconds) 17.0 ± 0.6 19.3 ± 0.7 0.011 
Hand Grip strength (kg) 27.2 ± 0.3 25.3 ± 0.4 < 0.001 
Tandem stand (completed) 237 (70) 152 (55) < 0.001 
Functional Status    
ADL scale score 0.8 ± 0.2 0.8 ± 0.2 0.893 
IADL scale score 1.4 ± 0.3 1.4 ± 0.3 0.979 
Health Related Quality of Life    
EQ-5D utility score 0.78 ± 0.01 0.72 ± 0.01 0.006 
SF-12 Physical Component Summary 46.5 ± 0.5 44.4 ± 0.6 0.006 
SF-12 Mental Component Summary 53.9 ± 0.5 51.9 ± 0.6 0.012 
Data was analyzed using general linear models, adjusted for age, gender, body mass index, 
Mini Mental State Examination and the number of comorbidities and given as mean ± 
standard error. ADL, Activities of Daily Living (range: 0-12, a higher number indicates 
higher impairment); IADL, Instrumental Activities of Daily Living (range: 0-14, a higher 
number indicates higher impairment); SF-12, Short-Form 12; EQ-5D, EuroQol 5D 
questionnaire. 
 








all of the HRQoL measures. Furthermore, the recurrent fallers reported significantly more 
problems than the single fallers, in all five domains of the EQ-5D (table 3). 
 
Table 1. Baseline characteristics according to history of falls 






Age (years) 76.0 ± 6.7 77.0 ± 7.1 0.069 
Gender (female) 199 (59) 182 (66) 0.094 
Mini Mental State Examination score 27.1 ± 2.3 26.8 ± 2.3 0.054 
Body mass index (kg/m2) 27.3 ± 4.5 28.0 ± 4.7 0.072 
Smoking 42 (12) 29 (10) 0.440 
Alcohol (units per day)   0.834 
                                       0   165 (49) 145 (52)  
                                       <1 51 (15) 38 (14)  
                                       1-3 83 (25) 67 (24)  
                                       >3 39 (12) 28 (10)  
Number of comorbidities 2.1 ± 1.1 2.1 ± 1.3 0.410 
Continuous data are shown as mean values ± standard deviation and were analyzed using a 
Student’s t-test. Categorical data are given as number with percentages, and were analyzed 




Table 2. Physical performance, functional status, and health-related quality of life according 
to history of falls 






Physical Performance    
Timed “Up & Go” (seconds) 10.9 ± 0.5 14.2 ± 0.6 < 0.001 
Five Time Sit to Stand (seconds) 17.0 ± 0.6 19.3 ± 0.7 0.011 
Hand Grip strength (kg) 27.2 ± 0.3 25.3 ± 0.4 < 0.001 
Tandem stand (completed) 237 (70) 152 (55) < 0.001 
Functional Status    
ADL scale score 0.8 ± 0.2 0.8 ± 0.2 0.893 
IADL scale score 1.4 ± 0.3 1.4 ± 0.3 0.979 
Health Related Quality of Life    
EQ-5D utility score 0.78 ± 0.01 0.72 ± 0.01 0.006 
SF-12 Physical Component Summary 46.5 ± 0.5 44.4 ± 0.6 0.006 
SF-12 Mental Component Summary 53.9 ± 0.5 51.9 ± 0.6 0.012 
Data was analyzed using general linear models, adjusted for age, gender, body mass index, 
Mini Mental State Examination and the number of comorbidities and given as mean ± 
standard error. ADL, Activities of Daily Living (range: 0-12, a higher number indicates 
higher impairment); IADL, Instrumental Activities of Daily Living (range: 0-14, a higher 





Table 3. Prevalence of problems on the five dimensions of the EQ-5D according to history of 
falls 






Mobility  137 (41) 178 (64) < 0.001 
Self-Care 41 (12) 65 (23) < 0.001 
Usual Activities 107 (32) 115 (41) 0.012 
Pain / Discomfort 174 (52) 173 (62) 0.007 
Anxiety / Depression 74 (22) 94 (34) 0.001 




In the present study we found that recurrent fallers had poorer physical performance, and 
lower EQ-5D and SF-12 scores than single fallers. The functional status scores did not differ 
significantly between single and recurrent fallers. 
Participants with a history of recurrent falls performed significantly poorer than single 
fallers at all the physical performance tests, these tests measure mobility, muscle strength and 
balance. In previous literature, 12 seconds has been suggested as a practical cut-off value for 
the TUG test, and has been found useful in detecting mobility impairment in elderly persons 
34. In the current study population recurrent fallers had below normal TUG test scores, and 
were significantly slower than the single fallers who had normal scores. Furthermore, poor 
muscle strength is a known risk factor for falls 35, it predicts disability 36, and mortality 37, and 
is one of the criteria used to define frailty 38.  
The recurrent fallers also reported lower HRQoL scores than the single fallers, 
including significantly lower EQ-5D utility scores and more problems in all the five EQ-5D 
domains. In addition, the recurrent fallers scored below the Dutch population norm for the SF-
12 PCS and MCS, while the single fallers scored above the norm. The Dutch SF-12 PCS and 
MCS population norms for the ≥ 65 age group are 45.2 and 52.9 33. Previous studies have 
reported lower quality of life scores in older fallers, than in older adults without a previous 
fall 3,39. However, in these studies no comparison was made between single and recurrent 
fallers. The scores from the current study demonstrate how dissimilar single and recurrent 
fallers are. It is striking to note that regardless of age, gender, MMSE, BMI, and the number 
of comorbidities being similar in both groups, the measures of mobility, muscle strength, 
balance and quality of life showed significant differences between single and recurrent fallers. 
This suggests that recurrent falls could be a symptom of underlying disease severity and 
frailty 38. Although guidelines concerning falls prevention make a clear distinction between 
single and recurrent fallers 6, these groups have not been thoroughly investigated. Previous 
studies report differences between single and recurrent fallers, with varying study methods. In 
some studies the population consisted of older adults admitted to hospital or aged-care 
facilities 11-13,15,20, generally an older and frailer population than the community dwelling 
older men and women  who participated in the current study. Another study only assessed 
community-dwelling women 8. Furthermore, varying outcome measures were used in the 
previous studies 8-20. In addition to investigating the TUG and FTSS tests, which has been 
done previously 10, we used  physical performance tests. And, as far as we are aware, this is 
the first time, that health related quality of life is assessed. Finally, the current study consisted 
of a large number of recurrent fallers, whereas other studies included relatively low numbers 
of recurrent fallers, the number of recurrent fallers included in the abovementioned studies 
ranged between 18 and 237. 
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done previously 10, we used  physical performance tests. And, as far as we are aware, this is 
the first time, that health related quality of life is assessed. Finally, the current study consisted 
of a large number of recurrent fallers, whereas other studies included relatively low numbers 
of recurrent fallers, the number of recurrent fallers included in the abovementioned studies 
ranged between 18 and 237. 
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The functional status scores did not differ between single and recurrent fallers, despite 
of recurrent fallers having poorer physical performance and lower HRQoL scores. A potential 
explanation for this finding is that the study population consisted of community-dwelling 
older adults. Being able to perform the individual components of ADL and IADL is a 
prerequisite for living independently. Possibly the sensitivity of the ADL and IADL 
questionnaires was not sufficient to detect differences in functional status. 
The following limitations should be acknowledged when interpreting the results of this 
study. First, the cross-sectional design limits the ability to infer a causal relationship between 
poor functional status, physical performance, HRQoL, and recurrent falls. Second, recall bias 
with respect to the history of falls in the 12 months prior to inclusion cannot be ruled out. If 
any, this effect is likely to be small, since usually patients can accurately recall whether they 
have experienced one or more prior falls in the preceding 12 months, and the participants’ 
medical records of the year preceding inclusion were made available to us. Third, the self-
report nature of ADL and IADL scales can be influenced by the interviewer, and the mood 
and personality of the participant. Nevertheless these instruments are validated and are widely 
used by healthcare professionals to determine functional status. Finally, the study population 
only included older men and women who visited the ED after a fall. Thus these results are not 
applicable to the general population. However, this is an important group of fallers, 
representing those with injurious falls. Strengths of this study are the study population size, 
the validated tests used to assess physical performance and that we adhered to current 
recommendations regarding HRQoL outcome measures 31. 
In conclusion, in the present study we found that compared to single falls, a history of 
recurrent falls was associated with poorer physical performance, and lower HRQoL scores in 
older community dwelling men and women.  
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[Cost]effectiveness of withdrawal 
of fall-risk increasing drugs versus 
conservative treatment in older 
fallers: design of a multicenter 







Background: Fall incidents represent an increasing public health problem in aging societies 
worldwide. A major risk factor for falls is the use of fall-risk increasing drugs. The primary 
aim of the study is to compare the effect of a structured medication assessment including the 
withdrawal of fall-risk increasing drugs on the number of new falls versus ‘care as usual’ in 
older adults presenting at the Emergency Department after a fall. 
Methods/Design: A prospective, multi-center, randomized controlled trial will be conducted 
in hospitals in the Netherlands. Persons aged ≥65 years who visit the Emergency Department 
due to a fall are invited to participate in this trial. All patients receive a full geriatric 
assessment at the research outpatient clinic. Patients are randomized between a structured 
medication assessment including withdrawal of fall-risk increasing drugs and ‘care as usual’. 
A 3-monthly falls calendar is used for assessing the number of falls and associated injuries 
over a one-year follow-up period. Measurements will be at three, six, nine, and 12 months and 
include functional outcome, healthcare consumption, socio-demographic characteristics, and 
clinical information. After one year a second visit to the research outpatient clinic will be 
performed, and adherence to new medication regimen in the intervention group will be 
measured. The primary outcome will be the incidence of new falls. Secondary outcome 
measurements are possible health effects of medication withdrawal, health-related quality of 
life (Short Form-12 and EuroQol-5D), costs, and cost-effectiveness of the intervention. Data 
will be analyzed using an intention-to-treat analysis. 
Conclusions: The successful completion of this trial will provide evidence on the 




Falls form one of the most common and serious public health problems in older populations. 
Fall incidents are associated with considerable morbidity and mortality.1, 2 Even a low 
energetic trauma, such as a unintended fall, can lead to major injuries in older adults with 
long-term consequences.3, 4 The incidence of falls and the severity of fall-related 
complications rises steeply beyond the age of 65 years.1-5 Approximately 72,000 older adults 
visit an Emergency Department in the Netherlands each year due to a fall. Hereof, over 
30,000 are hospitalized, and 1,600 elderly die due to a fall per year.6 The large burden of fall-
related healthcare consumption is leading to high healthcare costs in western societies.4, 7, 8 
Over the last decades several risk factors for falls have been identified. Major risk factors 
include one or more previous falls, mobility impairments, high age, and the use of fall-risk 
increasing drugs.9, 10 The majority (73%) of older persons use one or more drugs.11 In 2008, 
nearly half of all drug prescriptions in the Netherlands were delivered to persons aged 65 
years and older who constituted only 15% of the Dutch population in that year.12 Adverse 
Drug Reactions are frequently seen in older adults.13 A meta-analysis of observational studies 
showed an increased fall risk with certain drug groups, i.e., psychotropic14 and cardiovascular 
drugs.15 Approximately three-quarters of the community dwelling elderly used at least one 
prescribed drug, and about a third used at least one fall-risk increasing drug.11 
  There is evidence that withdrawal, reduction, or substitution of fall-risk increasing 
drugs can reduce fall risk in older adults. Only one small, randomized controlled trial on drug 
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Background: Fall incidents represent an increasing public health problem in aging societies 
worldwide. A major risk factor for falls is the use of fall-risk increasing drugs. The primary 
aim of the study is to compare the effect of a structured medication assessment including the 
withdrawal of fall-risk increasing drugs on the number of new falls versus ‘care as usual’ in 
older adults presenting at the Emergency Department after a fall. 
Methods/Design: A prospective, multi-center, randomized controlled trial will be conducted 
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due to a fall are invited to participate in this trial. All patients receive a full geriatric 
assessment at the research outpatient clinic. Patients are randomized between a structured 
medication assessment including withdrawal of fall-risk increasing drugs and ‘care as usual’. 
A 3-monthly falls calendar is used for assessing the number of falls and associated injuries 
over a one-year follow-up period. Measurements will be at three, six, nine, and 12 months and 
include functional outcome, healthcare consumption, socio-demographic characteristics, and 
clinical information. After one year a second visit to the research outpatient clinic will be 
performed, and adherence to new medication regimen in the intervention group will be 
measured. The primary outcome will be the incidence of new falls. Secondary outcome 
measurements are possible health effects of medication withdrawal, health-related quality of 
life (Short Form-12 and EuroQol-5D), costs, and cost-effectiveness of the intervention. Data 
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Falls form one of the most common and serious public health problems in older populations. 
Fall incidents are associated with considerable morbidity and mortality.1, 2 Even a low 
energetic trauma, such as a unintended fall, can lead to major injuries in older adults with 
long-term consequences.3, 4 The incidence of falls and the severity of fall-related 
complications rises steeply beyond the age of 65 years.1-5 Approximately 72,000 older adults 
visit an Emergency Department in the Netherlands each year due to a fall. Hereof, over 
30,000 are hospitalized, and 1,600 elderly die due to a fall per year.6 The large burden of fall-
related healthcare consumption is leading to high healthcare costs in western societies.4, 7, 8 
Over the last decades several risk factors for falls have been identified. Major risk factors 
include one or more previous falls, mobility impairments, high age, and the use of fall-risk 
increasing drugs.9, 10 The majority (73%) of older persons use one or more drugs.11 In 2008, 
nearly half of all drug prescriptions in the Netherlands were delivered to persons aged 65 
years and older who constituted only 15% of the Dutch population in that year.12 Adverse 
Drug Reactions are frequently seen in older adults.13 A meta-analysis of observational studies 
showed an increased fall risk with certain drug groups, i.e., psychotropic14 and cardiovascular 
drugs.15 Approximately three-quarters of the community dwelling elderly used at least one 
prescribed drug, and about a third used at least one fall-risk increasing drug.11 
  There is evidence that withdrawal, reduction, or substitution of fall-risk increasing 
drugs can reduce fall risk in older adults. Only one small, randomized controlled trial on drug 
withdrawal has been performed.16 Campbell et al. found that withdrawal of psychotropic 
medication significantly reduced the risk of falling, but permanent withdrawal proved very 
difficult to achieve. Therefore the authors made recommendations for a larger randomized 
controlled trial (RCT) to study the single effect of drugs assessment and drugs modification 
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on fall risk. A recent prospective cohort study with a two-month follow-up period showed that 
the withdrawal of fall-risk increasing drugs was associated with a reduction in falls.17  
  An increased susceptibility to certain adverse drug reactions may partly be due to 
genetic polymorphisms that alter responses of individual persons to various drugs.[13] A 
possible cause might be the pathway of hepatic drug metabolization by the cytochrome P-450 
family of biotransformation enzymes 18. Consequently, poor, extensive and ultra-rapid 
metabolizers for certain cytochrome pathways and membrane bound transporters can be 
distinguished,19 which influence the pharmacodynamics and pharmacokinetics. The majority 
of fall-risk increasing drugs are metabolized by a small number of enzymes, the major ones 
being CYP450 2D6, 2C9, 2C19 and 3A4/5.20 
  A systematic fall-related drugs assessment combined with medication changes and a 
one-year follow-up assessment among older fallers may contribute to a reduction in the 
incidence of new falls and related consequences.17 At this moment a structured medication 
assessment is not a standard part of the current care of older fallers presenting at the 
Emergency Department. In the Netherlands, the current care of fall-related injuries consists of 
treatment of the consequences of the fall. However, before a systemic fall-related medication 
assessment can be incorporated in the routine work-up of older persons presenting with a fall, 
further evidence is required. The aim of this randomized controlled trial is to compare the 
effect of withdrawal of fall-risk increasing drugs versus ‘care as usual’ on future falls. The 
primary outcome of this study is be the number of new falls. Secondary outcome 
measurements are possible health effects of medication withdrawal, health-related quality of 
life, costs, and cost-effectiveness of the intervention.  
 
METHODS 
The study is designed as a multicenter RCT with a one-year follow-up period in the 
Netherlands. The Medical Ethics review board of the Erasmus MC, University Medical 
Center, approved the study protocol. The study started in October 2008.  
 
Study population 
Patients aged 65 years and over, who visit the Emergency Department of a participating 
hospital due to a fall, are eligible for inclusion. A fall is defined as coming to rest 
unintentionally on the ground or a lower level with or without losing consciousness, but not 
induced by acute medical conditions, e.g. ,stroke, or exogenous factors like a traffic 
accident.21 
Patients meeting the following inclusion criteria are eligible for enrollment:  
1. Aged 65 years or older (no upper age limit)  
2. Attended the Emergency Department due to a fall incident 
3. Taking one or more fall-risk increasing drugs for at least two weeks prior to the fall 
4. Mini-Mental State Examination score of 21/30 points or over 
5. Able to walk independently 
6. Community dwelling 
7. Provision of informed consent by patient 
If any of the following criteria applies, patients will be excluded: 
1. Patient participation in another trial 
2. Fall not meeting criteria of specified definition 
3. Likely problems, in the judgment of the investigators, with maintaining follow-up (e.g., 
patients with no fixed address) 
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unintentionally on the ground or a lower level with or without losing consciousness, but not 
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If any of the following criteria applies, patients will be excluded: 
1. Patient participation in another trial 
2. Fall not meeting criteria of specified definition 
3. Likely problems, in the judgment of the investigators, with maintaining follow-up (e.g., 
patients with no fixed address) 
4. Not willing to complete the research protocol (such as attending for a control visit) 
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Figure 1. Flow chart 
 
Final visit 
Fall-risk profile, EQ-5D, SF-12 
Medical history and drug use  
Tests: timed up-and-go; 5x stand test; tandem stand test; orthostatic hypotension 
Follow-up (1-year): every 3 months falls-calendar and questionnaire 




Systemic drug assessment 
including drug modification 
 




No drug change 
Population 
Emergency Department attendance due to a fall in 
persons ≥65 yr. and the use of ≥1 fall-risk increasing 
drugs 
Research outpatient clinic visit 
1. Verify in- and exclusion criteria 
2. Informed Consent 
3. Fall-risk profile, EQ-5D, SF-12 
4. Medical history and drug use 
5. Comprehensive geriatric assessment 
6. Tests - timed up-and-go 
 - 5x stand test  
- tandem stand test 
- orthostatic hypotension measurement 
7. Routine laboratory blood test & DNA analysis 
8. X-ray or ECG on indication 
 
Randomization 




All persons visiting the Emergency Department due to a fall receive care as usual for their 
injuries. Within two weeks following the Emergency Department attendance, patients are 
contacted by telephone with information about the study. All eligible study participants will 
receive written information about the study and all interested patients will receive an 
appointment for the research outpatient clinic. The appointments take place within two 
months after Emergence Department presentation. If the patient meets all eligibility criteria 
and no exclusion criteria are present at the research outpatient clinic, the patient will be asked 
to sign the Informed Consent Form before the study procedures take place. Patients who do 
not meet the inclusion criteria will be excluded. During the outpatient clinic visit a falls risk 
profile (FRP), falls history, health-related quality of life (HRQoL) and physical performance 
are measured in all patients. Furthermore, a geriatric assessment and a standardized 
medication assessment will take place in all patients. Eligible patients will be randomized to 
one of the treatment arms, the intervention group versus ‘care as usual’. The aim in the 
intervention group will be to reduce fall-risk increasing drugs, and in the ‘care as usual’ group 
no medication change will be made. All included participants receive a Falls Calendar for 
reporting falls during a one-year follow-up period as well as a cost-evaluation form at three, 
six, nine and 12 months after the research outpatient clinic visit. One year after the first visit, 
the study participants are invited for a final visit to the research outpatient clinic in order to 
reassess the falls risk profile, falls history, HRQoL, and physical performance. Adherence to 
their medication is also evaluated. After the first and last visit to the outpatient clinic a brief 
information letter about the study start and completion will be sent to the patient’s General 
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Participants will be allocated to one of two treatment arms using a web-based randomization 
program that will be available 24 hours a day. Variable block randomization will be 
accomplished via a trial website. Allocation will be random. It is not possible to blind the 
geriatrician and patients for the allocation. In order to reduce bias, the patient’s General 




The single intervention will consist of a systematic fall-related medication assessment 
combined with drug withdrawal or modification, if safely possible. Fall-risk increasing drugs, 
as defined in the literature,14, 15, 17, 22 will be stopped, reduced or substituted with potentially 
safer drugs in the intervention group. A complete list of fall-risk increasing drugs is shown in 
Table 2, determined on the basis of the currently available evidence from the literature. 
  For each drug, the clinical investigator will assess whether the initial indication still 
exists. Proposed changes in medication will be discussed with a senior geriatrician and the 
participant's General Practitioner and with the prescribing doctor if other than the General 
Practitioner. If consensus is obtained, fall-risk increasing drugs will be stopped when 
considered redundant, reduced in dose over a one-month period, if safely possible, or 
substituted for potentially safer drugs if necessarily and available. For each drug modification, 
the clinical investigator will follow the standardized instructions of the Dutch National 
Formulary,23 and the clinical pharmacologist will be available for advice when needed. A 
research nurse will offer counseling and evaluate possible negative effects by weekly 
telephone calls over a period of 1 month, and discuss any problems with the clinical 
investigator and the geriatrician (project leader). 
 
Table 2. Drugs classified as fall-risk increasing drugs in the IMPROveFALL study 
Category Drug type 
Central nervous 
system 
anxiolytics/hypnotics (benzodiazepines and others); 
antidepressants (tricyclic antidepressants, selective serotonin 
reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors 
and monoamine oxidase inhibitors), neuroleptics (dopamine D2-
receptor agonists and serotonin dopamine receptor antagonists) 
Cardiovascular Antihypertensives (diuretics, beta-adrenoceptor blockers, alpha-
adrenoceptor blockers, centrally acting antihypertensives, calcium 
channel blockers, angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers); Anti-arrhythmic drugs 
(Antiarrhythmics, nitrates, digoxin, vasodilators) 
Anti-inflammation NSAIDs 
Gastro-Intestinal Antacids (H-2 receptor antagonists) 
Analgesics Opioids 
Pulmonal Sympaticamometica, anti-histaminics 
Diuretics Thiazide, loop diuretics 
 
Outcome measures 
The primary outcome measure will be the incidence of new falls, based on the Falls Calendar. 
Secondary outcome measures will be fall-related injuries, generic health-related HRQoL, 
compliance, quality adjusted life years (QALY), genetic polymorphisms associated with 





Medication use will be assessed by registering the drug names directly from the medication 
boxes. For each drug, both prescription and over-the-counter (OTC), the name, intake 
frequency, dosage, start and stop dates, and whether the drug has been prescribed after the fall 
will be registered. The information will be verified and compared with data retrieved from the 
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Quality of life 
 The level of independency of the activity of daily living (ADL) will be examined using the 
Barthel Index (ranging from zero for full independency to 20 for full dependency).24 Quality 
of life will be measured using the Dutch version of the SF-12 and EQ-5D (EuroQol) 
questionnaire. The EQ-5D has been designed by the Euro-HRQoL Group to assess the 
experienced general quality of life in large populations in order to provide a simple, generic 
measure of health for clinical and economic appraisal.25 The EQ-5D questionnaire covers five 
health domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) 
and a Visual Analogue Scale (VAS) to record the current experienced health status. The 
EuroQol (EQ-5D) is a validated and extensively used general health questionnaire to measure 
quality of life.26, 27 It is recommended for the assessment of HRQoL in trauma patients, 
especially for economic assessments.28 The SF-12 contains 12 questions and has been 
designed and validated to assess the quality of life in large population studies 29, 30. Fall-risk 
will be assessed using a validated FRP.31 The FRP contains five questions, two measurements 
(handgrip strength and body weight), and two interacting items. Hand grip strength will be 
measured using a digital strain-gauged dynamometer (Takei TKK 5401, Takei Scientific 
Instruments Co, Ltd., Tokyo, Japan). Body weight will be measured with a calibrated beam 
scale. For each item points are scored and summed (range 0-30), where zero represents a low 
risk of recurrent falling and 11 and over indicates a high risk of recurrent falling (2 or more 
falls in the next 12 months).31 
 
Physical performance 
In order to assess the physical activity, three tests will be conducted. First, the chair stand test, 
which is a standardized test in which the participant stands up and sits down five constitutive 
times. The patient is not allowed to use the chair’s arms supports during standing or sitting.32 
The Timed Up-and-Go test (TUG-test), in which the participant has to stand up from sitting 
position and walks three meters along a line, perform a 180 degree turn and walk back to the 
chair and sit down will be conducted.32 A tandem stand test will be used in order to assess 
balance. The test will be performed in standing position, in which the patient has to stand 
fully independently for 10 seconds with both feet in front of each other, and is scored as 
correct or failed. All three mobility tests are conducted twice, and the best time (where 
appropriate) will be used.  
  Orthostatic hypotension will be measured by using a calibrated sphygmomanometer, 
in supine position followed by five minutes standing straight up. The blood pressure will be 
measured in supine position, one, two, three, four, and five minutes standing. The blood 
pressure is registered in millimetres of mercury (mmHg), heart rate in beats per minute. 
Orthostatic hypotension is defined as a decrease of 20 mmHg systolic, of 10 mmHg diastolic 
in standing position.33 
 
Costs 
The total direct and indirect costs of both fall-risk increasing drugs withdrawal and ‘care as 
usual’ will be measured. All analysis will be performed in accordance with Dutch guidelines 
for economic evaluations.34  Direct healthcare costs include the additional costs of the 
systematic fall-related drugs assessment and modification, drug consumption (including the 
costs for substitution drugs), and fall-related and non-fall-related healthcare consumption 
during one year of follow-up (e.g., General Practitioner, outpatient visits, and hospital 
admissions).  
Real medical costs were calculated by multiplying the volumes of health care use with the 
corresponding unit prices. For the intervention (systematic fall-related drugs assessment) the 
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admissions).  
Real medical costs were calculated by multiplying the volumes of health care use with the 
corresponding unit prices. For the intervention (systematic fall-related drugs assessment) the 
full cost price will be calculated and for the other health care costs standard cost prices will be 
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used as published by Oostenbrink.34 The full cost price of patient identification at the 
Emergency Department and the systematic fall-related drugs assessment will be determined 
based upon time measurements and employment of personnel. Costs of medication use will be 
recorded in the study, and unit costs will be determined with information from the National 
Dutch Formulary.23  
Healthcare consumption, both fall and non-fall related, and patient costs will be recorded 
from the Hospital Information System for hospital care, and three-monthly written 
questionnaires for other healthcare and patient costs. These will be supplemented with data on 
healthcare costs of injury from previous research.7 The number of injuries prevented will be 
calculated with data recorded in the study, supplemented with epidemiological data on falls 
and injury risks.  
Cost-effectiveness was assessed by calculating the incremental cost-effectiveness ratio, 
defined here as the difference in average costs between medication assessment including 
withdrawal of fall-risk increasing drugs and ‘care as usual’ and by the difference in prevented 
fall-related injury. Secondary, a cost-utility analysis will be performed, i.e., as cost per 
Quality Adjusted Life Years (QALY). Policy makers and health economists have proposed 
that costs varying from €25,000 up to €75,000 per QALY may be considered as acceptable.35, 
36. The QALY combines mortality and morbidity into a single number. The morbidity 
component is referred to as health-related HRQoL and is based on a descriptive health-state 
measure. Because of a long track record in health economic analyses, the EQ-5D measure will 
be used for this purpose.26 Furthermore, the lifetime health effects (cardiovascular events such 
as myocardial infarction, stroke, and mortality) due to possible increased cardiovascular risks 
(i.e., cardiac failure, rebound hypertension) will be calculated with existing models for 
cardiovascular disease risk management. In accordance with guidelines for differential 
discounting, effects will be discounted at a rate of 1.5% and costs at 4% per year.37  
  Full blood for DNA isolation will be drawn during the first visit (5 mL). The blood 
will be stored by -80 degrees Celsius, until DNA-isolation will take place. After DNA 
isolation, polymorphisms will be analyzed using the TaqMan allelic discrimination assays on 
the ABI Prism 9700 HT sequence detection system. 
 
Follow-up 
Patients will be followed for one year. After the first visit to the research outpatient clinic 
patients receive a Falls Calendar.31 During a one-year follow-up period, the participant will be 
asked to record every week whether they experienced a fall that week. The 3-monthly 
calendar sheet will be returned once per 3-months by mail. Cost-effectiveness will be 
measured using a cost-evaluation questionnaire. Participant can register the number of visits 
to physicians, therapists, day care centers, hospitalizations, adaptations of the living area, and 
the current living location (e.g., home or nursing home). The cost-evaluation questionnaire 
will be returned with the falls calendar at three, six, nine, and 12 months after the first visit to 
the research outpatient clinic. In case no calendar sheet or questionnaire is received, or when 
it is completed incorrectly, the calendar sheet or questionnaire will be completed by 
telephone. 
During the last visit to the outpatient clinic, one year after the first visit, all physical 
performance tests are conducted, as well as questionnaires regarding medical history, drug 
use, quality of life, and fall risk profile. Adherence to the drug-use recommendations 
(complete withdrawal, lowering of dosage, or substitution) will be evaluated by reassessment 
of drug use as described above. Information of the participants regarding medical history and 
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Telephone call X      
Information package X      
Informed Consent  X     
Randomization  X     
Baseline data  X     
EQ-5D  X    X 
SF-12  X    X 
FRP  X    X 
Orthostatic hypotension test  X    X 
Complications   X X X X 
Falls calendar   X X X X 
Healthcare consumption   X X X X 
ADL  X    X 
Physical functioning (VAS)  X    X 
 EQ-5D, EuroQol 5-D questionnaire; SF-12, Short Form-12; FRP, Fall Risk Profile; ADL, 
Activities of Daily living; VAS, Visual Analogue Scale. 
 
Sample size calculation 
A total number of 620 patients will be included in the study, 310 in the control group and 310 
in the intervention group. Calculation of the required sample size is based on the assumption 
that the annual cumulative incidence of further falling is 50% without intervention,38 a 15% 
drop-out (including death), drug withdrawal being possible in 50% of the participants in the 
intervention group and a 50% decrease of further falls among participants with successful 
withdrawal. A single-sided test with an alpha level of 0.05 and a beta of 0.2 indicates that 310 
patients in both groups is sufficient in order to detect a 25% decrease of respondents reporting 
further falls in the intervention group. 
 
Statistical analysis 
Data will be primarily analyzed according to the intention-to-treat principle. Patients with 
protocol violations will be followed up, and data will be recorded. Data will be analyzed with 
and without inclusion of patients with protocol violation. At baseline, differences in baseline 
characteristics will be compared between the intervention and control group in order to assess 
comparability between the two groups. Student’s T-test (parametric numeric data), Mann-
Whitney U-test (nonparametric numeric data) or Chi-square test (categorical data). Data will 
be presented as mean ± SD (parametric data) or medians and percentiles (non-parametric 
data). 
  The hazard ratio for falling will be calculated using a Cox-regression model. Herein, 
the time between the intervention (i.e., drug assessment/change or not) and the first and/or 
second fall will serve as the primary outcome measure. Fallers will be defined as those who 
will fall once or more during the one-year follow-up. Differences in cumulative incidence of 
falls will be analyzed using log-linear or Poisson regression, adjusted for over dispersion 
because of interdependence among the dependent variable (falls). Differences in adverse 
health effects between both trial arms will be assessed using Chi2 testing. Several subgroups 
will be distinguished in order to examine whether the effect of the intervention depends upon 
sex, age, race and risk of future falls. Since healthcare costs per patient are typically highly 
skewed, non-parametric techniques will be used to derive a 95% confidence interval for the 
differences in distributions of the costs. In a sensitivity analysis the impact on cost-
effectiveness of statistical uncertainty on the main study outcomes will be determined (uni- 
and multi-variable).  
The association between polymorphisms and falls history will be evaluated using a 
multivariate logistic regression analysis. A p-value of <0.05 will be used as threshold for 
statistical significance.  
 
Ethical considerations 
The study will be conducted according to the principles of the Declaration of Helsinki (59th 
World Medical Association General Assembly, Seoul, October 2008) and in accordance with 
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board of the Erasmus MC acts as central ethics committee for this trial (reference number 
MEC-2008-254; NTR1593). In addition approval has been obtained from the local Medical 
Ethics review boards in all participating hospitals. An information letter notifying the 
patients’ participation and severe abnormal findings will be sent to their general practitioners, 
unless a patient does not agree with this. 
  Liability insurance has been obtained, which is in accordance with the legal 
requirements in the Netherlands (Article 7 WMO and the Measure regarding Compulsory 
Insurance for Clinical Research in Humans of 23th 2003). This insurance provides cover in 




The strength of this study is that a single intervention, the withdrawal of fall-risk increasing 
drugs, will be studied versus ‘usual care’ using a randomized controlled approach. The study 
results will provide valuable knowledge for clinicians and healthcare policymakers on the 
necessity of withdrawal of fall-risk increasing drugs in falls prevention strategies in the older 
population. If proven effective and cost-effective, fall-risk increasing drugs withdrawal in 
persons with a high risk of recurrent falling, might lower the risk of future falls and 
consequently contribute to reductions in fall-related injuries, related healthcare consumption, 
and costs. As far as we are aware, up till now no large RCT’s have been published reporting 
the effects of withdrawal, dose reduction or substitution of fall-risk increasing drugs after a 
fall. The inclusion of patients started October 2008 and is expected to be complete by July 
2011. Because of the one-year follow-up period, presentation of data can be expected in the 
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Importance: Fall incidents represent a public health problem in aging societies worldwide. A 
major risk factor for falls is the use of fall-risk increasing drugs (FRIDs).  
Objectives: To investigate the effect of withdrawal of FRIDs versus ‘care as usual’ on 
reducing falls in community-dwelling older men and women. 
Design: Randomized multicenter trial. 
Setting: Community, Primary care, Geriatric care. 
Participants: 612 older adults who visited an Emergency Department because of a fall. 
Interventions: A structured medication assessment including withdrawal of FRIDs. 
Main Outcomes and Measures: A 3-monthly falls calendar was used for assessing the 
number of falls and associated injuries during 12 months of follow-up. Primary outcome was 
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(secondary) analysis. Both overall FRID withdrawal as well as major subgroups (psychotropic 
and cardiovascular drugs) were assessed. The hazard ratios for time-to-fall were calculated 
using a Cox-regression model. Differences in cumulative incidence of falls were analysed 
using Poisson regression. 
Results: During the 12 months follow-up, 91 (34%) of the control participants and 115 (37%) 
of the intervention participants experienced a fall. FRIDs withdrawal did not have a 
significant effect on the time to the first fall (hazard ratio [HR] 1.17; 95% confidence interval 
[CI] 0.89-1.54), the time to the second fall (1.19; 0.78-1.82), the time to the first general 
practitioner consultation because of a fall (0.66; 0.42-1.06), or the time to the first Emergency 
Department visit because of a fall (0.85; 0.43-1.68). Cardiovascular FRID withdrawal 
increased the time to the first general practitioner consultation because of a fall (0.57; 0.34-
0.93). Per-protocol analyses did not alter the results. 
Conclusions and Relevance: The risk of falls did not differ between the usual care and 
intervention groups. There was a tendency towards fewer healthcare visits in the intervention 
group, and this was significant in the cardiovascular-drugs withdrawal subgroup. 
Surprisingly, no effect of psychotropic drug withdrawal was seen.  
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Falls affect a large proportion of persons aged 65 years and older 1, and are associated with 
negative consequences such as high morbidity and mortality rates 2-4, disability, loss of 
quality of life, and institutionalization 5-8. Furthermore, fall-related injuries place a substantial 
burden on healthcare systems due to the large number of visits to Emergency Departments 
(ED), hospital admissions, and admissions to long-term care and rehabilitation facilities 6,9-12. 
In order to reduce the prevalence of falls, risk factors have been identified and documented 13-
15, and  a substantial number of falls-prevention trials has been published 1,16,17.   
The use of certain drugs, i.e. the so-called fall-risk increasing drugs (FRIDs) 18-21, 
mainly psychotropic and cardiovascular drugs, has been associated with increased risk of falls 
and related injuries 18,19,21,22, and withdrawal of FRIDs appears to be feasible and effective 
20,23-25. Although FRIDs withdrawal is frequently incorporated in multifactorial intervention 
trials, evidence regarding overall FRID withdrawal as a single intervention is scarce 17.  
In the present study, we investigated the effect of a structured medication assessment 
including withdrawal of FRIDs versus ‘care as usual’ on reducing falls in community-





The IMPROveFALL study is a randomized, multicenter trial, assessing the effect of a 
structured medication assessment including withdrawal of FRIDs versus ‘care as usual’ as a 
method for falls reduction 26. Patients meeting the following inclusion criteria were eligible 
for enrolment: aged 65 years or older, visited the ED of a participating hospital because of a 
fall, use of one or more fall-risk increasing drugs 18,19,21,26 (Table 1), Mini-Mental State 
Examination (MMSE) score of at least 21 out of 30 points 27,28, ability to walk independently, 
and community dwelling. Participating hospitals included two academic and four regional 
hospitals in the Netherlands. Enrolment started in October 2008 and was completed in 
October 2011. The follow-up period was 12 months. The study was performed in accordance 
with the Declaration of Helsinki and all participants gave written informed consent. The local 




All persons visiting the ED because of a fall received care as usual for their injuries. 
Following the ED visit, patients were contacted by telephone. Subsequently, eligible and 
interested potential study participants received an appointment for the research outpatient 
clinic (OPC). The visits to the research OPC took place within two months after the fall-
related ED visit. If the patient met all eligibility criteria, the patient was asked to sign the 
Informed Consent Form. During the visit to the research OPC a fall-related assessment was 
performed by the clinical investigator. This included a falls history (a single faller was 
defined as someone who had fallen once in the 12 months preceding inclusion, a recurrent 
faller was defined as someone who had fallen twice or more in the 12 months preceding 
inclusion), a fall-risk questionnaire 29, medical history and physical examination, physical 
performance tests, and a blood sample. The blood sample was used for measuring 25-
hydroxyvitamin D levels, and to screen for hematologic, electrolyte, and liver and kidney 
function abnormalities. During the baseline assessment and at the follow-up research OPC 
visit, participants completed questionnaires on generic Health Related Quality of Life 
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visit, participants completed questionnaires on generic Health Related Quality of Life 
(HRQoL). HRQoL was measured using the Dutch versions of the EuroQol five dimensions 30, 
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and the Short Form-12 version 2 31, at baseline and at 12 months-follow-up. A detailed 
description of the study protocol can be found elsewhere 26. 
 
Randomization 
Participants were randomized to one of the treatment arms, the intervention group versus 
‘care as usual’, using a web-based variable block randomization program that was available 
24 hours a day. Randomization using the trial website was done by the research physician. A 
block randomization with a block size of 4 was used. Due to the nature of the intervention, 
participants, research physicians, and care-givers could not be blinded to group assignment. 
 
Intervention 
All participants received a structured medication assessment, which included withdrawal of 
FRIDs in the intervention group only. In the ‘care as usual’ group, the medication was not 
changed. The intervention consisted of a systematic FRIDs assessment combined with drug 
withdrawal or modification, when safely possible. FRIDs, as defined in the literature 18-21,26, 
were discontinued, reduced or substituted with potentially safer drugs in the intervention 
group. A complete list of FRIDs, based on current literature, is shown in Table 1. For each 
drug, the clinical investigator assessed whether the initial indication still existed. Proposed 
changes in medication were discussed with a senior geriatrician, and if necessary with the 
prescribing physician. The participant’s General Practitioner (GP), and the prescribing 
physician if other than the GP were informed of any changes. For each drug modification, the 
clinical investigator followed the standardized instructions of the Dutch National Formulary 
32, and a clinical pharmacologist was available for advice when needed. A research nurse 
offered counselling, evaluated possible negative effects via a standardized telephone follow-
up, and discussed any problems regarding the drug modification with the clinical investigator 
and geriatrician. 
All participants with follow-up were included in the intention-to-treat analyses. 
Regarding the per protocol analyses, the intervention group included both participants in 
whom FRID withdrawal/substitution was successful  and participants in whom FRID 
withdrawal was not necessary or safely possible. In the event of more than one attempted 
FRID withdrawal, the successful withdrawal/substitution of at least one FRID was considered 
successful. The control group only included the participants in the “care as usual” group in 
whom we did not withdraw/substitute FRIDs during the first research OPC visit. 
 
Definition fall incident 
A fall was defined as coming to rest unintentionally on the ground or a lower level with or 
without losing consciousness, but not induced by acute medical conditions, e.g., stroke, or 
exogenous factors such as a traffic accident 33. The history of falls was ascertained during a 
structured interview with the use of a falls questionnaire 29.  
All participants received a Falls Calendar for reporting falls during a one-year follow-
up period. Falls were recorded weekly on the Falls Calendars and had to be returned every 
three months. Follow-up started two weeks after completed intervention or two weeks after 
initial research OPC visit when no intervention was performed. 
 
Laboratory values 
Non-fasting blood samples were collected at the baseline assessment. Vitamin D deficiency 
was defined as serum 25(OH)D < 50 nmol/l 34,35. Anemia was defined as hemoglobin levels < 
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Statistical analyses  
All analyses were performed using the Statistical Package of the Social Sciences (SPSS 
version 17.0, Chicago, Ill.). A p-value of < 0.05 was used as threshold for statistical 
significance.  
After sample size calculations, our aim was to include a total number of 620 
participants in the study, 310 in the control group and 310 in the intervention group 26. 
Calculation of the required sample size was based on the assumption that the annual 
cumulative incidence of further falling is 50% without intervention 36, a 15% drop-out rate 
(including death) 1, drug withdrawal being possible in 50% of the participants in the 
intervention group and a 50% decrease of further falls among participants with successful 
withdrawal 24. A single-sided test with an alpha level of 0.05 and a beta of 0.2 indicated that 
310 patients in each group would be sufficient in order to detect a 25% decrease of 
participants reporting further falls in the intervention group 26. 
Data were analyzed according to the intention-to-treat principle (primary), and per-
protocol (secondary). The per-protocol analysis only included participants without a protocol 
violation as mentioned above. The hazard ratios for falling were calculated using a Cox-
regression model. Herein, the time between the start of follow-up and the first fall served as 
the primary outcome measure. The time between the start of follow-up and the second fall, 
first GP consultation and first ED visit because of a fall were also analyzed. Differences in 
cumulative incidence of falls, GP consultations and ED visit were analyzed using Poisson 
regression, adjusted for overdispersion because of interdependence among the dependent 
variable (falls). Subgroup analyses were performed, assessing the separate effect of 
cardiovascular and psychotropic drug withdrawal.  
Predefined models were constructed in order to adjust for age, gender and potential 
confounders. Potential predefined confounders that were considered for inclusion in the 
multivariate model were MMSE, BMI, the Charlson Comorbidity index, vitamin D 
deficiency, anemia HRQoL, physical performance, number of drugs, the number of FRIDs, 
smoking, alcohol intake, history of recurrent falls, use of walking aid, urinary incontinence, 
vision problems, fear of falling, and dizziness. Confounders that led to a change in the 




Figure 1. Flowchart of study participants 
 
*Of the participants that died during follow-up, most were included in the analyses, except for 
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In total, 7,081 ED visits were screened for possible trial participants, of which 3,294 were not 
eligible, and 1,954 refused to participate. Subsequently, 612 participants were randomized in 
the IMPROveFALL study (Figure 1). Randomization resulted in 293 participants being 
allocated to the control group and 319 participants to the intervention group (Figure 1). For 
the intention-to-treat analyses, 21 participants in the control group and 11 participants in the 
intervention group were excluded due to withdrawal from study or death. For the per protocol  
analyses, 9 participants in the control group and 66 participants in the intervention group were 
excluded due to protocol violations (Figure 1).  
The mean age was 76 years, and 62% of the study population was female. No obvious 
differences in baseline characteristics were noted between the intervention and control group 
(Table 2). The mean number of drugs and FRIDs used at baseline were six ± three and four ± 
two, respectively. Table 3 specifies the interventions according to FRID categories and 
specific drug types, and also includes details on compliance to attempted interventions. 
Notably, in 40% of all FRIDs, 62% of cardiovascular FRIDs, 32% of psychotropic FRIDs, 
and 78% of other FRIDs, an intervention was not deemed possible or necessary. Of all 
attempted interventions 35% failed (37% of cardiovascular FRID interventions,48% of 
psychotropic FRID interventions, and 31% of other FRID interventions), either due to non-
compliance or a return of the primary reason for which the drug was prescribed.  
The percentage of participants using ≥ 3 FRIDs at baseline was 72% in the control 
group and 70% in the intervention group,  these percentages did not decrease after 1 year 
follow-up, 75% and 70% respectively. Furthermore, in the intervention group 66 participants 
(22%) used a higher number of FRIDs after 12 months of follow-up than they used at 
baseline, compared to 68 (25%) in the control group (Supplementary data).  
 
Table 1. Fall-risk increasing drugs  
Drug category Drug type Therapeutic subgroups ATC code 
Psychotropic  Analgesics  Opioids N02A 




 Anti-Parkinson Dopaminergics, anticholenergics N04 
 Neuroleptics Dopamine D2-receptor agonists 
and serotonin dopamine receptor 
antagonists      
N05A 
 Anxiolytics & 
Sedative/Hypnotics  
Benzodiazepines and others N05B 
N05C 
Antidepressants Tricyclic antidepressants, 
selective serotonin reuptake 
inhibitors, serotonin-
norepinephrine reuptake 
inhibitors and monoamine 
oxidase inhibitors 
N06 
Other Anti-vertigo agents N07CA 
Cardiovascular  Cardiac therapy Digitalis, anti-arrhythmics, 
nitrates 
C01 
Anti-hypertensives Alpha-adrenoceptor blockers, 
centrally acting antihypertensives 
C02 
Diuretics Thiazide diuretics, loop diuretics C03 







HMG CoA reductase 
inhibitors 
 C10AA 
Other drugs Gastro-Intestinal Anticholenergics A03AA 
  Hypoglycemics A10 
 Urogenital system α –blockers, spasmolytics G04BD 
G04CA 
 Anti-inflammatory Steroids  H02AB, R01AD 




  Anti-gout  M04 
Muscle relaxant Hydroquinine M09AA 




*According to study protocol 26. ATC, Anatomical Therapeutic Chemical.   
 
The number of participants in the control group (n=91; 34%) and intervention group (n=115; 
37%) experiencing a fall during the one-year follow-up did not differ significantly (p = 0.33). 
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The number of participants in the control group (n=91; 34%) and intervention group (n=115; 
37%) experiencing a fall during the one-year follow-up did not differ significantly (p = 0.33). 
Similarly, the number of participants in the control group (n=38; 14%) and intervention group 
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(n=50; 16%) experiencing a recurrent fall during the one-year follow-up did not differ 
significantly (p = 0.45). 
 
Table 2. Baseline characteristics 
 Control 
n = 293 
Intervention 
n = 319 
Demographics   
Age (year) 76.4 ± 6.6 76.5 ± 7.2 
Gender (female) 182 (62) 198 (62) 
MMSE 27.0 ± 2.4 27.0 ± 2.3 
BMI (m2/kg) 27.6 ± 4.7 27.6 ± 4.6 
Home care 69 (24) 82 (26) 
Fall risk factors   
Charlson Comorbidity Index 1.9 ± 1.6 1.9 ± 1.6 
Number of drugs 6.4 ± 3.3 6.3 ± 3.3 
Number of FRIDs 3.9 ± 2.0 3.9 ± 2.1 
History of recurrent falls 128 (44) 148 (46) 
Use of walking aid  72 (27) 78 (27) 
Urinary incontinence 37 (13) 52 (16) 
Vision problems 85 (30) 98 (32) 
Nycturia 177 (60) 181 (57) 
Fear of falling 104 (36) 118 (37) 
Dizziness 75 (26) 102 (32) 
Indoor fall 107 (37) 148 (46) 
Smoking 37 (13) 34 (11) 
Alcohol intake (≥ 3 units/day) 33 (11) 34 (11) 
Functional status   
Activities of Daily Living 0.80 ± 4.5 0.80 ± 3.3 
Instrumental Activities of Daily Living 1.39 ± 5.4 1.37 ± 4.0 
Biochemical   
Vitamin D deficiency  119 (41) 135 (42) 
Anemia 34 (13) 58 (19) 
Continuous data are shown as mean values ± standard deviation, categorical data as number 
with percentage. MMSE, Mini-Mental State Examination; BMI, Body Mass Index; FRID, 
Fall-Risk Increasing Drugs. 
 
Furthermore, the number of fallers requiring a GP consultation (n=46; 17% vs. 36; 12%, 
p=0.07) or ED visit (n=21; 8% vs. 16; 5%, p=0.22) did not differ significantly. The mean 
number of falls during follow-up in the control group was 0.83 and the mean number of falls 
in the intervention group was 0.80 (p = 0.88). The mean number of GP consultations because 
of a fall in the control and intervention group were 0.21 and 0.16 respectively, p=0.25. The 
mean number of ED visits because of a fall in the control and intervention group were 0.08 
and 0.06 respectively, p=0.51. 
In the intention-to-treat analysis, cox-regression analyses adjusted for age and gender 
showed that FRIDs withdrawal had no significant effect on the time to first fall (hazard ratio 
[HR] 1.17; 95% confidence interval [CI] 0.89-1.54), or on the time to the second fall (1.19; 
0.78-1.82) (Table 4). Similarly, no significant effect on the time to the first GP consultation 
because of a fall (0.66; 0.42-1.06) or the time to the first ED visit because of a fall (0.85; 0.43-
1.68) was found (Table 4). Subgroup analyses of cardiovascular and psychotropic FRIDs 
withdrawal were similar, except for an increased time until the first GP consultation because 
of a fall for cardiovascular FRIDs withdrawal (0.57; 0.34-0.93). The per protocol analyses did 
not alter the results. 
Poisson regression analyses showed FRIDs withdrawal did not have a significant 
effect on the cumulative incidence of falls (β -0.05; 95% confidence interval [CI] -0.52-  
0.42), or on the cumulative incidence of GP consultations (-0.28; -0.75- 0.18) or ED visits (-
0.22; -0.88- 0.44) because of a fall. Subgroup analyses of cardiovascular and psychotropic 
FRIDs withdrawal were again similar, and per protocol analyses did not alter these results 
(Supplementary data). 
During the 12-months follow-up, 28 participants in the control group and 27 
participants in the intervention group sustained an injurious fall (p = 0.64). Seven participants 









(n=50; 16%) experiencing a recurrent fall during the one-year follow-up did not differ 
significantly (p = 0.45). 
 
Table 2. Baseline characteristics 
 Control 
n = 293 
Intervention 
n = 319 
Demographics   
Age (year) 76.4 ± 6.6 76.5 ± 7.2 
Gender (female) 182 (62) 198 (62) 
MMSE 27.0 ± 2.4 27.0 ± 2.3 
BMI (m2/kg) 27.6 ± 4.7 27.6 ± 4.6 
Home care 69 (24) 82 (26) 
Fall risk factors   
Charlson Comorbidity Index 1.9 ± 1.6 1.9 ± 1.6 
Number of drugs 6.4 ± 3.3 6.3 ± 3.3 
Number of FRIDs 3.9 ± 2.0 3.9 ± 2.1 
History of recurrent falls 128 (44) 148 (46) 
Use of walking aid  72 (27) 78 (27) 
Urinary incontinence 37 (13) 52 (16) 
Vision problems 85 (30) 98 (32) 
Nycturia 177 (60) 181 (57) 
Fear of falling 104 (36) 118 (37) 
Dizziness 75 (26) 102 (32) 
Indoor fall 107 (37) 148 (46) 
Smoking 37 (13) 34 (11) 
Alcohol intake (≥ 3 units/day) 33 (11) 34 (11) 
Functional status   
Activities of Daily Living 0.80 ± 4.5 0.80 ± 3.3 
Instrumental Activities of Daily Living 1.39 ± 5.4 1.37 ± 4.0 
Biochemical   
Vitamin D deficiency  119 (41) 135 (42) 
Anemia 34 (13) 58 (19) 
Continuous data are shown as mean values ± standard deviation, categorical data as number 
with percentage. MMSE, Mini-Mental State Examination; BMI, Body Mass Index; FRID, 
Fall-Risk Increasing Drugs. 
 
Furthermore, the number of fallers requiring a GP consultation (n=46; 17% vs. 36; 12%, 
p=0.07) or ED visit (n=21; 8% vs. 16; 5%, p=0.22) did not differ significantly. The mean 
number of falls during follow-up in the control group was 0.83 and the mean number of falls 
in the intervention group was 0.80 (p = 0.88). The mean number of GP consultations because 
of a fall in the control and intervention group were 0.21 and 0.16 respectively, p=0.25. The 
mean number of ED visits because of a fall in the control and intervention group were 0.08 
and 0.06 respectively, p=0.51. 
In the intention-to-treat analysis, cox-regression analyses adjusted for age and gender 
showed that FRIDs withdrawal had no significant effect on the time to first fall (hazard ratio 
[HR] 1.17; 95% confidence interval [CI] 0.89-1.54), or on the time to the second fall (1.19; 
0.78-1.82) (Table 4). Similarly, no significant effect on the time to the first GP consultation 
because of a fall (0.66; 0.42-1.06) or the time to the first ED visit because of a fall (0.85; 0.43-
1.68) was found (Table 4). Subgroup analyses of cardiovascular and psychotropic FRIDs 
withdrawal were similar, except for an increased time until the first GP consultation because 
of a fall for cardiovascular FRIDs withdrawal (0.57; 0.34-0.93). The per protocol analyses did 
not alter the results. 
Poisson regression analyses showed FRIDs withdrawal did not have a significant 
effect on the cumulative incidence of falls (β -0.05; 95% confidence interval [CI] -0.52-  
0.42), or on the cumulative incidence of GP consultations (-0.28; -0.75- 0.18) or ED visits (-
0.22; -0.88- 0.44) because of a fall. Subgroup analyses of cardiovascular and psychotropic 
FRIDs withdrawal were again similar, and per protocol analyses did not alter these results 
(Supplementary data). 
During the 12-months follow-up, 28 participants in the control group and 27 
participants in the intervention group sustained an injurious fall (p = 0.64). Seven participants 
in the control group and six participants in the intervention group sustained a fracture because 
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of a fall (p = 0.66). Two participants, both in the control group, sustained a traumatic brain 
injury because of a fall (p = 0.14). Six participants died in the control group, causes were a 
ruptured coronary artery during a coronary angiography [1], kidney failure [1], esophageal 
cancer [1], leukemia [1], motor vehicle collision [1], and unknown [1]. Thirteen participants 
died in the intervention group, causes were sepsis [4], cancer [3], cerebrovascular accident 
[2], encephalopathy [1], cardiac failure [1], and unknown [2] (p = 0.15).  











All FRIDs 308  122 186  66 120 
Cardiovascular FRIDs 265  164 101  37 64 
   Digitalis 4  3 1  1 0 
   Anti-arrhythmics 16  14 2  2 0 
   Nitrates 28  24 4  1 3 
   Antihypertensives 8  6 2  0 2 
   Diuretics 123  83 40  20 20 
   Beta-blockers 132  99 33  15 18 
   Calcium channel blockers 64  49 15  7 8 
   ACE/Angiotensin-II inhibitors 143  121 22  3 19 
   HMG CoA reductase inhibitors 119  117 2  0 2 
        
Psychotropic FRIDs 114  37 77  37 40 
   Opioids 20  15 5  1 4 
   Anti-epileptic 10  8 2  1 1 
   Anti-Parkinson 9  6 3  0 3 
   Neuroleptics 3  1 2  2 0 
   Anxiolytics 27  4 23  10 13 
   Sedatives/Hypnotics 43  10 33  22 11 
   Antidepressants 36  20 16  8 8 
   Anti-vertigo 5  3 2  0 2 
        
Other FRIDs 222  174 48  15 33 
   Anticholinergics (GI) 4  3 1  1 0 
   Hypoglycemics 51  49 2  1 1 
   Anti-spasmodics (GU) 15  6 9  5 4 
   Alfa-blockers (GU) 23  16 7  2 5 
   Steroids  16  15 1  0 1 
   NSAID 144  135 9  2 7 
   Anti-gout 12  10 2  1 1 
   Hydroquinine (muscle relaxant) 5  3 2  1 1 
   Adrenergics (respiratory) 25  23 2  0 2 
   Cough suppressants (opioids) 18  12 6  2 4 
   Antihistamines 11  2 9  3 6 
*Participants in intervention group where withdrawal, dose reduction and/or substitution of 
FRID was not necessary or safely possible. FRID, Fall-Risk Increasing Drugs; ACE, 
Angiotensin-Converting-Enzyme; GI, Gastrointestinal; GU, Genitourinary; NSAID, Non-
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Table 4. Cox-regression analyses including subgroup analyses  
 Intention to treat Per protocol 
 HR 95% CI p-value HR 95% CI p-value 
All FRIDs       
First fall 1.17 0.89; 1.54 0.27 1.19 0.89; 1.60 0.24 
Second fall 1.19 0.78; 1.82 0.41 1.26 0.80; 1.99 0.31 
GP consultation 0.66 0.42; 1.06 0.09 0.61 0.37; 1.02 0.06 
ED visit 0.85 0.43; 1.68 0.64 0.78 0.37; 1.63 0.50 
Cardiovascular FRIDs       
First fall 1.10 0.82; 1.49 0.51 1.12 0.81; 1.54 0.49 
Second fall 1.21 0.78; 1.88 0.41 1.31 0.81; 2.12 0.27 
GP consultation 0.57 0.34; 0.93 0.03 0.52 0.30; 0.91 0.02 
ED visit 0.77 0.38; 1.58 0.48 0.68 0.31; 1.50 0.34 
Psychotropic FRIDs       
First fall 1.28 0.84; 1.94 0.26 1.44 0.91; 2.29 0.12 
Second fall 1.17 0.64; 2.15 0.60 1.37 0.71; 2.67 0.35 
GP consultation  0.74 0.37; 1.48 0.40 0.88 0.42; 1.85 0.74 
ED visit 0.78 0.28; 2.16 0.64 0.93 0.32; 2.69 0.89 
Adjusted for age and gender. FRID, fall-risk increasing drug. 





Baseline FRIDs   
0 - 1 31 (11) 36 (11) 
2 45 (17) 58 (19) 
≥ 3 196 (72) 214 (70) 
Follow-up FRIDs   
0 - 1 30 (11) 52 (17) 
2 37 (14) 41 (13) 
≥ 3 205 (75) 215 (70) 
Change in amount of FRIDs    
Decrease 53 (20) 115 (38) 
No change 151 (56) 127 (41) 
Increase 68 (25) 66 (22) 
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0 - 1 31 (11) 36 (11) 
2 45 (17) 58 (19) 
≥ 3 196 (72) 214 (70) 
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Categorical data are given as number with percentages.
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eTable 2. Poisson distribution of fall incidence  
 Intention to treat Per protocol 
 β 95% CI p-value β 95% CI p-value 
All FRIDs       
Falls -0.05 -0.52; 0.42 0.84 -0.01 -0.53; 0.52 0.98 
GP consultations  -0.28 -0.75; 0.18 0.23 -0.28 -0.78; 0.22 0.27 
ED visits  -0.22 -0.88; 0.44 0.51 -0.37 -1.08; 0.34 0.30 
Cardiovascular FRIDs       
Falls -0.06 -0.57 5; 0.46 0.83 -0.01 -0.59; 0.57 0.97 
GP consultations -0.34 -0.84; 0.16 0.18 -0.35 -0.88; 0.20 0.21 
ED visits  -0.19 -0.90; 0.52 0.59 -0.38 -1.16; 0.39 0.33 
Psychotropic FRIDs       
Falls 0.31 -0.22; 0.84 0.25 0.53 -0.05; 1.10 0.07 
GP consultations  -0.32 -1.03; 0.40 0.38 -0.15 -0.91; 0.61 0.70 
ED visits  -0.25 -1.26; 0.75 0.62 -0.17 -1.22; 0.89 0.76 
Adjusted for age and gender. FRID, fall-risk increasing drug. 
DISCUSSION 
 
In the present randomized controlled trial we found that a structured medication assessment 
including withdrawal of FRIDs did not reduce the risk of falls in community dwelling elderly 
with a history of previous fall. There was a tendency towards fewer healthcare visits in the 
intervention group, which was significant in the cardiovascular-drug withdrawal subgroup.  
In previous studies, the withdrawal of FRIDs has been shown to be safely possible and 
effective 20,23-25. However, evidence regarding FRIDs withdrawal as single intervention is 
scarce 17,24,25. In a study by Pit et al. the intervention was carried out by the participants’ GP, 
probably increasing and sustaining the number of successful withdrawals due to the more 
substantial doctor-patient relationship 25. Campbell et al. performed a psychotropic drug 
withdrawal intervention that was complete and double-blinded, demonstrating the 
effectiveness of total psychotropic drug withdrawal on preventing falls 24. Yet this complete 
withdrawal was difficult to maintain. This was also a limitation in our study. Notably, in our 
study the withdrawal of cardiovascular FRIDs appeared to reduce risk of GP consultations 
because of a fall, possibly due to fewer injurious falls. Most studies associate greater fall risk 
with psychotropic drugs 19,21, however, besides our finding, another study has also reported 
greater risk reduction after withdrawal of cardiovascular drugs 20. Furthermore, a recent large 
study found that antihypertensive medications were associated with an increased risk of 
serious fall injuries 37.  
There are several possible explanations for our findings. First, since in the last decade, 
falls prevention guidelines have been incorporated into usual care, this may well have blunted 
the effect of the intervention. Second, in our intervention group a large proportion of FRIDs 
were prescribed adequately and thus withdrawal was not appropriate (Table 3). Third, a large 
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probably increasing and sustaining the number of successful withdrawals due to the more 
substantial doctor-patient relationship 25. Campbell et al. performed a psychotropic drug 
withdrawal intervention that was complete and double-blinded, demonstrating the 
effectiveness of total psychotropic drug withdrawal on preventing falls 24. Yet this complete 
withdrawal was difficult to maintain. This was also a limitation in our study. Notably, in our 
study the withdrawal of cardiovascular FRIDs appeared to reduce risk of GP consultations 
because of a fall, possibly due to fewer injurious falls. Most studies associate greater fall risk 
with psychotropic drugs 19,21, however, besides our finding, another study has also reported 
greater risk reduction after withdrawal of cardiovascular drugs 20. Furthermore, a recent large 
study found that antihypertensive medications were associated with an increased risk of 
serious fall injuries 37.  
There are several possible explanations for our findings. First, since in the last decade, 
falls prevention guidelines have been incorporated into usual care, this may well have blunted 
the effect of the intervention. Second, in our intervention group a large proportion of FRIDs 
were prescribed adequately and thus withdrawal was not appropriate (Table 3). Third, a large 
proportion of the participants in the intervention group was not compliant to the intervention, 
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especially concerning psychotropic drugs withdrawal. Fourth, it might be possible that 
participants in the intervention group were more diligent when filling out their Falls 
Calendars than the usual care group. The time till first and second fall were recorded from the 
Falls Calendars which participants from both group filled out and the time till the first GP 
consultation and ED visit were recorded from GP data. Although not statistically significant, 
the intervention group displayed a tendency towards a shorter time until the first fall, yet a 
longer time until the first GP consultation or ED visit because of a fall. Furthermore, when 
studying the participants in the successful withdrawal group individually, it was apparent that 
although one or more FRIDs were successfully withdrawn, reduced, or substituted, several 
participants were prescribed additional FRIDs during the follow-up year by their GP or other 
specialist, often for new conditions. Furthermore, the percentage of participants using ≥ 3 
FRIDs in the intervention group (70%) was not decreased at 1 year follow-up.  
Notably, during follow-up, six participants in the control group and thirteen 
participants in the intervention group died, however, this was not a significant difference. 
Furthermore, looking at the separate causes of death the distribution of these deaths seem 
coincidental and not due to adverse effects of drug withdrawal. Also, another falls prevention 
trial including FRID withdrawal observed the opposite distribution 16. 
In addition to the potential explanations mentioned above, the following limitations should be 
taken into account when interpreting our results. First, recruiting participants proved 
challenging. Possible reasons for refusing to participate have been reported previously 38. 
Most common reasons for refusal were the added burden of additional visits to the hospital; 
highly independent older adults feeling “too healthy”; and personal opinions regarding the 
cause of the fall. Second, possibly the method of reporting falls was not as accurate as 
anticipated; as mentioned above, the intervention group reported as many falls as the control 
group, but the numbers of healthcare visits because of a fall (which were verified with GP 
records) were higher in the control group. The newest guidelines state fall incidence is best 
monitored with weekly phone calls instead of self-report calendars 39. Third, as mentioned 
before, in the intervention group compliance with withdrawal was limited, especially in the 
group with psychotropic drug withdrawal. This might be improved if  the prescribing 
physician performs the withdrawal, as was the case in the study by Pit et al. 25. A major 
strength of this study is that current recommendations regarding falls prevention studies were 
followed 40, i.e., addressing a single intervention in a randomized controlled trial. 
Furthermore, participants included were high-risk fallers, i.e., older men and women who 
visited the ED because of a fall. In this target group even a small reduction of their fall risk 
might prevent loss of independence. 
Overall, FRIDs withdrawal did not result in reduced incidence of falls, whereas, 
cardiovascular FRIDs withdrawal did reduce  healthcare visits because of a fall. Surprisingly, 
no effect of psychotropic drug withdrawal was seen, which might have been caused by low 
compliance to the intervention. This study increases insight into both the effectiveness of 
FRIDs withdrawal as a method for falls reduction in older adults, and into the complexity of 
this intervention in an older, multi-morbid population. The current study adds to the 
understanding of effective falls-prevention interventions. Further research is warranted 
focusing on the optimal method for implementation, thus ensuring participation and 
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Background: Falls affect a large proportion of the persons aged 65 years and older, and are 
associated with substantial loss of quality of life, and high cost.  
Objectives: To investigate the effect of a structured medication assessment including 
withdrawal of fall-risk increasing drugs versus ‘care as usual’ on the costs, health-related 
quality of life (HRQoL), and cost-utility  in community-dwelling older men and women. 
Design: Randomized multicenter trial. 
Participants: 612 older adults who visited an Emergency Department due to a fall. 
Measurements: HRQoL was measured at baseline and at 12 months follow-up using the 
EuroQol-5D and Short Form-12 version 2. Cost-utility  was assessed by calculating the  cost 
per Quality Adjusted Life Years (QALY) gained.  
Results: Costs for the intervention were €39 higher than usual care. The control group had a 
greater decline in EuroQol-5D utility score during the 12 month follow-up than the 
intervention group  (p = 0.02). The change in the Short Form-12 Physical Component 
Summary and Mental Component Summary scores did not differ significantly between the 
two groups. Incremental cost-utility of the intervention was €780/QALY gained. 
Conclusion: Compared to usual care, FRID withdrawal led to higher costs, but was 
associated with less decline in HRQoL as measured with the EQ-5D utility score.  




Falls affect a large proportion of the persons aged 65 years and older and are associated with 
consequences such as loss of quality of life and high cost 1-5. In 2000 the fall-related medical 
costs in the population 65 years and older in the United States amounted to US$19 billion for 
non-fatal injuries and US$200 million for fatal injuries 6. Between 2003 and 2007 the average 
annual cost for fall-related injuries in the Netherlands was US$ 640 million (€470 million), 
and the overall cost per fall was US$9,530 (€7,048) 7. In order to reduce the prevalence of 
falls, risk factors have been well documented 8-10, and there have been a substantial amount of 
fall-prevention trials 5,11-20.   
However, past variations in outcome definitions and measures of fall-prevention trials 
have hindered comparative research and meta-analysis, and thus the Prevention of Falls 
Network Europe (ProFaNE) established a common set of outcome definitions and measures 
for use in trials. These include cost, health-related quality of life (HRQoL) outcomes, and a 
follow-up duration of 12 months 21. To our knowledge no studies have reported the cost-
utility of withdrawal of fall-risk increasing drug (FRID) as a single intervention 22-35. 
Furthermore, few fall-prevention trials have documented quality of life outcomes 15,36-39, and 
only one reported HRQoL as recommended by ProFaNE 15.  
The use of certain drugs has been associated with increased risk of falls and related 
injuries 40-43, and in previous literature the withdrawal of FRIDs was shown to be safely 
possible and to generate significant cost savings 11,20,44. The present study investigated the 
costs, the effect on HRQoL, and the cost-utility of a structured medication assessment 
including withdrawal of FRIDs versus ‘care as usual’ in community-dwelling older men and 
women, who visited the emergency department (ED) after experiencing a fall 45.  
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The IMPROveFALL study was a randomized, multicenter trial, assessing the effect of a 
structured medication assessment including withdrawal of FRIDs versus ‘care as usual’ as a 
method for falls reduction 45. Patients meeting the following inclusion criteria were eligible 
for enrolment: aged 65 years or older, visited the ED of a participating hospital due to a fall, 
use of one or more fall-risk increasing drugs 40,41,43,45, Mini-Mental State Examination 
(MMSE) score of at least 21 out of 30 points 46, ability to walk independently, community 
dwelling, and provision of written informed consent by the patient. Participating hospitals 
included two academic and four regional hospitals in the Netherlands. Enrolment started in 
October 2008 and was completed in October 2011. The follow-up period was 12 months. The 
study was performed in accordance with the Declaration of Helsinki and all participants gave 
written informed consent. The local Medical Research Ethics Committees in all participating 
hospitals approved the study protocol.  
All persons visiting the ED due to a fall received care as usual for their injuries and 
were contacted by telephone after their ED visit. Eligible study participants received written  
information concerning the study and those interested in participating were invited to the 
research outpatient clinic. The visits to the outpatient clinic took place within two months 
after the ED visit. During the visit at the outpatient clinic a fall-related assessment was 
performed by the clinical investigator and supervised by a geriatrician. A detailed description 
of the study protocol can be found elsewhere 45.  
 
Definition fall incident 
A fall was defined as coming to rest unintentionally on the ground or a lower level with or 
without losing consciousness, but not induced by acute medical conditions, e.g., stroke, or 
exogenous factors such as a traffic accident 47. All participants received a Falls Calendar for 
reporting falls during a one-year follow-up period. Falls were recorded weekly on the Fall 
Calendars and had to be returned every three months. Follow-up started two weeks after 
completed intervention or two weeks after initial research clinic visit when no intervention 
was performed. The number of injuries prevented was calculated with data recorded in the 
study, supplemented with epidemiological data on falls and injury risks.  
 
Costs 
The total direct and indirect costs of both FRID withdrawal and ‘care as usual’ were 
measured. Costs were calculated by multiplying the volumes of healthcare use with the 
corresponding unit prices (Table 1). Direct healthcare costs included the costs of the FRID 
assessment and modification, drug consumption (i.e., the cost of substitution drugs), and fall-
related healthcare consumption during one year of follow-up (e.g., outpatient visits, hospital 
admissions, General Practitioner consultations, home care, nursing home care). Indirect costs 
included patient travel costs. For the intervention (systematic fall-related drugs assessment) 
the full cost was calculated and for the other healthcare costs standard Dutch cost prices were 
used as published by Hakkaart-van Roijen et al. 48. Costs of medication use were recorded in 
the study, and unit costs were determined with information from the National Dutch 
Formulary 49. Healthcare consumption, both fall and non-fall related, and patient costs were 
recorded from the three-monthly questionnaires for healthcare consumption and patient costs 
and data received from the participants’ General Practitioner.  
 
Health-related quality of life 
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During the baseline assessment and at the follow-up clinic visit, all participants completed 
questionnaires on generic HRQoL under supervision of the clinical investigator or research 
nurse. Based upon the recommendations of ProFaNE 21, HRQoL was measured using the 
Dutch versions of the EuroQol-5D (EQ-5D) 50 and the Short Form-12 (SF-12) version 2 51 at 
baseline and at 12 months-follow-up. The EQ-5D utility score covers five health domains 
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each 
dimension has three levels; no problem, moderate problem, or severe problem. In addition, a 
scoring algorithm based on empiric valuations from the United Kingdom general population 
and subsequent statistical modeling is available by which each health status description can be 
expressed into a utility score 52. This utility score ranges from 1 for full health to 0 for death, 
and can be interpreted as a judgment on the relative desirability of a health status compared 
with perfect health. The EQ-5D is a validated and extensively used general health 
questionnaire to measure quality of life 50. It is recommended for the assessment of HRQoL in 
trauma patients, especially for economic assessments 53. The SF-12 contains eight domains 
measuring physical and mental health outcomes; physical functioning, role physical, bodily 
pain, general health, vitality, social functioning, role emotional, and mental health. Data from 
all eight domains is used to construct the physical and mental component summary measures 
(PCS and MCS) 51. 
 
Cost-utility analysis 
The long-term effectiveness of the interventions was expressed in terms of the cumulative 
number of life years and quality-adjusted life years (QALYs) gained. The QALY combines 
morbidity and mortality into a single number. QALYs were calculated by weighting life years 
for the quality of life using the EQ-5D utility score. The gain in QALY is equal to difference 
between QALY measures.  
Finally, the cost per QALY gained was calculated as the ratio of total intervention 
costs minus savings in fall-related healthcare costs compared with control divided by the 
cumulative QALYs gained compared with control. All analyses were performed in 
accordance with Dutch guidelines for economic evaluations 54. 
 
Statistical analyses  
All analyses were performed using the Statistical Package of the Social Sciences (SPSS 
version 17.0, Chicago, Ill.) and a p-value < 0.05 was considered statistically significant. 
Baseline characteristics were compared using Student t-test analyses for continuous variables 
and chi-squared analyses for dichotomous variables. The change in EQ-5D utility score and 
SF-12 PCS and MCS scores over 12 months (i.e., after 12 months follow-up versus baseline 
data) within the control and intervention groups were compared using the Wilcoxon Signed 
Rank test for continuous variables and the McNemar test for dichotomous variables. The 
change in scores between the control and intervention groups were compared using a two-way 
analysis of variance (ANOVA). Analyses of the individual health domains of the EQ-5D and 
SF-12 were also performed. Secondary analyses were performed, comparing the HRQoL 




In total, 7,081 patients visiting the ED were screened for possible trial participants, 
subsequently 612 participants were randomized in the IMPROveFALL study (Figure 1). 
Randomization resulted in 293 participants being allocated to the control group and 319 
participants to the intervention group, of those 265 and 287 had complete quality of life 
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and 62% of the study population was female. No significant differences in baseline 
characteristics were found between the control and intervention group (Table 2).  
 
Figure 1. Flowchart of study participants 
 
*Of the participants who died during follow-up, most were included in the analyses, except 
for two in the control and one in the intervention group. **Nine and 23 participants in the 
control and intervention group declined or were unable to complete EQ-5D questionnaires 
after 12-months follow-up.  
 
Table 3 specifies the interventions according to FRID categories and specific drug types, and 
also includes details on compliance to attempted interventions. Notably, in 40% of all FRIDs, 
an intervention was not deemed possible or necessary. Of all attempted interventions 36% 
failed, either due to non-compliance or a return of the primary indication for which the drug 
was prescribed. The number of participants in the control group and intervention group 
experiencing a fall or recurrent fall during the one-year follow-up did not differ significantly 
(Chapter 3.2).  
 
Table 1. List of costs  
 Cost categories Parameter Cost price 
(€, 2009) 
Intervention costs * Variable 
Medication costs DDD Variable 
Hospital stay costs Day 457  
Emergency Department costs Visit 151 
General Practitioner costs Consultation 28 
Specialist consult costs Consultation 72 
Home care costs Per hour 35 
Physical therapy costs Visit 36 
Nursing home costs Day 238 
Intermediate care facility costs  Day 90 
Rehabilitation center costs Day 340 
Patient costs (travel costs) Per kilometer Variable** 
DDD: Defined Daily Dose; GP, General Practitioner. *Geratric consultation (€72) + routine 
blood test (€20) + extra consults (€72). **Private motor vehicle / public transportation / taxi. 
 
Costs 
The mean cost of the FRIDs intervention was €120 which included the initial Geriatric 
consultation (€72), routine blood tests (€20) and necessary additional consultations (€72). The 








and 62% of the study population was female. No significant differences in baseline 
characteristics were found between the control and intervention group (Table 2).  
 
Figure 1. Flowchart of study participants 
 
*Of the participants who died during follow-up, most were included in the analyses, except 
for two in the control and one in the intervention group. **Nine and 23 participants in the 
control and intervention group declined or were unable to complete EQ-5D questionnaires 
after 12-months follow-up.  
 
Table 3 specifies the interventions according to FRID categories and specific drug types, and 
also includes details on compliance to attempted interventions. Notably, in 40% of all FRIDs, 
an intervention was not deemed possible or necessary. Of all attempted interventions 36% 
failed, either due to non-compliance or a return of the primary indication for which the drug 
was prescribed. The number of participants in the control group and intervention group 
experiencing a fall or recurrent fall during the one-year follow-up did not differ significantly 
(Chapter 3.2).  
 
Table 1. List of costs  
 Cost categories Parameter Cost price 
(€, 2009) 
Intervention costs * Variable 
Medication costs DDD Variable 
Hospital stay costs Day 457  
Emergency Department costs Visit 151 
General Practitioner costs Consultation 28 
Specialist consult costs Consultation 72 
Home care costs Per hour 35 
Physical therapy costs Visit 36 
Nursing home costs Day 238 
Intermediate care facility costs  Day 90 
Rehabilitation center costs Day 340 
Patient costs (travel costs) Per kilometer Variable** 
DDD: Defined Daily Dose; GP, General Practitioner. *Geratric consultation (€72) + routine 
blood test (€20) + extra consults (€72). **Private motor vehicle / public transportation / taxi. 
 
Costs 
The mean cost of the FRIDs intervention was €120 which included the initial Geriatric 
consultation (€72), routine blood tests (€20) and necessary additional consultations (€72). The 
Chapter 3.3
142
mean costs saved with medication withdrawal, dose reduction and drug substitution was €38 
per participant.  The savings in fall-related healthcare costs of the intervention group (€ 2324 - 
2285 = €39) compared with control did not differ significantly (Table 4).  
 
Table 2. Baseline characteristics of the control and intervention group  
 Control 
n = 293 
Intervention 
n = 319 
Demographics   
Age (year) 76.4 ± 6.6 76.5 ± 7.2 
Female gender 182 (62) 198 (62) 
MMSE 27.0 ± 2.4 27.0 ± 2.3 
BMI (m2/kg) 27.6 ± 4.7 27.6 ± 4.6 
Fall risk factors   
Charlson Comorbidity Index 1.9 ± 1.6 1.9 ± 1.6 
Number of drugs 6.4 ± 3.3 6.3 ± 3.3 
Number of FRIDs 3.9 ± 2.0 3.9 ± 2.1 
History of recurrent falls 128 (44) 148 (46) 
Smoking 37 (13) 34 (11) 
Alcohol intake (≥ 3 units/day) 33 (11) 34 (11) 
Functional status   
Home care 69 (24) 82 (26) 
Activities of Daily Living 0.80 ± 4.5 0.80 ± 3.3 
Instrumental Activities of Daily Living 1.39 ± 5.4 1.37 ± 4.0 
Continuous data are shown as mean values ± standard deviation, categorical data as number 
with percentage. MMSE, Mini-Mental State Examination; BMI, Body Mass Index; FRID, 
Fall-Risk Increasing Drugs. 
 
Table 3. Specification of interventions and compliance in intervention group 
 Intervention 
group 






All FRIDs 308  122 186  66 120 
Cardiovascular FRIDs 265  164 101  37 64 
Psychotropic FRIDs 114  37 77  37 40 
Other FRIDs 222  174 48  15 33 
*Participants in intervention group where withdrawal, dose reduction and/or substitution of 
FRID was not necessary or safely possible. FRID, Fall-Risk Increasing Drugs. Data are 
shown as number of patients. 
 
Health-related quality of life 
9 and 23 participants in the control and intervention group declined or were unable to 
complete EQ-5D questionnaires after 12-months follow-up, and an additional 5 and 2 
participants in the control and intervention group had incomplete SF-12 questionnaires after 
12-months follow-up. 
The baseline and follow-up HRQoL scores of the control and intervention group are 
shown in Table 5. The control group had a greater decline in EQ-5D utility score during the 
12 month follow-up compared to the intervention group,  (p = 0.02).  The decline in the SF-12 
PCS and MCS score did not differ significantly between the intervention and control group (p 
= 0.08 and p = 0.90). The problems in the EQ-5D domains of the control and intervention 
group reported at baseline and at follow-up are shown in Table 6.  
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Intervention costs - 120† * 
General Practitioner consult costs 29 20 * 
Specialist consult costs 51 40  
Emergency Department costs 12 10  
Hospital stay costs 360 383  
Home care costs 662 630  
Physical therapy costs 290 218  
Intermediate care facility costs  220 74  
Nursing home costs 424 156  
Rehabilitation center costs 229 708  
Patient costs (travel costs) 3 2  
Medication cost saved -3 -38 * 
Total costs  2285 2324  
Data are given as mean values in euro (€).†Average;* < 0.05 
 
The overall mean baseline EQ-5D utility score of those with and without a fall during follow-
up was 0.69 ± 0.27 and 0.80 ± 0.21, respectively (p < 0.01; data not shown). The overall mean 
baseline SF-12 PCS scores of those with and without a fall during follow-up were 44.4 ± 9.9, 
and 46.6 ± 9.6, p = 0.01. The overall mean baseline SF-12 MCS scores of those with and 
without a fall during follow-up were 53.2 ± 10.0, and 53.3 ± 9.0, p = 0.87.  Thus, the 
participants who fell during follow-up had significantly lower EQ-5D and SF-12 PCS scores 
at baseline. A secondary analysis was performed of the decline in HRQoL in the participants 
of the control and intervention group with and without a fall during follow-up (Table 7). In 
the participants with a fall during follow-up, the change in quality of life did not differ 
significantly between both groups. In the participants without a fall during follow-up, the 
control group had a greater decline in the SF-12 PCS score (p = 0.01), when compared to the 
intervention group.  
 
Table 5. Quality of life scores of the control and intervention groups at baseline and 12 
months follow-up, and the change over 12 months 
 Group N† Baseline Follow-up p-values* Change p-values** 
EQ-5D utility score C 263 0.78 ± 0.22 0.74 ± 0.25 0.01 -0.04 ± 0.22 0.02 
 I 285 0.74 ± 0.26 0.75 ± 0.26 0.75 0.01 ± 0.24  
SF-12 PCS score C 258 46.2 ± 9.9 42.2 ± 11.6 <0.01 -3.9 ± 8.5 0.08 
 I 283 45.6 ± 9.5 43.0 ± 10.7 <0.01 -2.6 ± 8.5  
SF-12 MCS score C 258 53.2 ± 9.0 52.5 ± 9.2 0.28 -0.7 ± 9.7 0.90 
 I 283 53.3 ± 9.5 52.5 ± 9.0 0.20 -0.8 ± 9.7  
C, control; I, intervention. Data are given as mean values ± standard deviation.  
†9 and 23 participants in the control and intervention group declined or were unable to 
complete EQ-5D questionnaires after 12-months follow-up, an additional 5 and 2 participants 
in the control and intervention group had incomplete SF-12 questionnaires after 12-months 
follow-up. *Wilcoxon Signed Rank test (comparing baseline and follow-up), **Two-way 
ANOVA of the change over 12 months. 
 
Cost-utility 
The mean QALY difference between both groups was 0.05 QALY  (gained by the 
intervention group) over the trial period. The costs in the intervention group were €39 higher 
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per patient  than usual care. This results in an incremental cost-utility ratio of €780/QALY 
gained.  
 
Table 6. Prevalence of problems on the five dimensions of the EQ-5D in the control and 
intervention groups at baseline and 12 months follow-up 
 Group N† Baseline Follow-up p-value* 
Mobility  C 263 119 (45) 141 (54) 0.01 
 I 285 152 (53) 150 (53) 0.90 
Self-Care C 263 37 (14) 37 (14) 1.00 
 I 285 48 (17) 37 (13) 0.08 
Usual Activities C 263 80 (30) 89 (34) 0.30 
 I 285 104 (37) 97 (34) 0.49 
Pain/Discomfort C 263 138 (53) 152 (58) 0.13 
 I 285 165 (58) 151 (53) 0.12 
Anxiety/Depression C 263 74 (28) 78 (30) 0.70 
 I 285 73 (26) 84 (30) 0.19 
C, control; I, intervention. Data are presented as number and percentages (%). 
†9 and 23 participants in the control and intervention group declined or were unable to 
complete EQ-5D questionnaires after 12-months follow-up. *McNemar test. 
 
Table 7. Quality of life scores of the participants with and without a fall during follow-up 
Fall Group N Baseline Follow-up p-values* Change p-values** 
EQ-5D utility score UC 87 0.71 ± 0.25 0.64 ± 0.28 0.01 -0.07 ± 0.29 0.13 
 I 101 0.68 ± 0.29 0.67 ± 0.28 0.70 -0.01 ± 0.27  
SF-12 PCS score UC 88 44.0 ± 10.4 39.3 ± 13.1 <0.01 -4.7 ± 9.8 0.72 
 I 107 44.8 ± 9.5 40.7 ± 11.2 <0.01 -4.2 ± 10.2  
SF-12 MCS score UC 88 53.6 ± 9.1 51.6 ± 10.5 0.14 -1.9 ± 10.8 0.56 
 I 107 52.4 ± 10.6 51.7 ± 9.2 0.25 -1.0 ± 11.1  
No fall Group N Baseline Follow-up p-values* Change p-values** 
EQ-5D utility score UC 169 0.81 ± 0.19 0.80 ± 0.22 0.27 -0.02 ± 0.16 0.08 
 I 180 0.77 ± 0.24 0.80 ± 0.23 0.44 0.02 ± 0.16  
SF-12 PCS score UC 172 47.3 ± 9.6 43.9 ± 10.4 <0.01 -3.5 ± 7.8 0.01 
 I 178 46.1 ± 9.6 44.5 ± 10.2 <0.01 -1.5 ± 7.1  
SF-12 MCS score UC 172 53.1 ± 9.0 53.0 ± 8.5 0.76 -0.1 ± 9.2 0.46 
 I 178 53.9 ± 8.8 53.0 ± 8.9 0.40 -0.9 ± 8.8  
C, control; I, intervention. Data are given as mean values ± standard deviation. *Wilcoxon 




To the best of our knowledge this  is the first cost-utility analysis comparing  a structured 
medication assessment including withdrawal of FRIDs versus ‘care as usual’ in community-
dwelling older men and women. The total cost did not differ significantly between the control 
and intervention group, whereas, the total healthcare related costs in the intervention group 
were €39 higher than usual care. Notably, the control group reported a significantly greater 
decline in HRQoL during the 12 month follow-up as measured with the EQ-5D utility score 
than the intervention group. The intervention resulted in an incremental cost-utility ratio of 
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€780/QALY gained. Policy makers and health economists have proposed that costs up to 
€20,000 per QALY are considered as acceptable 55. 
 Various studies have reported cost and cost-effectiveness data regarding fall 
prevention trials with varying results, however, most studies evaluated multifactorial 
interventions 23,25,26,28-31,33-35,56. One study reported on the cost-effectiveness of FRID 
withdrawal as a single intervention, and reported significant national cost savings 44. In this 
study, the total healthcare related costs in the intervention group were €39 higher than usual 
care, yet no reduction in fall risk was found. Possible reasons for this lack of fall risk 
reduction are extensively discussed elsewhere (Chapter 3.2). In short, since in the last decade 
fall prevention guidelines have been incorporated into usual care, this may well have blunted 
the effect of the intervention. Second, a large proportion of FRIDs turned out to be prescribed 
adequately and thus withdrawal was not appropriate. In addition, a large proportion of the 
participants was not compliant to the intervention, especially with respect to psychotropic 
drugs (Table 2). Higher compliance rates might have led to lower fall risk and lower related 
healthcare costs, and increased savings due to reduced medication costs (mean reduction of 
€38 per participant in this study). Furthermore, a less costly method of FRID withdrawal 
could be accomplished by having the GP perform the intervention, thus further lowering costs 
per QALY. 
The mean EQ-5D utility score of the entire study population at baseline was 0.75 ± 
0.25, and the overall percentage of problems reported at baseline were 52% for mobility, 17% 
for self-care, 36% for usual activities, 57% for pain/discomfort, and 28% for 
anxiety/depression. These rates were higher than the Dutch population norms for the 70-79 
age group, which are 43% for mobility, 9% for self-care, 23% for usual activities, and 42% 
for pain/discomfort, and 12% for anxiety/depression 57. The mean SF-12 PCS and MCS 
 
scores at baseline were 45.5 ± 9.8 and 53.0 ± 9.5, respectively. These were similar to the 
Dutch population norms for the 65-74 age group 51.  
Until now, only one fall prevention trial reported HRQoL as recommended by 
ProFaNE, a multifactorial intervention trial, and reported no significant change in EQ-5D and 
SF-12 scores between the intervention and control group 15. Four other trials used varying 
methods to measure HRQoL. Two found no difference in SF-36 score between the control 
and intervention group 36,37. Another multifactorial fall prevention trial, which used the 15D 
instrument, concluded the intervention produced positive effects in some dimensions of 
HRQoL 39. Still another trial used the World Health Organization Quality of Life instrument 
WHOQoL) and measured higher quality of life in one of the treatment groups 38. It is difficult 
to compare results, partly due to varying outcome measures. Another reason is the diversity of 
interventions, an intervention such as exercise training will most likely improve quality of life 
38, while withdrawal of certain drugs might do the opposite.  
It is important to note that except for a structured medication assessment, including the 
withdrawal of FRIDs, both groups received identical care. Furthermore, withdrawal of certain 
commonly prescribed FRIDs such as benzodiazepines, antidepressants and opiates 45, could 
have resulted in lower quality of life scores in the intervention group. Nonetheless, in this 
study the withdrawal of FRIDs did not lower the HRQoL. Remarkably, in the secondary 
analysis comparing the participants without a fall during follow-up the intervention group had 
lesser decline in the SF-12 PCS score than the control group. The fact that the intervention did 
not lower the HRQoL and possibly even improved it, is on its own an important outcome. 
Notably, the participants who fell during follow-up had significantly lower EQ-5D and SF-12 
PCS scores at baseline. This is in a group of community-dwelling elderly who all recently 
visited the ED due to a fall; those who fell during follow-up had lower quality of life scores 
ahead of the recurrent fall. To the best of our knowledge, this finding has not been reported in 
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adequately and thus withdrawal was not appropriate. In addition, a large proportion of the 
participants was not compliant to the intervention, especially with respect to psychotropic 
drugs (Table 2). Higher compliance rates might have led to lower fall risk and lower related 
healthcare costs, and increased savings due to reduced medication costs (mean reduction of 
€38 per participant in this study). Furthermore, a less costly method of FRID withdrawal 
could be accomplished by having the GP perform the intervention, thus further lowering costs 
per QALY. 
The mean EQ-5D utility score of the entire study population at baseline was 0.75 ± 
0.25, and the overall percentage of problems reported at baseline were 52% for mobility, 17% 
for self-care, 36% for usual activities, 57% for pain/discomfort, and 28% for 
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age group, which are 43% for mobility, 9% for self-care, 23% for usual activities, and 42% 
for pain/discomfort, and 12% for anxiety/depression 57. The mean SF-12 PCS and MCS 
 
scores at baseline were 45.5 ± 9.8 and 53.0 ± 9.5, respectively. These were similar to the 
Dutch population norms for the 65-74 age group 51.  
Until now, only one fall prevention trial reported HRQoL as recommended by 
ProFaNE, a multifactorial intervention trial, and reported no significant change in EQ-5D and 
SF-12 scores between the intervention and control group 15. Four other trials used varying 
methods to measure HRQoL. Two found no difference in SF-36 score between the control 
and intervention group 36,37. Another multifactorial fall prevention trial, which used the 15D 
instrument, concluded the intervention produced positive effects in some dimensions of 
HRQoL 39. Still another trial used the World Health Organization Quality of Life instrument 
WHOQoL) and measured higher quality of life in one of the treatment groups 38. It is difficult 
to compare results, partly due to varying outcome measures. Another reason is the diversity of 
interventions, an intervention such as exercise training will most likely improve quality of life 
38, while withdrawal of certain drugs might do the opposite.  
It is important to note that except for a structured medication assessment, including the 
withdrawal of FRIDs, both groups received identical care. Furthermore, withdrawal of certain 
commonly prescribed FRIDs such as benzodiazepines, antidepressants and opiates 45, could 
have resulted in lower quality of life scores in the intervention group. Nonetheless, in this 
study the withdrawal of FRIDs did not lower the HRQoL. Remarkably, in the secondary 
analysis comparing the participants without a fall during follow-up the intervention group had 
lesser decline in the SF-12 PCS score than the control group. The fact that the intervention did 
not lower the HRQoL and possibly even improved it, is on its own an important outcome. 
Notably, the participants who fell during follow-up had significantly lower EQ-5D and SF-12 
PCS scores at baseline. This is in a group of community-dwelling elderly who all recently 
visited the ED due to a fall; those who fell during follow-up had lower quality of life scores 




previous literature, and is valuable for future investigations regarding risk factors associated 
with falls in community-dwelling older men and women. 
An unexpected finding was that regardless of similar baseline characteristics including 
age, gender, and number of comorbidities, the baseline EQ-5D utility score was lower in the 
intervention group. This could not be attributed to differences in reporting procedures, as the 
method and timing of HRQoL questionnaire completion were identical for the control and 
intervention groups. Another possible reason could be the presence of more severe injuries in 
the intervention group at baseline, however, the injuries sustained by the participants at 
baseline were similar in both groups (data not shown).  
The following limitations should be taken into account when interpreting our results. 
First, the dropout during the 12 month follow-up could be due to the selected study population 
which had a high risk of falling. These patients often had mobility impairments and other 
comorbid conditions that may have resulted in a refusal to continue participating in the study 
and visit our outpatient clinic after 12 months follow-up. Thus the most at-risk and frail 
participants could have been excluded from the analysis, however, the randomization would 
have equally divided these patients across the intervention and control group. Second, the SF-
12 has been evaluated for use in large group comparisons, this may not be correct for our 
secondary analyses where we solely included participants with and without a fall during 
follow-up 51. Third, as mentioned before, in the intervention group compliance with 
withdrawal was limited, especially in the group with psychotropic drug withdrawal. This 
might be improved if  the prescribing physician performs the withdrawal, as was the case in 
the study by Pit et al. 58. Fourth, the main aim of this study was to study the effectiveness of 
the intervention that is why the power calculation was based on a falls reduction rather than 
QALYs or costs. A major strength of this study is that it was a single intervention study, 
making it easier to be included in comparative research and meta-analysis, and it follows 
 
current recommendations regarding HRQoL outcome measures 21. Furthermore, participants 
included were high-risk fallers, i.e., older men and women who visited the ED due to a fall.  
In this study comparing withdrawal of FRIDs versus ‘care as usual’ in community-
dwelling older men and women, the total healthcare related costs in the intervention group 
were €39 higher than the control group. The incremental cost-utility ratio was €780/QALY 
gained and remained below the €20,000 per QALY which is considered acceptable by policy 
makers. Notably, the withdrawal of FRIDs reduced medication costs with a mean of  €38 per 
participant, this in combination with less decline in HRQoL should not be overlooked.  
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Falls affect a large proportion of persons aged 65 years and older 1, and are associated with 
serious consequences such as high morbidity and mortality rates 2-4, disability, loss of quality 
of life, and institutionalization 5-8. Furthermore, fall-related injuries place a substantial burden 
on healthcare systems due to the large number of visits to emergency departments (ED), 
hospital admissions, and admissions to long-term care and rehabilitation facilities 6, 9-12; and 
high medical costs7. 
Approximately one out of three persons aged ≥ 65 years experiences a fall every year 
1. A fall is usually defined as coming to rest unintentionally on the ground or a lower level 
with or without losing consciousness, but not induced by an acute medical condition, e.g. 
stroke, or exogenous factors, such as a traffic accident 13. Falls are precipitated by a number of 
risk factors, these can be grouped into intrinsic and extrinsic factors. Intrinsic risk factors 
include old age (>80 years), a history of falls, gait deficit, balance deficit, visual impairment, 
cognitive impairment, cardiovascular problems (e.g. orthostatic hypotension, arrhythmia), and 
urinary incontinence. Vitamin D deficiency has also been shown to be a key contributor to a 
decline in physical performance and increase in fall incidence 14-21. Extrinsic risk factors 
include the environment (e.g., poor lighting, rugs, and loose wiring), and improper use of 
walking aids  22-25. Furthermore, approximately 33 percent of persons over 65 years use so-
called fall-risk-increasing drugs (FRIDs) such as cardiovascular and psychotropic drugs 26-28.  
The most common injuries due to falls in persons aged 65 years or older in the 
Netherlands are superficial injuries, hip fractures, wrist fractures, and traumatic brain injury 
(TBI) 10. In addition to the effects on morbidity and mortality, falls result in a significant 
reduction in health-related quality of life and substantial functional impairment 5, 8. 
Furthermore, between 2003 and 2007 the average annual cost for fall-related injuries in the 





As stated above, falls in older adults are a major public health problem, yet essentially 
preventable. The rationale for the studies presented in this thesis is to gain insight into falls 
prevention in older adults. Researchers started documenting fall-related risk-factors in the 
1980s, afterwards the first fall prevention trials were conducted 1, 22, 23, 29, 30.  Early on 
Campbell et al. performed a psychotropic drug withdrawal intervention that was complete and 
double-blinded, demonstrating the effectiveness of total psychotropic drug withdrawal on 
preventing falls 29. The use of certain drugs, i.e. the so-called fall-risk increasing drugs 
(FRIDs) 26-28, 31, mainly psychotropic and cardiovascular drugs, has been associated with 
increased risk of falls and related injuries 26-28, 32, and withdrawal of FRIDs appears to be 
feasible and effective 29, 31, 33, 34. Although FRIDs withdrawal is frequently incorporated in 
multifactorial intervention trials, evidence regarding overall FRIDs withdrawal as a single 
intervention is scarce 35.  
 The aim of this thesis was twofold. First, we investigated factors associated with falls 
in older adults. We separated these into several components starting with the circumstances 
surrounding injurious falls 36,  then we investigated the effect of serum vitamin D on physical 
performance 37, and finally we compared functional, physical and health related quality of life 
scores between single and recurrent fallers 38. Second, we conducted a multicenter 
randomized controlled trial and investigated the effect of a structured medication assessment 
including withdrawal of FRIDs versus ‘care as usual’ on reducing falls in community-
dwelling older men and women, who visited the ED after experiencing a fall 39. We also 
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In this chapter we summarize the main findings and discuss the strengths and 
limitations of this study. In addition we present the clinical implications of our findings and 




Chapter 2.1 Circumstances surrounding injurious falls 
We investigated the activity distributions leading to indoor and outdoor falls requiring an 
emergency department visit, and those resulting in traumatic brain injuries and hip fractures.  
In total 5880 fall-related emergency department visits were included. Two-thirds of all falls 
occurred indoors. However, this differed between age and gender categories, with higher 
proportions of outdoor falls at ages 65-79 years and among men. The overall most common 
indoor activities leading to injurious falls were walking and walking up or down stairs. The 
overall most common outdoor activities leading to injurious falls were walking and cycling. 
We found that the indoor activities leading to major injuries, i.e. TBIs and hip fractures, 
differed. Walking up or down stairs and housekeeping were the most common activities 
leading to a TBI whereas walking and sitting or standing were the most common activities 
leading to a hip fracture. Notably, about half of the traumatic brain injuries and hip fractures 
in men and women aged 65-79 years occurred outdoors. The most common outdoor activities 
leading to both injuries were walking and cycling. It should be noted that in the Netherlands 
about 27% of all travel is done by bicycle. As a consequence, the data presented is more 
relevant in countries where cycling is common.  
Falls are the leading cause of TBIs and hip fractures in the elderly population 7, 40, 41. 
Falls cause 61% of traumatic brain injuries in persons aged 65 years and older in the US 40, 
and recent studies in the US, the Netherlands, and Finland showed an increase in fall-related 
 
TBIs 11, 40, 42. About 30% of people with a hip fracture will die in the following year, and 
many more will experience significant functional loss 2. Furthermore, TBIs and hip fractures 
contribute considerably to healthcare costs 7. These results provide new insights into patterns 
leading to injurious falls by age, gender and injury type, and may guide the targeting of falls 
prevention at specific activities and risk groups.  
Up to now, little to no special attention has been paid to outdoor activities such as 
cycling and ‘higher level’ activities such as housekeeping. Few have incorporated strategies 
for falls prevention derived from these specific circumstances. Partly, this can be 
accomplished by education of the risk groups. Healthy and highly functional older adults may 
be unaware that their higher activity levels may increase their risk for falling and subsequent 
injuries 43. Another possibility is the elimination of outdoor environmental hazards involving 
sidewalks, curbs, and streets, such as by promptly repairing uneven surfaces, removing debris, 
and painting curbs 44, 45. Furthermore, promotion of measures which can reduce the severity of 
injuries following a fall, such as bicycle helmets, should also be considered 46.  
 
Chapter 2.2 Vitamin D and physical performance 
We investigated whether higher serum 25-hydroxy vitamin D [25(OH)D] concentrations were 
associated with better strength and physical performance. Muscle tissue is an important target 
tissue of vitamin D 47. Furthermore, vitamin D deficiency has been shown to be a key 
contributor to a decline in physical performance and increase in fall incidence 14-21. However, 
most studies demonstrating the relationship between vitamin D levels and physical 
performance were conducted in female-only populations 14, 17-20.  In addition, recent studies 
investigating the relationship between serum 25(OH)D levels and physical performance in 
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population of highly functional, younger men with a low prevalence of vitamin D deficiency. 
Furthermore, evidence regarding an underlying gender-specific mechanism is lacking.  
As was hypothesized, serum 25(OH)D levels were significantly associated with 
muscle strength and physical performance, not only in community-dwelling older women, but 
also in men. Furthermore, it was striking to note how few of the older fallers in our study 
were prescribed vitamin D supplements, especially in the male population; though 44% of the 
men and women were deficient in vitamin D, only 6% of the men and 17% of the women 
used vitamin D supplements. The under-prescribing of vitamin D in this age group has 
previously been reported 50. Yet, despite evidence that vitamin D supplementation has been 
shown to increase muscle strength and reduce the risk of falls 51, vitamin D deficiency is still 
common in community-dwelling elderly, with a prevalence of 40-100% in U.S. and European 
older men and women 47. Furthermore, while we set the levels ≥50 nmol/L as vitamin D 
sufficient, another opinion is that optimal vitamin D levels should be ≥75 nmol/L 52. This is 
interesting to note when considering our results, where it seems levels closer to 75 nmol/L 
result in continued physical performance benefits, especially in men. 
 
Chapter 2.3 Single and Recurrent fallers 
Fallers are classified in different ways. A single faller is generally defined as someone who 
has fallen at least once during a defined time period, usually 6 or 12 months. A recurrent faller 
is someone who has fallen twice or more during a defined time period 53. Guidelines 
concerning falls prevention make a clear distinction between single and recurrent fallers, a 
recurrent faller is at greater risk for future falls 25, 54.  
Several studies have reported specific differences between single and recurrent fallers, 
using varying outcome measures like sensory and motor function outcomes 55, certain 
physical performance tests 56-58, the Mini-Mental State Examination (MMSE) 59, 
 
posturography 60, 61, and dual-tasking tests 62, 63. Most studies compared the prevalence of 
specific risk factors in single and recurrent fallers 64-67. In addition to investigating the 
differences in physical performance and functional status between single and recurrent fallers, 
we assessed differences in health related quality of life (HRQoL).  
Recurrent fallers scored significantly poorer than the single fallers in all the physical 
performance tests, these tests measure mobility, muscle strength and balance. In previous 
literature, 12 seconds has been suggested as a practical cut-off value for the Timed “Up & 
Go” test, and has been found useful in detecting mobility impairment in elderly persons 68. In 
the current study population recurrent fallers had below normal Timed “Up & Go” test scores, 
and were significantly slower than the single fallers who had normal scores. Furthermore, 
poor muscle strength is a known risk factor for falls 24, it predicts disability 69, and mortality 
70, and is one of the criteria used to define frailty 71. The recurrent fallers also reported lower 
HRQoL scores than the single fallers, including significantly lower EQ-5D utility scores and 
more problems in all the five EQ-5D domains. In addition, recurrent fallers scored below the 
Dutch population norm for the SF-12 PCS and MCS, while the single fallers scored above the 
norm. Surprisingly, the functional status scores did not differ between single and recurrent 
fallers, despite of recurrent fallers having poorer physical performance and lower HRQoL 
scores. A potential explanation for this finding is that the study population consisted of 
community-dwelling older adults. Being able to perform the individual components of ADL 
and IADL is a prerequisite for living independently. Possibly the sensitivity of the ADL and 
IADL questionnaires was not sufficient to detect differences in functional status. 
 
Chapter 3.2 The effect of fall-risk increasing drug withdrawal on reducing incidence of falls 
The use of FRIDs 26-28, 31, mainly psychotropic and cardiovascular drugs, has been associated 
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feasible and effective 29, 31, 33, 34. Although FRIDs withdrawal is frequently incorporated in 
multifactorial intervention trials, evidence regarding overall FRID withdrawal as a single 
intervention is scarce 35.  
We investigated the effect of a structured medication assessment including withdrawal 
of FRIDs versus ‘care as usual’ on reducing falls in community-dwelling older men and 
women, who visited the ED after experiencing a fall 39. Overall, FRIDs withdrawal did not 
result in reduced incidence of falls, whereas, cardiovascular FRIDs withdrawal did reduce  
healthcare visits because of a fall. Surprisingly, no effect of psychotropic drug withdrawal 
was seen. 
There are several possible explanations for our findings. First, since in the last decade, 
falls prevention guidelines have been incorporated into usual care, this may well have blunted 
the effect of the intervention. Second, in our intervention group a large proportion of FRIDs 
were prescribed adequately and thus withdrawal was not appropriate . Third, a large 
proportion of the participants in the intervention group was not compliant to the intervention, 
especially concerning psychotropic drugs withdrawal. Fourth, it might be possible that 
participants in the intervention group were more diligent when filling out their Falls 
Calendars than the usual care group. The time till first and second fall were recorded from the 
Falls Calendars which participants from both group filled out and the time till the first GP 
consultation and ED visit were recorded from GP data. Although not statistically significant, 
the intervention group displayed a tendency towards a shorter time until the first fall, yet a 
longer time until the first GP consultation or ED visit because of a fall. Furthermore, when 
studying the participants in the successful withdrawal group individually, it was apparent that 
although one or more FRIDs were successfully withdrawn, reduced, or substituted, several 
participants were prescribed additional FRIDs during the follow-up year by their GP or other 
 
specialist, often for new conditions. The percentage of participants using ≥ 3 FRIDs in the 
intervention group (70%) was not decreased at 1 year follow-up. 
In a study by Pit et al. the intervention was carried out by the participants’ GP, 
probably increasing and sustaining the number of successful withdrawals due to the more 
substantial doctor-patient relationship 34. Campbell et al. performed a psychotropic drug 
withdrawal intervention that was complete and double-blinded, demonstrating the 
effectiveness of total psychotropic drug withdrawal on preventing falls 29. Yet this complete 
withdrawal was difficult to maintain. Notably, in our study the withdrawal of cardiovascular 
FRIDs appeared to reduce risk of GP consultations because of a fall, possibly due to fewer 
injurious falls. Most studies associate greater fall risk with psychotropic drugs 26, 28, however, 
besides our finding, another study has also reported greater risk reduction after withdrawal of 
cardiovascular drugs 31. Furthermore, another recent large study found that antihypertensive 
medications were associated with an increased risk of serious fall injuries 72. 
 
Chapter 3.3 The costs, the effect on HRQoL, and the cost-utility of FRID withdrawal 
Falls affect a large proportion of the persons aged 65 years and older and are associated with 
consequences such as loss of quality of life and high cost 1, 5-8. In 2000 the fall-related medical 
costs in the population 65 years and older in the United States amounted to US$19 billion for 
non-fatal injuries and US$200 million for fatal injuries 4. Between 2003 and 2007 the average 
annual cost for fall-related injuries in the Netherlands was US$ 640 million (€470 million), 
and the overall cost per fall was US$9,530 (€7,048) 7. Various studies have reported cost and 
cost-effectiveness data regarding fall prevention trials with varying results, however, most 
studies evaluated multifactorial interventions 73-83. One study reported on the cost-
effectiveness of FRID withdrawal as a single intervention, and reported significant national 
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withdrawal was difficult to maintain. Notably, in our study the withdrawal of cardiovascular 
FRIDs appeared to reduce risk of GP consultations because of a fall, possibly due to fewer 
injurious falls. Most studies associate greater fall risk with psychotropic drugs 26, 28, however, 
besides our finding, another study has also reported greater risk reduction after withdrawal of 
cardiovascular drugs 31. Furthermore, another recent large study found that antihypertensive 
medications were associated with an increased risk of serious fall injuries 72. 
 
Chapter 3.3 The costs, the effect on HRQoL, and the cost-utility of FRID withdrawal 
Falls affect a large proportion of the persons aged 65 years and older and are associated with 
consequences such as loss of quality of life and high cost 1, 5-8. In 2000 the fall-related medical 
costs in the population 65 years and older in the United States amounted to US$19 billion for 
non-fatal injuries and US$200 million for fatal injuries 4. Between 2003 and 2007 the average 
annual cost for fall-related injuries in the Netherlands was US$ 640 million (€470 million), 
and the overall cost per fall was US$9,530 (€7,048) 7. Various studies have reported cost and 
cost-effectiveness data regarding fall prevention trials with varying results, however, most 
studies evaluated multifactorial interventions 73-83. One study reported on the cost-
effectiveness of FRID withdrawal as a single intervention, and reported significant national 




We investigated the costs, the effect on HRQoL, and the cost-utility of a structured 
medication assessment including withdrawal of FRIDs versus ‘care as usual’. The total 
healthcare related costs in the intervention group were €39 higher than usual care. FRID 
withdrawal was associated with less decline in HRQoL as measured with the EQ-5D utility 
score.  The intervention resulted in an incremental cost-utility ratio of €780/QALY gained. 
Policy makers and health economists have proposed that costs up to €20,000 per QALY are 
considered as acceptable 85.  
Higher compliance rates might have led to lower fall risk and lower related healthcare 
costs, and increased savings due to reduced medication costs (mean reduction of €38 per 
participant in this study). Furthermore, a less costly method of FRID withdrawal could be 
accomplished by having the GP perform the intervention, thus further lowering costs per 
QALY. 
Notably, the control group reported a significantly greater decline in HRQoL during 
the 12 month follow-up as measured with the EQ-5D utility score than the intervention group. 
It is important to note that except for a structured medication assessment, including the 
withdrawal of FRIDs, both groups received identical care. Furthermore, withdrawal of certain 
commonly prescribed FRIDs such as benzodiazepines, antidepressants and opiates 39, could 
have resulted in lower quality of life scores in the intervention group. Nonetheless, in this 
study the withdrawal of FRIDs did not lower the HRQoL. Remarkably, in the secondary 
analysis comparing the participants without a fall during follow-up the intervention group had 
lesser decline in the SF-12 PCS score than the control group. The fact that the intervention did 
not lower the HRQoL and possibly even improved it, is on its own an important outcome.  
 
STRENGTHS AND LIMITATIONS 
 
A major strength of this study is that current recommendations regarding falls prevention 
studies were followed 86, i.e., addressing a single intervention in a randomized controlled trial. 
Furthermore, participants included were high-risk fallers, i.e., older men and women who 
visited the ED because of a fall. In this target group even a small reduction of their fall risk 
might prevent loss of independence. In addition, the study population size, the validated tests 
used to assess physical performance and HRQoL outcome measures are also strengths 86. 
Finally, the execution of the IMPROveFALL study came very close to current clinical 
practice, thus our results can be applied directly. 
The following limitations should be taken into account when interpreting our results. 
First, recruiting participants proved challenging. Possible reasons for refusing to participate 
have been reported previously 87. Most common reasons for refusal were the added burden of 
additional visits to the hospital; highly independent older adults feeling “too healthy”; and 
personal opinions regarding the cause of the fall. Second, possibly the method of reporting 
falls was not as accurate as anticipated; as mentioned above, the intervention group reported 
as many falls as the control group, but the numbers of healthcare visits because of a fall 
(which were verified with GP records) were higher in the control group. The newest 
guidelines state fall incidence is best monitored with weekly phone calls instead of self-report 
calendars 88. Third, as mentioned before, in the intervention group compliance with 
withdrawal was limited, especially in the group with psychotropic drug withdrawal. This 
might be improved if  the prescribing physician performs the withdrawal, as was the case in 
the study by Pit et al. 34. Fourth, the dropout during the 12 month follow-up could be due to 
the selected study population which had a high risk of falling. These patients often had 
mobility impairments and other comorbid conditions that may have resulted in a refusal to 
continue participating in the study and visit our outpatient clinic after 12 months follow-up. 
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however, the randomization would have equally divided these patients across the intervention 
and control group. 
And solely regarding the cost-utility analyses, the SF-12 has been evaluated for use in 
large group comparisons, this may not be correct for our secondary analyses where we solely 
included participants with and without a fall during follow-up 89. Furthermore, the main aim 
of this study was to study the effectiveness of the intervention that is why the power 
calculation was based on a falls reduction rather than QALYs or costs. 
 
CLINICAL IMPLICATIONS AND FUTURE RESEARCH 
This study increases insight into both the effectiveness of FRIDs withdrawal as a method for 
falls reduction in older adults, and into the complexity of this intervention in an older, multi-
morbid population. The current study adds to the understanding of effective falls-prevention 
interventions.  Overall, FRIDs withdrawal did not result in reduced incidence of falls, 
whereas, cardiovascular FRIDs withdrawal did reduce  healthcare visits because of a fall. 
Surprisingly, no effect of psychotropic drug withdrawal was seen, which might have been 
caused by low compliance to the intervention. The potential harm versus benefit of 
antihypertensive medications should be weighed in older adults with multiple chronic 
conditions 72. The method of implementation of fall-risk increasing drugs withdrawal is 
essential, compliance might be improved if  the prescribing physician performs the 
withdrawal. Further research is warranted focusing on the optimal method for 




1. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the 
risk of falling among elderly people living in the community. N Engl J Med 1994;331:821-7. 
2. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip 
fractures in the United States. Jama 2009;302:1573-9. 
3. Kochanek KD, Xu JQ, Murphy SL, al. e. Deaths: Preliminary data for 2009. . In: 
Hyattsville, MD: National Center for Health Statistics. ; 2011. 
4. Stevens JA, Corso PS, Finkelstein EA, Miller TR. The costs of fatal and non-fatal falls 
among older adults. Inj Prev 2006;12:290-5. 
5. Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P. Functional 
outcome and quality of life following hip fracture in elderly women: a prospective controlled 
study. Osteoporos Int 2004;15:87-94. 
6. Close JC, Lord SR, Antonova EJ, et al. Older people presenting to the emergency 
department after a fall: a population with substantial recurrent healthcare use. Emerg Med J 
2012;29:742-7. 
7. Hartholt KA, van Beeck EF, Polinder S, et al. Societal consequences of falls in the 
older population: injuries, healthcare costs, and long-term reduced quality of life. J Trauma 
2011;71:748-53. 
8. Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. 
Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 
2000;11:460-6. 
9. Greenspan AI, Coronado VG, Mackenzie EJ, Schulman J, Pierce B, Provenzano G. 
Injury hospitalizations: using the nationwide inpatient sample. J Trauma 2006;61:1234-43. 
10. Hartholt KA, van der Velde N, Looman CW, et al. Trends in fall-related hospital 
admissions in older persons in the Netherlands. Arch Intern Med 2010;170:905-11. 
11. Hartholt KA, Van Lieshout EMM, Polinder S, Panneman MJ, Van der Cammen TJM, 
Patka P. Rapid increase in hospitalizations resulting from fall-related traumatic head injury in 
older adults in The Netherlands 1986-2008. J Neurotrauma 2011;28:739-44. 
12. Scuffham P, Chaplin S, Legood R. Incidence and costs of unintentional falls in older 
people in the United Kingdom. J Epidemiol Community Health 2003;57:740-4. 
13. KIWG. The prevention of falls in later life. A report of the Kellogg International Work 
Group on the Prevention of Falls by the Elderly. Dan Med Bull 1987;34 Suppl 4:1-24. 
14. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D 
concentrations are associated with better lower-extremity function in both active and inactive 
persons aged > or =60 y. Am J Clin Nutr 2004;80:752-8. 
15. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of 
fallers in a community-dwelling elderly population with a minimum calcium intake of more 
than 500 mg daily. J Am Geriatr Soc 2004;52:230-6. 
16. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with 
estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 
2001;86:3618-28. 
17. Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy 
vitamin D levels, physical activity, muscle strength and fractures in the prospective 
population-based OPRA Study of Elderly Women. Osteoporos Int 2005;16:1425-31. 
18. Okuno J, Tomura S, Yabushita N, et al. Effects of serum 25-hydroxyvitamin D(3) 











however, the randomization would have equally divided these patients across the intervention 
and control group. 
And solely regarding the cost-utility analyses, the SF-12 has been evaluated for use in 
large group comparisons, this may not be correct for our secondary analyses where we solely 
included participants with and without a fall during follow-up 89. Furthermore, the main aim 
of this study was to study the effectiveness of the intervention that is why the power 
calculation was based on a falls reduction rather than QALYs or costs. 
 
CLINICAL IMPLICATIONS AND FUTURE RESEARCH 
This study increases insight into both the effectiveness of FRIDs withdrawal as a method for 
falls reduction in older adults, and into the complexity of this intervention in an older, multi-
morbid population. The current study adds to the understanding of effective falls-prevention 
interventions.  Overall, FRIDs withdrawal did not result in reduced incidence of falls, 
whereas, cardiovascular FRIDs withdrawal did reduce  healthcare visits because of a fall. 
Surprisingly, no effect of psychotropic drug withdrawal was seen, which might have been 
caused by low compliance to the intervention. The potential harm versus benefit of 
antihypertensive medications should be weighed in older adults with multiple chronic 
conditions 72. The method of implementation of fall-risk increasing drugs withdrawal is 
essential, compliance might be improved if  the prescribing physician performs the 
withdrawal. Further research is warranted focusing on the optimal method for 




1. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the 
risk of falling among elderly people living in the community. N Engl J Med 1994;331:821-7. 
2. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip 
fractures in the United States. Jama 2009;302:1573-9. 
3. Kochanek KD, Xu JQ, Murphy SL, al. e. Deaths: Preliminary data for 2009. . In: 
Hyattsville, MD: National Center for Health Statistics. ; 2011. 
4. Stevens JA, Corso PS, Finkelstein EA, Miller TR. The costs of fatal and non-fatal falls 
among older adults. Inj Prev 2006;12:290-5. 
5. Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P. Functional 
outcome and quality of life following hip fracture in elderly women: a prospective controlled 
study. Osteoporos Int 2004;15:87-94. 
6. Close JC, Lord SR, Antonova EJ, et al. Older people presenting to the emergency 
department after a fall: a population with substantial recurrent healthcare use. Emerg Med J 
2012;29:742-7. 
7. Hartholt KA, van Beeck EF, Polinder S, et al. Societal consequences of falls in the 
older population: injuries, healthcare costs, and long-term reduced quality of life. J Trauma 
2011;71:748-53. 
8. Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. 
Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 
2000;11:460-6. 
9. Greenspan AI, Coronado VG, Mackenzie EJ, Schulman J, Pierce B, Provenzano G. 
Injury hospitalizations: using the nationwide inpatient sample. J Trauma 2006;61:1234-43. 
10. Hartholt KA, van der Velde N, Looman CW, et al. Trends in fall-related hospital 
admissions in older persons in the Netherlands. Arch Intern Med 2010;170:905-11. 
11. Hartholt KA, Van Lieshout EMM, Polinder S, Panneman MJ, Van der Cammen TJM, 
Patka P. Rapid increase in hospitalizations resulting from fall-related traumatic head injury in 
older adults in The Netherlands 1986-2008. J Neurotrauma 2011;28:739-44. 
12. Scuffham P, Chaplin S, Legood R. Incidence and costs of unintentional falls in older 
people in the United Kingdom. J Epidemiol Community Health 2003;57:740-4. 
13. KIWG. The prevention of falls in later life. A report of the Kellogg International Work 
Group on the Prevention of Falls by the Elderly. Dan Med Bull 1987;34 Suppl 4:1-24. 
14. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D 
concentrations are associated with better lower-extremity function in both active and inactive 
persons aged > or =60 y. Am J Clin Nutr 2004;80:752-8. 
15. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of 
fallers in a community-dwelling elderly population with a minimum calcium intake of more 
than 500 mg daily. J Am Geriatr Soc 2004;52:230-6. 
16. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with 
estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 
2001;86:3618-28. 
17. Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy 
vitamin D levels, physical activity, muscle strength and fractures in the prospective 
population-based OPRA Study of Elderly Women. Osteoporos Int 2005;16:1425-31. 
18. Okuno J, Tomura S, Yabushita N, et al. Effects of serum 25-hydroxyvitamin D(3) 





19. Pfeifer M, Begerow B, Minne HW, et al. Vitamin D status, trunk muscle strength, 
body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp 
Clin Endocrinol Diabetes 2001;109:87-92. 
20. Stewart JW, Alekel DL, Ritland LM, Van Loan M, Gertz E, Genschel U. Serum 25-
hydroxyvitamin D is related to indicators of overall physical fitness in healthy 
postmenopausal women. Menopause 2009;16:1093-101. 
21. Wicherts IS, van Schoor NM, Boeke AJ, et al. Vitamin D status predicts physical 
performance and its decline in older persons. J Clin Endocrinol Metab 2007;92:2058-65. 
22. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons 
living in the community. N Engl J Med 1988;319:1701-7. 
23. Nevitt MC, Cummings SR, Kidd S, Black D. Risk factors for recurrent nonsyncopal 
falls. A prospective study. Jama 1989;261:2663-8. 
24. Moreland JD, Richardson JA, Goldsmith CH, Clase CM. Muscle weakness and falls in 
older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2004;52:1121-9. 
25. AGS/BGS/AAOS. Guideline for the prevention of falls in older persons. American 
Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic 
Surgeons Panel on Falls Prevention. J Am Geriatr Soc 2001;49:664-72. 
26. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 
medication classes on falls in elderly persons. Arch Intern Med 2009;169:1952-60. 
27. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic 
review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999;47:40-50. 
28. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic 
review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47:30-9. 
29. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM. Psychotropic 
medication withdrawal and a home-based exercise program to prevent falls: a randomized, 
controlled trial. J Am Geriatr Soc 1999;47:850-3. 
30. Close J, Ellis M, Hooper R, Glucksman E, Jackson S, Swift C. Prevention of falls in 
the elderly trial (PROFET): a randomised controlled trial. Lancet 1999;353:93-7. 
31. van der Velde N, Stricker BH, Pols HA, van der Cammen TJ. Risk of falls after 
withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 
2007;63:232-7. 
32. Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ. Dose-response 
relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in 
nursing home residents with dementia. Br J Clin Pharmacol 2012;73:812-20. 
33. Alsop K, Mac Mahon M. Withdrawing cardiovascular medications at a syncope clinic. 
Postgrad Med J 2001;77:403-5. 
34. Pit SW, Byles JE, Henry DA, Holt L, Hansen V, Bowman DA. A Quality Use of 
Medicines program for general practitioners and older people: a cluster randomised controlled 
trial. Med J Aust 2007;187:23-30. 
35. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in 
older people living in the community. Cochrane Database Syst Rev 2012;9:CD007146. 
36. Boyé ND, Mattace-Raso FU, Van der Velde N, et al. Circumstances leading to 
injurious falls in older men and women in the Netherlands. Injury 2014;45:1224-30. 
37. Boyé ND, Oudshoorn C, van der Velde N, et al. Vitamin D and physical performance 
in older men and women visiting the emergency department because of a fall: data from the 
improving medication prescribing to reduce risk of falls (IMPROveFALL) study. J Am 
Geriatr Soc 2013;61:1948-52. 
38. Boyé ND, Mattace-Raso FU, Van Lieshout EM, Hartholt KA, Van Beeck EF, Van der 
Cammen TJ. Physical performance and quality of life in single and recurrent fallers: Data 
 
from the Improving Medication Prescribing to Reduce Risk of Falls study. Geriatr Gerontol 
Int 2014. 
39. Hartholt KA, Boyé NDA, Van der Velde N, et al. [Cost]effectiveness of withdrawal of 
fall-risk increasing drugs versus conservative treatment in older fallers: design of a 
multicenter randomized controlled trial (IMPROveFALL-study). BMC Geriatr 2011;11:48. 
40. Faul M, Xu L, Wald MM, Coronado VG. Traumatic Brain Injury in the United States: 
Emergency Department Visits, Hospitalizations and Deaths 2002–2006. In: Centers for 
Disease Control and Prevention NCfIPaC, ed.; 2010. 
41. Hartholt KA, van Beeck EF, Polinder S, et al. Societal consequences of falls in the 
older population: injuries, healthcare costs, and long-term reduced quality of life. J Trauma 
2010;71:748-53. 
42. Kannus P, Niemi S, Parkkari J, Palvanen M, Sievanen H. Alarming rise in fall-induced 
severe head injuries among elderly people. Injury 2007;38:81-3. 
43. Bath PA, Morgan K. Differential risk factor profiles for indoor and outdoor falls in 
older people living at home in Nottingham, UK. Eur J Epidemiol 1999;15:65-73. 
44. Lai PC, Wong WC, Low CT, Wong M, Chan MH. A small-area study of 
environmental risk assessment of outdoor falls. J Med Syst 2011;35:1543-52. 
45. Li W, Keegan TH, Sternfeld B, Sidney S, Quesenberry CP, Jr., Kelsey JL. Outdoor 
falls among middle-aged and older adults: a neglected public health problem. Am J Public 
Health 2006;96:1192-200. 
46. Macpherson A, Spinks A. Bicycle helmet legislation for the uptake of helmet use and 
prevention of head injuries. Cochrane Database Syst Rev 2008:CD005401. 
47. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. 
48. Ceglia L, Chiu GR, Harris SS, Araujo AB. Serum 25-hydroxyvitamin D concentration 
and physical function in adult men. Clin Endocrinol (Oxf) 2011;74:370-6. 
49. Dam TT, von Muhlen D, Barrett-Connor EL. Sex-specific association of serum 
vitamin D levels with physical function in older adults. Osteoporos Int 2009;20:751-60. 
50. Lang PO, Hasso Y, Drame M, et al. Potentially inappropriate prescribing including 
under-use amongst older patients with cognitive or psychiatric co-morbidities. Age Ageing 
2012;39:373-81. 
51. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on 
falls: a meta-analysis. Jama 2004;291:1999-2006. 
52. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of 
optimal vitamin D status. Osteoporos Int 2005;16:713-6. 
53. Masud T, Morris RO. Epidemiology of falls. Age Ageing 2001;30 Suppl 4:3-7. 
54. AGS/BGS. Summary of the Updated American Geriatrics Society/British Geriatrics 
Society clinical practice guideline for prevention of falls in older persons. J Am Geriatr Soc 
2010;59:148-57. 
55. Lord SR, Ward JA, Williams P, Anstey KJ. Physiological factors associated with falls 
in older community-dwelling women. J Am Geriatr Soc 1994;42:1110-7. 
56. Anstey KJ, Wood J, Kerr G, Caldwell H, Lord SR. Different cognitive profiles for 
single compared with recurrent fallers without dementia. Neuropsychology 2009;23:500-8. 
57. Buatois S, Perret-Guillaume C, Gueguen R, et al. A simple clinical scale to stratify 
risk of recurrent falls in community-dwelling adults aged 65 years and older. Phys Ther 
2010;90:550-60. 
58. Tinetti ME, Williams TF, Mayewski R. Fall risk index for elderly patients based on 
number of chronic disabilities. Am J Med 1986;80:429-34. 
59. Chen X, Van Nguyen H, Shen Q, Chan DK. Characteristics associated with recurrent 
falls among the elderly within aged-care wards in a tertiary hospital: the effect of cognitive 










19. Pfeifer M, Begerow B, Minne HW, et al. Vitamin D status, trunk muscle strength, 
body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp 
Clin Endocrinol Diabetes 2001;109:87-92. 
20. Stewart JW, Alekel DL, Ritland LM, Van Loan M, Gertz E, Genschel U. Serum 25-
hydroxyvitamin D is related to indicators of overall physical fitness in healthy 
postmenopausal women. Menopause 2009;16:1093-101. 
21. Wicherts IS, van Schoor NM, Boeke AJ, et al. Vitamin D status predicts physical 
performance and its decline in older persons. J Clin Endocrinol Metab 2007;92:2058-65. 
22. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons 
living in the community. N Engl J Med 1988;319:1701-7. 
23. Nevitt MC, Cummings SR, Kidd S, Black D. Risk factors for recurrent nonsyncopal 
falls. A prospective study. Jama 1989;261:2663-8. 
24. Moreland JD, Richardson JA, Goldsmith CH, Clase CM. Muscle weakness and falls in 
older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2004;52:1121-9. 
25. AGS/BGS/AAOS. Guideline for the prevention of falls in older persons. American 
Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic 
Surgeons Panel on Falls Prevention. J Am Geriatr Soc 2001;49:664-72. 
26. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 
medication classes on falls in elderly persons. Arch Intern Med 2009;169:1952-60. 
27. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic 
review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999;47:40-50. 
28. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic 
review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47:30-9. 
29. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM. Psychotropic 
medication withdrawal and a home-based exercise program to prevent falls: a randomized, 
controlled trial. J Am Geriatr Soc 1999;47:850-3. 
30. Close J, Ellis M, Hooper R, Glucksman E, Jackson S, Swift C. Prevention of falls in 
the elderly trial (PROFET): a randomised controlled trial. Lancet 1999;353:93-7. 
31. van der Velde N, Stricker BH, Pols HA, van der Cammen TJ. Risk of falls after 
withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 
2007;63:232-7. 
32. Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ. Dose-response 
relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in 
nursing home residents with dementia. Br J Clin Pharmacol 2012;73:812-20. 
33. Alsop K, Mac Mahon M. Withdrawing cardiovascular medications at a syncope clinic. 
Postgrad Med J 2001;77:403-5. 
34. Pit SW, Byles JE, Henry DA, Holt L, Hansen V, Bowman DA. A Quality Use of 
Medicines program for general practitioners and older people: a cluster randomised controlled 
trial. Med J Aust 2007;187:23-30. 
35. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in 
older people living in the community. Cochrane Database Syst Rev 2012;9:CD007146. 
36. Boyé ND, Mattace-Raso FU, Van der Velde N, et al. Circumstances leading to 
injurious falls in older men and women in the Netherlands. Injury 2014;45:1224-30. 
37. Boyé ND, Oudshoorn C, van der Velde N, et al. Vitamin D and physical performance 
in older men and women visiting the emergency department because of a fall: data from the 
improving medication prescribing to reduce risk of falls (IMPROveFALL) study. J Am 
Geriatr Soc 2013;61:1948-52. 
38. Boyé ND, Mattace-Raso FU, Van Lieshout EM, Hartholt KA, Van Beeck EF, Van der 
Cammen TJ. Physical performance and quality of life in single and recurrent fallers: Data 
 
from the Improving Medication Prescribing to Reduce Risk of Falls study. Geriatr Gerontol 
Int 2014. 
39. Hartholt KA, Boyé NDA, Van der Velde N, et al. [Cost]effectiveness of withdrawal of 
fall-risk increasing drugs versus conservative treatment in older fallers: design of a 
multicenter randomized controlled trial (IMPROveFALL-study). BMC Geriatr 2011;11:48. 
40. Faul M, Xu L, Wald MM, Coronado VG. Traumatic Brain Injury in the United States: 
Emergency Department Visits, Hospitalizations and Deaths 2002–2006. In: Centers for 
Disease Control and Prevention NCfIPaC, ed.; 2010. 
41. Hartholt KA, van Beeck EF, Polinder S, et al. Societal consequences of falls in the 
older population: injuries, healthcare costs, and long-term reduced quality of life. J Trauma 
2010;71:748-53. 
42. Kannus P, Niemi S, Parkkari J, Palvanen M, Sievanen H. Alarming rise in fall-induced 
severe head injuries among elderly people. Injury 2007;38:81-3. 
43. Bath PA, Morgan K. Differential risk factor profiles for indoor and outdoor falls in 
older people living at home in Nottingham, UK. Eur J Epidemiol 1999;15:65-73. 
44. Lai PC, Wong WC, Low CT, Wong M, Chan MH. A small-area study of 
environmental risk assessment of outdoor falls. J Med Syst 2011;35:1543-52. 
45. Li W, Keegan TH, Sternfeld B, Sidney S, Quesenberry CP, Jr., Kelsey JL. Outdoor 
falls among middle-aged and older adults: a neglected public health problem. Am J Public 
Health 2006;96:1192-200. 
46. Macpherson A, Spinks A. Bicycle helmet legislation for the uptake of helmet use and 
prevention of head injuries. Cochrane Database Syst Rev 2008:CD005401. 
47. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. 
48. Ceglia L, Chiu GR, Harris SS, Araujo AB. Serum 25-hydroxyvitamin D concentration 
and physical function in adult men. Clin Endocrinol (Oxf) 2011;74:370-6. 
49. Dam TT, von Muhlen D, Barrett-Connor EL. Sex-specific association of serum 
vitamin D levels with physical function in older adults. Osteoporos Int 2009;20:751-60. 
50. Lang PO, Hasso Y, Drame M, et al. Potentially inappropriate prescribing including 
under-use amongst older patients with cognitive or psychiatric co-morbidities. Age Ageing 
2012;39:373-81. 
51. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on 
falls: a meta-analysis. Jama 2004;291:1999-2006. 
52. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of 
optimal vitamin D status. Osteoporos Int 2005;16:713-6. 
53. Masud T, Morris RO. Epidemiology of falls. Age Ageing 2001;30 Suppl 4:3-7. 
54. AGS/BGS. Summary of the Updated American Geriatrics Society/British Geriatrics 
Society clinical practice guideline for prevention of falls in older persons. J Am Geriatr Soc 
2010;59:148-57. 
55. Lord SR, Ward JA, Williams P, Anstey KJ. Physiological factors associated with falls 
in older community-dwelling women. J Am Geriatr Soc 1994;42:1110-7. 
56. Anstey KJ, Wood J, Kerr G, Caldwell H, Lord SR. Different cognitive profiles for 
single compared with recurrent fallers without dementia. Neuropsychology 2009;23:500-8. 
57. Buatois S, Perret-Guillaume C, Gueguen R, et al. A simple clinical scale to stratify 
risk of recurrent falls in community-dwelling adults aged 65 years and older. Phys Ther 
2010;90:550-60. 
58. Tinetti ME, Williams TF, Mayewski R. Fall risk index for elderly patients based on 
number of chronic disabilities. Am J Med 1986;80:429-34. 
59. Chen X, Van Nguyen H, Shen Q, Chan DK. Characteristics associated with recurrent 
falls among the elderly within aged-care wards in a tertiary hospital: the effect of cognitive 




60. Bigelow KE, Berme N. Development of a protocol for improving the clinical utility of 
posturography as a fall-risk screening tool. J Gerontol A Biol Sci Med Sci 2011;66:228-33. 
61. Buatois S, Gueguen R, Gauchard GC, Benetos A, Perrin PP. Posturography and risk of 
recurrent falls in healthy non-institutionalized persons aged over 65. Gerontology 
2006;52:345-52. 
62. Beauchet O, Annweiler C, Allali G, Berrut G, Herrmann FR, Dubost V. Recurrent 
falls and dual task-related decrease in walking speed: is there a relationship? J Am Geriatr Soc 
2008;56:1265-9. 
63. Faulkner KA, Redfern MS, Cauley JA, et al. Multitasking: association between poorer 
performance and a history of recurrent falls. J Am Geriatr Soc 2007;55:570-6. 
64. Fletcher PC, Hirdes JP. Risk factors for falling among community-based seniors using 
home care services. J Gerontol A Biol Sci Med Sci 2002;57:M504-10. 
65. Melzer I, Kurz I. Self reported function and disability in late life: a comparison 
between recurrent fallers and non-fallers. Disabil Rehabil 2009;31:791-8. 
66. Rossat A, Fantino B, Nitenberg C, et al. Risk factors for falling in community-
dwelling older adults: which of them are associated with the recurrence of falls? J Nutr Health 
Aging 2010;14:787-91. 
67. Vassallo M, Sharma JC, Allen SC. Characteristics of single fallers and recurrent 
fallers among hospital in-patients. Gerontology 2002;48:147-50. 
68. Bischoff HA, Stahelin HB, Monsch AU, et al. Identifying a cut-off point for normal 
mobility: a comparison of the timed 'up and go' test in community-dwelling and 
institutionalised elderly women. Age Ageing 2003;32:315-20. 
69. Hairi NN, Cumming RG, Naganathan V, et al. Loss of muscle strength, mass 
(sarcopenia), and quality (specific force) and its relationship with functional limitation and 
physical disability: the Concord Health and Ageing in Men Project. J Am Geriatr Soc 
2010;58:2055-62. 
70. Bohannon RW. Hand-grip dynamometry predicts future outcomes in aging adults. J 
Geriatr Phys Ther 2008;31:3-10. 
71. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a 
phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56. 
72. Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall 
injuries in a nationally representative sample of older adults. JAMA Intern Med 
2014;174:588-95. 
73. Campbell AJ, Robertson MC, La Grow SJ, et al. Randomised controlled trial of 
prevention of falls in people aged > or =75 with severe visual impairment: the VIP trial. BMJ 
2005;331:817. 
74. Church J, Goodall S, Norman R, Haas M. An economic evaluation of community and 
residential aged care falls prevention strategies in NSW. N S W Public Health Bull 
2011;22:60-8. 
75. Davis JC, Marra CA, Robertson MC, et al. Economic evaluation of dose-response 
resistance training in older women: a cost-effectiveness and cost-utility analysis. Osteoporos 
Int 2011;22:1355-66. 
76. Heinrich S, Rapp K, Stuhldreher N, Rissmann U, Becker C, Konig HH. Cost-
effectiveness of a multifactorial fall prevention program in nursing homes. Osteoporos Int 
2013;24:1215-23. 
77. Hendriks MR, Evers SM, Bleijlevens MH, van Haastregt JC, Crebolder HF, van Eijk 
JT. Cost-effectiveness of a multidisciplinary fall prevention program in community-dwelling 
elderly people: a randomized controlled trial (ISRCTN 64716113). Int J Technol Assess 
Health Care 2008;24:193-202. 
 
78. Irvine L, Conroy SP, Sach T, et al. Cost-effectiveness of a day hospital falls 
prevention programme for screened community-dwelling older people at high risk of falls. 
Age Ageing 2010;39:710-6. 
79. Jenkyn KB, Hoch JS, Speechley M. How much are we willing to pay to prevent a fall? 
Cost-effectiveness of a multifactorial falls prevention program for community-dwelling older 
adults. Can J Aging 2012;31:121-37. 
80. Peeters GM, Heymans MW, de Vries OJ, Bouter LM, Lips P, van Tulder MW. 
Multifactorial evaluation and treatment of persons with a high risk of recurrent falling was not 
cost-effective. Osteoporos Int 2011;22:2187-96. 
81. Rizzo JA, Baker DI, McAvay G, Tinetti ME. The cost-effectiveness of a multifactorial 
targeted prevention program for falls among community elderly persons. Med Care 
1996;34:954-69. 
82. Robertson MC, Devlin N, Gardner MM, Campbell AJ. Effectiveness and economic 
evaluation of a nurse delivered home exercise programme to prevent falls. 1: Randomised 
controlled trial. BMJ 2001;322:697-701. 
83. Sach TH, Logan PA, Coupland CA, et al. Community falls prevention for people who 
call an emergency ambulance after a fall: an economic evaluation alongside a randomised 
controlled trial. Age Ageing 2012;41:635-41. 
84. van der Velde N, Meerding WJ, Looman CW, Pols HA, van der Cammen TJ. Cost 
effectiveness of withdrawal of fall-risk-increasing drugs in geriatric outpatients. Drugs Aging 
2008;25:521-9. 
85. NICE guide to the methods of health technology appraisal. In. London: National 
Institute for Health and Clinical Excellence; 2004. 
86. Lamb SE, Jorstad-Stein EC, Hauer K, Becker C. Development of a common outcome 
data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. J 
Am Geriatr Soc 2005;53:1618-22. 
87. Elskamp AB, Hartholt KA, Patka P, van Beeck EF, van der Cammen TJ. Why older 
people refuse to participate in falls prevention trials: a qualitative study. Exp Gerontol 
2012;47:342-5. 
88. Reelick MF, Faes MC, Lenferink A, Esselink RA, Olde Rikkert MG. The fall 
telephone for falls assessment in frail older persons; feasibility, reliability, and validity. J Am 
Geriatr Soc 2011;59:372-3. 
89. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and 
scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. 











60. Bigelow KE, Berme N. Development of a protocol for improving the clinical utility of 
posturography as a fall-risk screening tool. J Gerontol A Biol Sci Med Sci 2011;66:228-33. 
61. Buatois S, Gueguen R, Gauchard GC, Benetos A, Perrin PP. Posturography and risk of 
recurrent falls in healthy non-institutionalized persons aged over 65. Gerontology 
2006;52:345-52. 
62. Beauchet O, Annweiler C, Allali G, Berrut G, Herrmann FR, Dubost V. Recurrent 
falls and dual task-related decrease in walking speed: is there a relationship? J Am Geriatr Soc 
2008;56:1265-9. 
63. Faulkner KA, Redfern MS, Cauley JA, et al. Multitasking: association between poorer 
performance and a history of recurrent falls. J Am Geriatr Soc 2007;55:570-6. 
64. Fletcher PC, Hirdes JP. Risk factors for falling among community-based seniors using 
home care services. J Gerontol A Biol Sci Med Sci 2002;57:M504-10. 
65. Melzer I, Kurz I. Self reported function and disability in late life: a comparison 
between recurrent fallers and non-fallers. Disabil Rehabil 2009;31:791-8. 
66. Rossat A, Fantino B, Nitenberg C, et al. Risk factors for falling in community-
dwelling older adults: which of them are associated with the recurrence of falls? J Nutr Health 
Aging 2010;14:787-91. 
67. Vassallo M, Sharma JC, Allen SC. Characteristics of single fallers and recurrent 
fallers among hospital in-patients. Gerontology 2002;48:147-50. 
68. Bischoff HA, Stahelin HB, Monsch AU, et al. Identifying a cut-off point for normal 
mobility: a comparison of the timed 'up and go' test in community-dwelling and 
institutionalised elderly women. Age Ageing 2003;32:315-20. 
69. Hairi NN, Cumming RG, Naganathan V, et al. Loss of muscle strength, mass 
(sarcopenia), and quality (specific force) and its relationship with functional limitation and 
physical disability: the Concord Health and Ageing in Men Project. J Am Geriatr Soc 
2010;58:2055-62. 
70. Bohannon RW. Hand-grip dynamometry predicts future outcomes in aging adults. J 
Geriatr Phys Ther 2008;31:3-10. 
71. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a 
phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56. 
72. Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall 
injuries in a nationally representative sample of older adults. JAMA Intern Med 
2014;174:588-95. 
73. Campbell AJ, Robertson MC, La Grow SJ, et al. Randomised controlled trial of 
prevention of falls in people aged > or =75 with severe visual impairment: the VIP trial. BMJ 
2005;331:817. 
74. Church J, Goodall S, Norman R, Haas M. An economic evaluation of community and 
residential aged care falls prevention strategies in NSW. N S W Public Health Bull 
2011;22:60-8. 
75. Davis JC, Marra CA, Robertson MC, et al. Economic evaluation of dose-response 
resistance training in older women: a cost-effectiveness and cost-utility analysis. Osteoporos 
Int 2011;22:1355-66. 
76. Heinrich S, Rapp K, Stuhldreher N, Rissmann U, Becker C, Konig HH. Cost-
effectiveness of a multifactorial fall prevention program in nursing homes. Osteoporos Int 
2013;24:1215-23. 
77. Hendriks MR, Evers SM, Bleijlevens MH, van Haastregt JC, Crebolder HF, van Eijk 
JT. Cost-effectiveness of a multidisciplinary fall prevention program in community-dwelling 
elderly people: a randomized controlled trial (ISRCTN 64716113). Int J Technol Assess 
Health Care 2008;24:193-202. 
 
78. Irvine L, Conroy SP, Sach T, et al. Cost-effectiveness of a day hospital falls 
prevention programme for screened community-dwelling older people at high risk of falls. 
Age Ageing 2010;39:710-6. 
79. Jenkyn KB, Hoch JS, Speechley M. How much are we willing to pay to prevent a fall? 
Cost-effectiveness of a multifactorial falls prevention program for community-dwelling older 
adults. Can J Aging 2012;31:121-37. 
80. Peeters GM, Heymans MW, de Vries OJ, Bouter LM, Lips P, van Tulder MW. 
Multifactorial evaluation and treatment of persons with a high risk of recurrent falling was not 
cost-effective. Osteoporos Int 2011;22:2187-96. 
81. Rizzo JA, Baker DI, McAvay G, Tinetti ME. The cost-effectiveness of a multifactorial 
targeted prevention program for falls among community elderly persons. Med Care 
1996;34:954-69. 
82. Robertson MC, Devlin N, Gardner MM, Campbell AJ. Effectiveness and economic 
evaluation of a nurse delivered home exercise programme to prevent falls. 1: Randomised 
controlled trial. BMJ 2001;322:697-701. 
83. Sach TH, Logan PA, Coupland CA, et al. Community falls prevention for people who 
call an emergency ambulance after a fall: an economic evaluation alongside a randomised 
controlled trial. Age Ageing 2012;41:635-41. 
84. van der Velde N, Meerding WJ, Looman CW, Pols HA, van der Cammen TJ. Cost 
effectiveness of withdrawal of fall-risk-increasing drugs in geriatric outpatients. Drugs Aging 
2008;25:521-9. 
85. NICE guide to the methods of health technology appraisal. In. London: National 
Institute for Health and Clinical Excellence; 2004. 
86. Lamb SE, Jorstad-Stein EC, Hauer K, Becker C. Development of a common outcome 
data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. J 
Am Geriatr Soc 2005;53:1618-22. 
87. Elskamp AB, Hartholt KA, Patka P, van Beeck EF, van der Cammen TJ. Why older 
people refuse to participate in falls prevention trials: a qualitative study. Exp Gerontol 
2012;47:342-5. 
88. Reelick MF, Faes MC, Lenferink A, Esselink RA, Olde Rikkert MG. The fall 
telephone for falls assessment in frail older persons; feasibility, reliability, and validity. J Am 
Geriatr Soc 2011;59:372-3. 
89. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and 
scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. 










Summary and Conclusions 
 
Part I starts with a literature overview on the impact of falls in the elderly, the burden on 
healthcare, and the costs for society. Falls affect a large proportion of persons aged 65 years 
and older, and are associated with serious consequences such as high morbidity and mortality 
rates, disability, loss of quality of life, and institutionalization. Furthermore, fall-related 
injuries place a substantial burden on healthcare systems due to the large number of visits to 
emergency departmenst (ED), hospital admissions, admissions to long-term care and 
rehabilitation facilities; and high medical costs. 
 Part II provides insight into various factors associated with falls in older adults. We 
separated these into several components starting with the circumstances surrounding injurious 
falls,  then we investigated the effect of serum vitamin D on physical performance, and finally 
we compared functional, physical and health related quality of life scores between single and 
recurrent fallers. Chapter 2.1 provides an overview of the activity distributions leading to 
indoor and outdoor falls requiring an ED visit, and those resulting in traumatic brain injuries 
(TBI) and hip fractures. Two-thirds of all falls occurred indoors. The overall most common 
indoor activities leading to injurious falls were walking and walking up or down stairs. The 
overall most common outdoor activities leading to injurious falls were walking and cycling. 
We found that the indoor activities leading to major injuries, i.e. TBIs and hip fractures 
differed. Walking up or down stairs and housekeeping were the most common activities 
leading to a TBI whereas walking and sitting or standing were the most common activities 
leading to a hip fracture. Notably, about half of the traumatic brain injuries and hip fractures 
in men and women aged 65-79 years occurred outdoors. The most common outdoor activities 
leading to both injuries were walking and cycling. In Chapter 2.2 we demonstrate that serum 
 
25(OH)D levels are significantly associated with muscle strength and physical performance, 
not only in community-dwelling older women, but also in men. And in Chapter 2.3 we 
present evidence supporting current guidelines, which state that recurrent fallers should have a 
multifactorial fall risk assessment. Recurrent fallers scored significantly poorer than the single 
fallers in all the physical performance tests, these tests measure mobility, muscle strength and 
balance. Furthermore, recurrent fallers also reported lower health related quality of life scores 
than the single fallers, including significantly lower EQ-5D utility scores and more problems 
in all the five EQ-5D domains. 
Part III includes the IMPROveFALL study protocol in Chapter 3.1 16. The 
IMPROveFALL study is a multicenter randomized controlled trial investigating the effect of 
a structured medication assessment including withdrawal of FRIDs versus ‘care as usual’ on 
reducing falls in community-dwelling older men and women, who visited the ED after 
experiencing a fall. Chapter 3.2 discusses the results of the IMPROveFALL study. Overall, 
FRIDs withdrawal did not result in a reduced incidence of falls. However, cardiovascular 
FRIDs withdrawal did reduce visits to the general practitioner because of a fall. Surprisingly, 
no effect of psychotropic drug withdrawal was seen. Chapter 3.3 describes the related costs, 
the effects on health related quality of life, and the cost-utility of the intervention. The total 
healthcare related costs in the intervention group were €39 higher than usual care. FRID 
withdrawal was associated with less decline in HRQoL as measured with the EQ-5D utility 
score. The intervention resulted in an incremental cost-utility ratio of €780/QALY gained. 
Policy makers and health economists have proposed that costs up to €20,000 per QALY are 
considered as acceptable.  
Part IV starts with the general discussion, wherein we summarize the main findings 
and discuss the strengths and limitations of the IMPROveFALL  study. In addition we present 
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 This study increases our insights into both the effectiveness of FRIDs withdrawal as a 
method for falls reduction in older adults, and into the complexity of this intervention in an 
older, multi-morbid population. The study adds to the understanding of effective falls-
prevention interventions. Overall, FRIDs withdrawal did not result in a reduced incidence of 
falls. However,cardiovascular FRIDs withdrawal did reduce visits to the general practitioner 
because of a fall. The potential harm versus benefit of antihypertensive medications should be 
weighed in older adults with multiple chronic conditions. The method of implementation of 
fall-risk increasing drugs withdrawal is essential, compliance might be improved if  the 
prescribing physician performs the withdrawal. 
 
Samenvatting en Conclusies 
 
Deel I is een overzicht van de literatuur over de effecten van valincidenten op de oudere 
persoon, de gezondheidszorg en de kosten voor de samenleving. Een groot aantal ouderen van 
65 jaar en ouder maakt in een jaar één of meerdere valincidenten door. Valincidenten leiden 
tot ernstige problemen zoals hoge morbiditeit en mortaliteit, verminderd fysiek functioneren, 
verlies in kwaliteit van leven, en verlies van zelfstandigheid met als gevolg langdurige 
opnames in zorginstellingen. Verder drukken valgerelateerde letsels op de gezondheidszorg 
met een groot aantal spoedeisende hulp bezoeken, ziekenhuisopnames, opnames in verpleeg- 
en revalidatie-instellingen en veroorzaken deze letsels hoge gezondheidszorgkosten. 
 Deel II biedt inzicht in diverse factoren die aan valincidenten in de oudere populatie 
gerelateerd zijn. Deze factoren, zoals de omstandigheden die leiden tot schadelijke 
valincidenten en het effect van vitamine D op fysieke prestaties worden besproken. Tenslotte 
wordt een vergelijking van functionele, fysieke en gezondheidsgerelateerde kwaliteit van 
leven scores in eenmalige en frequente vallers gemaakt. Hoofdstuk 2.1 is een overzicht van 
de activiteiten binnenshuis en buitenshuis die hebben geleid tot valincidenten die een bezoek 
aan de spoedeisende hulp vereisen en valincidenten die hebben geleid tot ernstige 
verwondingen zoals traumatisch hersenletsel en heupfracturen. Twee derde van alle 
valincidenten vond binnenshuis plaats. De  meest voorkomende activiteiten voorafgaand aan 
een val met letsels binnenshuis waren lopen en traplopen. De meest voorkomende activiteiten 
voorafgaand aan een val met letsels buitenshuis waren lopen en fietsen. Activiteiten 
binnenshuis die leidden tot traumatisch hersenletsel respectievelijk heupfracturen verschilden. 
Traplopen en huishoudelijke werkzaamheden waren de meest voorkomende activiteiten 
voorafgaand aan traumatisch hersenletsel, terwijl lopen en zitten of staan behoorden tot de 
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ongeveer de helft van alle traumatische hersenletsels en heupfracturen bij mannen en vrouwen 
tussen 65-79 jaar buitenshuis zijn opgetreden. De meest voorkomende activiteiten buitenshuis 
die leidden tot beide letsels waren lopen en fietsen. In Hoofdstuk 2.2 laten we zien dat de 
serum 25(OH)D-spiegel significant gerelateerd is aan spierkracht en fysieke prestatie in de 
studie-populatie van zelfstandig-wonende oudere mannen en vrouwen. In Hoofdstuk 2.3 
worden gegevens gepresenteerd die richtlijnen ondersteunen waarin gesteld wordt dat 
frequente vallers een indicatie hebben voor een multifactoriële evaluatie van valgerelateerde 
risicofactoren. Deze groep vallers scoorden significant minder goed in alle fysieke prestatie 
toetsen (mobiliteit, spierkracht en balans). Verder hadden  frequente vallers lagere 
gezondheidsgerelateerde kwaliteit van leven scores, inclusief significant lagere EQ-5D scores 
en meer problemen in alle vijf de EQ-5D domeinen. 
 Deel III beschrijft het protocol van de IMPROveFALL studie (Hoofdstuk 3.1). De 
IMPROveFALL studie is een multicenter gerandomiseerd onderzoek dat het effect van het 
gestructureerd afbouwen van valrisicoverhogende geneesmiddelen vergelijkt met 
‘gebruikelijke zorg’ op  het voorkomen van valincidenten bij zelfstandig wonende oudere 
mannen en vrouwen. Hoofdstuk 3.2 vermeldt de resultaten van de IMPROveFALL studie. In 
het algemeen heeft het afbouwen van valrisicoverhogende geneesmiddelen niet geleid tot een 
vermindering van valincidenten in het follow-up jaar. Echter, het afbouwen van 
cardiovasculaire geneesmiddelen resulteerde in een lager  aantal huisartsbezoeken vanwege 
een val ten opzichte van de controle groep. Verrassend was dat er geen effect op de 
valincidentie werd gevonden na het afbouwen van psychotropica. Hoofdstuk 3.3 biedt  
inzicht in de gezondheidszorg gerelateerde kosten, het effect op de gezondheidsgerelateerde 
kwaliteit van leven en de kosten-utiliteit van de interventie. De totale 
gezondheidszorggerelateerde kosten in de interventiegroep waren €39 hoger dan in de 
controle groep. Het afbouwen van valrisicoverhogende geneesmiddelen was gerelateerd aan 
 
minder achteruitgang van gezondheidsgerelateerde kwaliteit van leven zoals gemeten met de 
EQ-5D score. De interventie had een incrementele kosten-utiliteits ratio van  €780 per 
gewonnen QALY. Beleidsmakers en gezondheid economen hebben eerder € 20.000 per 
gewonnen QALY voorgesteld als acceptabel  
 Deel IV bevat een algemene discussie met een samenvatting van de uitkomsten en een 
bespreking van de beperkingen en sterke punten van de  IMPROveFALL studie. De gevolgen 
van de studieresultaten voor de kliniek worden hier besproken evenals de aanbevelingen voor 
toekomstig onderzoek.  
 Dit proefschrift verbreedt het inzicht in het effect van het afbouwen van 
valrisicoverhogende geneesmiddelen als methode voor het reduceren van valincidenten in een 
populatie van thuiswonende oudere mannen en vrouwen. De complexiteit van deze interventie 
in een oudere populatie met multimorbiditeit wordt aan de orde gesteld. In het algemeen heeft 
het afbouwen van valrisicoverhogende geneesmiddelen niet geleid tot een vermindering van 
valincidenten. Echter, het afbouwen van cardiovasculaire geneesmiddelen heeft het aantal 
huisartsbezoeken vanwege een val wel verminderd. De methode van implementeren van deze 
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Onderzoek doe je niet alleen. Dit proefschrift zou niet tot stand zijn gekomen zonder 
samenwerking van een grote groep toegewijde mensen. Een aantal van hen wil ik graag hier 
in het bijzonder noemen. 
Mijn promotor, prof.dr. P. Patka. Geachte professor Patka, ik ben ontzettend dankbaar dat u 
mij vier jaar geleden de gelegenheid gaf dit promotietraject in te gaan. Ik heb uw inzet tijdens 
de maandelijkse vergaderingen en achter de schermen enorm gewaardeerd. Dank voor uw 
scherpe inzicht, nuttige commentaar en fijne samenwerking.  
Mijn tweede promotor, prof.dr. T.J.M. van der Cammen. Beste Tischa, uw enthousiasme en 
toewijding aan dit onderzoek is aan niemand voorbij gegaan. Dank voor de altijd interessante 
gesprekken en discussies met uitslagen uit de meest recente literatuur. Alle tijd en moeite die 
u in mijn proefschrift heeft geïnvesteerd waardeer ik enorm. 
Mijn copromotor, dr. E.F. van Beeck. Beste Ed, ik heb bewondering voor uw kennis en 
inzicht, en uw inzet om deze over te brengen aan jonge onderzoekers. Na onze gesprekken 
kwam ik altijd weg met nieuwe ideeën en een verse kijk op alle data en uitslagen. Hartelijk 
dank voor de goede begeleiding. 
De leescommissie, prof. dr. S.E.J.A. de Rooij, prof. dr. A. Burdorf en prof. dr. M.H.J. 
Verhofstad, dank voor het lezen en beoordelen van mijn proefschrift.  
 
Beste Esther, in 2010 kwam ik als jonge student bij jou terecht voor mijn keuze-onderzoek. In 
deze periode heb je mij enthousiast gemaakt voor wetenschappelijk onderzoek, ik ben 
tenslotte via jou beland in dit mooie promotietraject. Jouw gedrevenheid, gestructureerde 
manier van werken en enthousiasme voor onderzoek zijn ongeëvenaard. Jouw deur was altijd 
open om mijn vragen te beantwoorden en te helpen als ik vastliep. Dank voor lezen van mijn 
 
manuscripten in de avonduren, dank voor jou altijd kritische blik. Maar bovenal dank voor 
alle steun en vertrouwen afgelopen jaren.   
Nathalie, hartelijk dank voor alle tijd en energie die jij in dit proefschrift hebt gestoken. Als 
jonge onderzoeker heb ik veel gehad aan jouw kennis en ervaring. Tevens is het fundament 
voor de IMPROveFALL studie mede door jouw inspanningen gelegd.  
Francesco, dankzij de manier waarop wij met elkaar omgingen ben ik nooit met tegenzin naar 
het D-gebouw gegaan. Je enthousiasme en warme persoonlijkheid maakten het heel prettig 
om samen te werken. Besprekingen met jou waren altijd erg effectief, bespreken wat er 
besproken moet worden en dan weer aan de slag. Je hulp bij het tot stand komen van artikelen 
was erg leerzaam. Molte grazie!  
Klaas, dank voor jouw aandeel bij het opstartten van de IMPROveFALL inclusie. Het was erg 
fijn om op een rijdende trein te kunnen stappen. Je was altijd bereikbaar en bereid om te 
helpen in de jaren daarna. Ik wens je alle succes toe in de toekomst, gaat helemaal goed 
komen met je ambities.  
Beste Oscar en prof. Lips, ontzettend veel dank voor alle hulp, waardevolle feedback en 
prettige samenwerking. Beste Suzanne, dank voor de prettige en ontspannen samenwerking!  
Beste Carolien, fijn dat ik altijd bij jou terecht kon voor een kop koffie (en ook alle vragen). 
Beste Liz, Dineke, en Ingrid hartelijk dank voor alle moeite die jullie hebben gedaan voor de 
IMPROveFALL deelnemers en studie. Jullie waren onmisbaar voor de uitvoering van dit 
onderzoek en ik heb veel gehad aan jullie inzet. Alle studenten die hard hebben gewerkt aan 
het verzamelen van data wil ik ook hartelijk danken: Sama Najidh, Steven Venema, Eunice 
Comvalius, Carla Cok, Els van Leest en Tiemen Lammerink. 
Gijs en Kiran mijn ‘roomies’ en ook Steven, Stephanie, Paul en Siebe, mijn mede Z-flat 
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Mahabier, mijn paranimfen, ik ben blij dat jullie 9 oktober, letterlijk en figuurlijk achter mij 
staan.  
Collegae in het Maasstad en nu het Hagaziekenhuis, hartelijk dank voor de tot nu toe 
geweldige tijd in de kliniek! 
Masha danki na mi mayornan, bosnan nunka a pone limitashon riba mi soñonan. Ta un honor 
pa ta boso yu. 
Mi dushi, Josuah, jij bent mijn thuis. Bedankt voor de vrijheid die jij me geeft om te zijn wie 
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